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Summary 
Live attenuated Salmonella vectors provide unique alternative in terms of 
antigen presentation by acting as a vector for heterologous antigens. The 
efficiency of any live bacterial vector rests with its ability to present sufficient 
foreign antigen to the human or animal immune system to initiate the 
desirable protective immune response. 
 
 Salmonella vectors encoding heterologous protective antigens can elicit the 
relevant immune responses, be it humoral, mucosal or cell-mediated. STM-1 
is a Salmonella mutant developed by RMIT, harbours a mutation in the aroA 
gene that renders it attenuated, and is a well characterised vaccine strain 
currently in use to protect livestock against Salmonella infection. In previous 
work in this laboratory, STM1 was shown to be capable of eliciting immune 
responses in mouse to plasmid-borne antigens. 
 
 In this study STM-1 was analysed for its ability to vector chicken ovalbumin 
model antigen and C. jejuni major outer membrane test antigen using in vivo 
inducible promoters such as pagC and nirB from the plasmid location. Also 
the expression and immune induction of these constructs was characterised 
from the chromosomal location using the same promoter constructs. Induction 
of immune responses, both humoral and cell mediated, was analysed to test 
the ability of STM1 to present heterologous antigens to the host immune 
system. Another issue addressed in this study was effect of pre-existing 
immune responses in the animal host against the vector or related strains and 
 1
the effects on generation of immune responses against the subsequently 
vectored antigen.  
 
The aroA gene region was the point of insertion for the designed constructs. 
However, this region was uncharacterised in STM-1 mutant, and so an 
analysis of this region was first completed. The lesion in STM-1 was created 
by an insertion of aroA554::Tn10 in the wild type Salmonella strain.  
 
The sequence analysis and PCR results of STM-1 characterisation reveal that 
there is an insertion and a deletion in STM-1, with respect to the parent strain. 
The IS10 left hand side (IS10 LH) of the Tn10 element (approximately 1.4 kb) 
is inserted adjacent to aroA. Several genes including serC, ycaP, ycoA, fcoA 
and part of the pflB have been deleted. Also deleted is the first 90 bp of the 
aroA gene. The presence of the composite Tn10 element has also induced a 
rearrangement in STM-1 chromosome. This rearrangement is not an inversion 
but may be a crossover between two points, not due to specific target 
sequence but due to the conserved three dimensional structure of the 
bacterial chromosome.  
 
In chapter 4 constructs were designed and created, with genes encoding 
chicken ovalbumin (the model antigen) and C. jejuni major outer membrane 
protein (Momp, test antigen) put under the control of an in vivo inducible 
promoter and incorporated into a plasmid.  Similar constructs were integrated 
in the aroA gene of STM-1 using the Lambda Red system, based on phage 
recombination. Expression was analysed for both ovalbumin and Momp 
 2
antigens using western blotting. A similar level of expression from the two in 
vivo inducible promoters, from both plasmid and chromosomal locations, was 
achieved. However, the expression analysis using western blotting is an 
indicative measure, with the induction of immune responses after vaccination 
is a more realistic measure of in vivo expression. 
 
Analysis of immune responses in mice vaccinated with STM-1 expressing 
ovalbumin under the pagC promoter and the nirB promoter, when compared 
with mice vaccinated with either STM-1 only or STM-1 harbouring empty 
plasmid, yielded significantly increased humoral and T cells responses 
(P<0.001). As with the in vitro expression results, no difference was observed 
in humoral or T cell responses when the efficiency of the two promoters to 
induce responses was compared. Similarly no difference in the induction of 
immune responses was observed when comparing constructs that expressed 
antigen from the chromosomal location or the plasmid location, indicating no 
advantage of multiple gene dosage. Immune responses from STM-1 
expressing ovalbumin under control of the nirB promoter were higher, 
although not significantly, especially when the expression was from the 
chromosomal location. Therefore in the second vaccine trials STM-1 
constructs expressing Momp driven from the nirB promoter were used for the 
vaccination. 
 
The analysis of anti-Momp humoral and T cell immune responses 
demonstrated significantly higher responses in the vaccinated mice when 
compared with controls (P<0.001). No difference was observed between the 
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groups receiving STM-1 expressing Momp antigen from the plasmid location 
and the chromosomal location.  
 
The impact of pre-existing immune responses was analysed after the ability of 
STM-1 to vector heterologous antigen was established. If STM-1 is to be used 
in field, any negative impact on immune responses against the vectored 
antigens due to pre-existing immunity against the bacterial vector or related 
strains would be a significant problem. However, the results from this study 
indicate that pre-existing immune responses against the bacterial vector or a 
related strain do in fact enhance both humoral and T cell responses against 
the heterologous antigen.  
 
In conclusion, the determination of the architecture around the lesion in STM-
1 allowed the development of constructs expressing heterlologous antigen 
from the chromosome. Humoral and cellular immune responses to vectored 
ovalbumin and C. jejuni Momp antigens were observed following vaccination 
with STM-1, when antigens were expressed from either the plasmid or 
chromosomal location. Up-regulation of immune responses, both humoral and 
cell mediated was observed against the vectored antigens in animals which 
were pre-exposed to either the bacterial vector or related strains. These 
results indicate that STM-1 has the potential to be used as a vector to deliver 
heterologous vaccine antigens from a single copy gene in the field.  
 4
Chapter-1  
Literature Review 
1.1 Introduction 
Since the origin of human life, the struggle against disease-causing 
microorganisms has continued. Several methods have been tried and tested 
for preventing or overcoming infections, such as chemical treatments, 
antibiotics and vaccination. Some of these methods were used with great 
success and some were not so successful. However, the methods which were 
successful, such as the use of antibiotics, have limited application as they are 
only effective in the case of bacterial diseases. Even the use of antibiotics is 
becoming less effective, due to the continuing problem of bacterial drug 
resistance. The presence of plasmids carrying antibiotic resistance genes 
helps disseminate antibiotic resistance strains, compromising the treatment of 
severe infections (Sherratt 2001). 
 
Edward Jenner and Louis Pasteur pioneered the use of vaccines, which was 
one of the most notable achievements in the field of medical science. These 
vaccines have helped in overcoming many debilitating and deadly diseases. 
Since then vaccine development has made some remarkable progress, but 
the demand for improved vaccines against pathogenic organisms continues. 
Despite the successful use of vaccines, modern medicine was confronted with 
new challenges during the last half of the 20th century because of the 
emergence of pathogens such as the Human Immunodeficiency virus and the 
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re-emergence of diseases such as tuberculosis, which were believed to be 
conquered. While there is a great need to develop new vaccines against 
these highly pathogenic organisms, there is also some interest in the 
development of vaccines in the field of veterinary science, the food industry 
and against the adverse use of pathogens as weapons (Kochi 2003; Atkins et 
al. 2006). The requirement to develop new and advanced vaccines has 
changed the approach to vaccine development. Several new techniques, such 
as vaccination with DNA or subunit vaccines have been developed by using 
molecular and immuno-biological techniques. 
 
Vaccines need to satisfy some important criteria (Table 1.1) before being 
used in the general population. Safety is a major concern if vaccines are to be 
administered in large population therefore even a low level of toxicity is 
unacceptable. Secondly, long lasting immune responses which includes both 
cellular and humoral immune response must be induced following 
administration of these vaccines (Atkins et al. 2006). Finally, a vaccine must 
be inexpensive if it is to be administered on a large population, particularly in 
a third world country. Similar constraints apply to veterinary vaccines.  
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 Table1.1: Features of effective vaccines (Janeway 2001) 
Safe 
 
 
Protective 
 
 
Protection 
 
 
 
Induces neutralizing antibody 
 
 
 
 
 
Induces appropriate responses 
 
 
 
Practical Considerations 
Vaccine must not itself cause illness or 
death 
 
Vaccine must protect against illness 
resulting from exposure to live pathogen 
 
Protection against illness must last for 
several years or lifelong 
 
 
Some pathogens (such as poliovirus) 
infect cells that cannot be replaced (e.g. 
neurons). Neutralizing antibody is 
essential to prevent infection of such cells. 
 
 
Some pathogens, particularly intracellular, 
are more effectively dealt with by cell-
mediated immune responses 
 
Low-cost per dose 
Biological stability 
Ease of administration 
Few side effects 
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 1.2 Types of Vaccines 
Jenner pioneered the use of vaccines against pathogenic organisms and 
since that time, the term vaccine has been used for any preparation of dead 
or attenuated pathogens or their products, where these preparations when 
introduced into the body stimulates the production of protective immune 
responses without causing the disease. Most of the vaccines available at 
present are either attenuated or killed (inactivated) organisms (Table 1.2) 
(Goldsby 2000). 
 
1.3 Killed organisms 
The killed organisms are non-infective and the whole preparation is used as a 
vaccine. Killed bacterial vaccines have been accepted since their 
development in the 1890s. There was no other alternative to prevent and treat 
certain serious infections apart from this method, especially in the case of 
typhoid fever which was wide-spread throughout the world (Mims 1998). 
However, the major disadvantage of killed vaccines is their efficacy.  These 
vaccines are particularly good in inducing both cellular and humoral 
responses, However booster dose or addition of adjuvant is required for the 
generation of long lasting immune responses. 
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Table1.2 Classification of common human vaccines (Goldsby 
et al. 2000; Farlane et al. 2003)  
Disease or pathogen Type of vaccine 
Whole organism  
Bacterial Cells  
Anthrax Inactivated 
Cholera Inactivated 
Plague Inactivated 
Pertusis Inactivated 
Tuberculosis Live attenuated BCG 
Typhoid Live attenuated 
Viral particles  
Hepatitis A Inactivated 
Influenza Inactivated 
Measles Live attenuated 
Mumps Live attenuated 
Polio (sabin) Live attenuated 
Polio (salk) Inactivated 
Rabies Inactivated 
Rubella Inactivated 
Varicella Zoster (chickenpox) Live attenuated 
Yellow fever Live attenuated 
 
Purified macromolecules
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Toxoid  
Diphtheria Inactivated exotoxin 
Tetanus Inactivated exotoxin 
Capsular Polysaccharides  
Hemophilus influenza type B Polysaccharide +protein carrier 
Neisseria meningiditis Polysaccharide 
Streptococcus pneumoniae 23 distinct capsular polysaccharide 
Subunit Vaccines  
Hepatitis B vaccine Surface antigen 
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1.4 Purified microbial component vaccines 
The use of cell surface macromolecules and cytosolic macromolecules 
derived from pathogens for vaccine purposes eliminates some of the risks 
associated with killed vaccines. The cellular components of cells such as 
capsular polysaccharide, proteins or inactivated exotoxins can be used as 
vaccine preparations. A commonly used microbial component vaccine is a 
preparation to protect against Neisseria meningitides, a common cause of 
bacterial meningitis (van den Dobbelsteen et al. 1995) and for Streptococcus 
pneumoniae (Vila et al. 2004).  These vaccines are formulated with capsular 
polysaccharide component of bacterial cell wall. However, an inability to 
stimulate robust T cell responses is one serious limitation of these vaccines. 
 
1.5 Synthetic peptide Vaccines 
The generation of synthetic peptide based antigens is an alternative path for 
vaccine development. However, these synthetic peptides are often not as 
immunogenic as the whole protein, therefore need to be optimised for the 
level of immunogenicity. Several methods such as coupling the peptide with 
micro-particles or fusions with other molecules can be used to enhance the 
immunogenicity of synthetic peptide vaccines.  
 
1.6 Subunit vaccines 
Subunit vaccines are based on specific purified or semi purified antigens. 
They can be native antigens, as in the case of toxoids, or recombinantly 
produced. In this case a gene-coding antigen is cloned into a vector. This type 
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of approach has led to the development of a hepatitis B vaccine (André et al. 
1990). 
 
1.7 DNA vaccines 
DNA vaccines are one of the latest developments in the field of vaccine 
technology. DNA vaccines have been extensively studied in animal models in 
the past decade for their effectiveness and mode of action. A study by Tang et 
al. (1992) used a gene gun to deliver plasmid DNA into the epidermis of mice 
and found that an immune response was generated against the encoded 
protein. In addition, Ulmer (1993) showed that vaccination with DNA encoding 
the influenza-A nucleoprotein generated a protective immune response in 
mice, not only against homologous virus, but also against heterologous 
strains. These experiments demonstrated the effectiveness of DNA vaccines 
in generating broad immune responses including CTL responses.  
 
1.8 Live attenuated vaccines 
The prospective of live, attenuated vaccines has been acknowledged during 
the earlier studies. Calmette and Guerin (1921) first used this technology with 
Mycobacterium bovis. They passaged the bacteria in culture to reduce its 
virulence. Live attenuated strains provide exceptional choice for the delivery 
of antigens not only against homologous pathogenic organisms but can also 
be used as a vector to deliver passenger antigens. One of the most 
successful live attenuated vaccines produced is the Ty21a live S. Typhi 
vaccine. Chemical mutagenesis process was used for inducing attenuation, 
which eliminated the O antigen from the LPS molecule. This live oral bacterial 
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vaccine generated antigen-specific CD4+ and CD8+ memory T cells (Lundin et 
al. 2002). The live attenuated bacteria as a vaccine and vector offers many 
advantages compared with killed and subunit vaccines. Live attenuated 
strains can be delivered by a simple oral mode of inoculation and may confer 
protection following a single dose due to replication (albeit limited) in the host 
(Kochi 2003). In addition they are economical to develop (Trach et al. 2002) 
can be manufactured commercially on a large scale (Lockman et al. 1999). 
The use of live oral vaccines also enhances the repertoire of antigens 
presented to the mucosal immune system compared with the antigens 
presented in complexes of killed organisms. Killed bacterial vaccines which 
are prepared for parental or oral administration are subjected to acetone, 
formalin, or heat to kill the organism, all of which have the potential to 
denature relevant immunologic determinants. The attenuated organisms also 
provide long lasting immunity as the intracellular organism can only be 
eliminated by elicitation of strong cellular responses, including CD4+ and 
CD8+ T lymphocytes (Kaufmann 1998).  
 
The early live attenuated vaccines, for example Salmonella typhi Ty21a 
(Germanier and Fuer 1975) and Mycobacterium- BCG (Guleria 1996) were 
developed by randomly generated undefined mutations. However, application 
of modern DNA technology have led to the generation live attenuated 
vaccines where the organisms are attenuated by the deletion of genes 
encoding metabolic functions. These attenuated organisms can effectively 
colonise and undergo several round of replication inside the host cell.  
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Another advantage of live attenuated organisms is that they can be 
genetically engineered to express a heterologous antigen. These live 
attenuated bacterial vectors not only confer long lasting immunological 
memory against the homologous antigens but also against the heterologous 
antigens presented by the bacterial vectors (Wyszynska et al. 2004).  
 
Despite the fact that a number of organisms have shown potential to be used 
as attenuated vaccine, only a few can be effectively used. Major 
apprehension in using attenuated organisms as a vector, apart from 
immunogenicity, is safety (Kochi et al. 2003). This requires development of 
strains that have restricted survival in a host and in the environment, yet still 
induce protective immune response. Only a few genera such as Shigella, 
Salmonella, Leisteria, Mycobacterium and Vibrio have shown the ability 
required to be used as a vector for the delivery of heterologous antigen for 
vaccine purpose and proved effective in terms of antigen delivery and immune 
presentation. Salmonella, due to an extensive knowledge of the organism’s 
biology, have been used most widely as a vector to deliver heterologous 
vaccine antigen from both prokaryotic and eukaryotic origin (Mastroeni et al. 
2001; Lundin et al. 2002; Baud et al. 2004; Berndt and Methner 2004; Liu et 
al. 2006). 
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1.9 Salmonella as a candidate 
Salmonella are Gram-negative, facultative anaerobic, motile, non-lactose 
fermenting rods, belonging to the family of Enterobacteriaceae. Salmonella 
infect humans and animals generally by the oro-fecal route (Curtiss et al. 
1993). They have a wide range of animal hosts and can be frequently found in 
sewage, sea and river water and contaminated food (Coburn et al. 2007).  
 
Initially the use of S. Typhi Ty21a, as vaccine against the typhoid fever 
developed great interest in using Salmonella genus to deliver antigenic 
proteins, however, lack of reliable animal models for this species shifted the 
attention of researchers towards the use of S. enterica var. Typhimurium to 
deliver antigenic determinants (Levine et al. 1997). However, recently several 
studies have been conducted using S. Typhi as a vector to deliver 
heterologous vaccine antigen in both animals and humans where it has 
shown some promise as a live attenuated vector (Capozzo et al. 2004; 
Metzger et al. 2004). The progress of serovar Typhimurium as vectors is 
based on the concept that the survival of organism in the intestine may induce 
mucosal and systemic immune responses (Angelakopoulos and Hohmann 
2000). 
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 1.9.1 Pathogenesis of Salmonella  
Salmonella infects humans and animals generally by oral route. The organism 
has the capability to resist the low pH of the stomach allowing it to reach the 
distal ileum and the caecum. The bacteria then invades the mucosa, and 
replication takes place in the sub-mucosa and the peyer’s-patches (Carter 
and Collins 1974). Invasion occurs via M cells with the contribution of 
products of the invasion genes encoded within pathogenicity island 1 (SPI1). 
After entering the peyer’s patches, bacteria are transported via the lymphatic 
and blood streams to the mesenteric lymph nodes, liver and spleen (Darwin 
and Miller 1999), or via an alternative pathway which involves systemic 
dissemination, if the bacteria are present within CD18+ cells (Vazquez-Torres 
et al. 1999). In systemic infection, the bacteria are engulfed by the phagocytes 
of the spleen, the liver and the bone marrow. Salmonella is phagocytosed by 
APC’s due to the presence of opsonising antibodies and complement 
activation at the bacterial surface (Liang-Takasaki et al. 1983; Saxen et al. 
1987). 
 
Virulent property of Salmonella is due to its ability to grow within 
macrophages, DC’s and polymorphonuclear phagocytes during systemic 
infection. (Hoiseth and Stocker 1981; Lissner et al. 1983; Fields et al. 1986; 
Dunlap et al., 1991; Mastroeni et al. 1995; Richter-Dahlfors et al. 1997).  
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1.9.2 Immune response against Salmonella 
Cellular immune responses are crucial both for protective immunity against 
salmonellosis and for the immunogenicity of oral vaccines which are based on 
avirulent live Salmonella as antigen carriers. A primary infection leads to the 
induction of antibodies against antigens such as lipopolysaccharide (LPS), 
flagellin and lipo-protein with the induction of Th1 or Th2 type T-cell memory 
and CTL responses (Hormaeche et al. 1991). 
 
The initial stages of infection are characterised by an innate immune response 
triggered by the host recognition of several microbial structures (Wick 2004) 
which is followed by the induction of antigen specific CD4+, CD8+ and B cells 
all of which contribute to protective immunity (John et al. 2002). 
 
 
1.9.2.1 Role of Antigen presenting cells in Salmonella 
immunity 
As S. Typhimurium is an intracellular pathogen, T cells are critical 
components of the specific immune response. The bacterium specific CD4 
and CD8 effector T cells are essential for a complete immune response 
against S. Typhimurium (Mittrucker and Kaufmann 2000).  Macrophages and 
immature dendritic cells (DC) play an important role in the development of 
innate and adaptive immune responses to bacterial infections. They act as 
antigen presenting cells (APC), capturing and degrading bacteria in a defined 
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proteolytic pathway. The processed bacterial antigens are displayed on the 
APC surface by the major histocompatibility complex (MHC) (Watts 1997).  
 
 Non-overlapping antigenic peptides which are accessible to CD8+ CTL and 
CD4+ helper T cells (TH) are presented by MHC Class I and the Class II 
molecules expressed on APC’s (Gotch et al. 1987; Babbitt et al. 2005). The 
Class I molecules containing degraded antigenic fragments are transported to 
the endoplasmic reticulum before being transferred to the MHC molecule 
before being recognised by CTL (Germain 1995; Heemels and Ploegh 1995). 
Majority of Class II complex peptides accessible to TH cells are membrane 
proteins. These degraded exogenous products after endocytosis fuse with 
lysosomes before entering Class II molecules pathway (Cresswell 1994; 
Teyton 1994). Yrlid et al. (2001) showed that three major phagocytic cells, 
which include neutrophils, macrophages and dendritic cells are all associated 
with the induction of S. Typhimurium specific T cell responses. However, DC’s 
have a superior capacity to stimulate naïve T cells in comparison to 
macrophages. 
 
 Immature DCs are efficient in capturing and processing antigen but lack the 
capacity to induce naïve T cells. However, after maturation they are an 
effective T cell activator (Banchereau et al. 2000). Several studies also 
suggest the involvement of DC in M cell-independent transport of non-
invasive Salmonella from the intestine (Rescigno et al. 2001). A potential role 
in mediating bacterial transit across the intestinal epithelium is supported by 
the observation that CD8α- CD11b- DC are in peyer’s patches and in the 
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follicle associated epithelium and can be in close contact with M cells (Iwasaki 
and Kelsall 2001). These data suggest a role of intestinal DC in sampling 
intestinal bacteria and facilitating their penetration across the gut. Once 
Salmonella penetrates the intestine, other organs which are subsequently 
infected include the mesenteric lymph nodes, the spleen and the liver.  
 
The presentation of Salmonella antigens to T cells by infected DC occurs 
when the DC are infected with Salmonella that do no induce death in the cells. 
However, Salmonella-induced apoptosis of macrophages provides a reservoir 
of Salmonella antigens t hat can be presented by bystander DC’s (Yrlid and 
Wick 2000). Interestingly, the capacity to act as a bystander APC appears to 
be a unique feature of DC, as bystander macrophages ingest Salmonella-
induced apoptotic cells but do not present peptides from Salmonella antigen 
(Banchereau et al.1998). Thus, depending upon the type of Salmonella DC 
encounter, Salmonella infected DC can process Salmonella for direct 
presentation of Salmonella antigen to T cells or can act as bystander APC 
that engulf the antigenic material from neighbouring cells that have undergone 
Salmonella-induced apoptotic death. 
 
1.9.2.2 T cell responses 
Infection with live S. Typhimurium can result in broad activation of CD4+ and 
CD8+ T cells and generation of Salmonella specific IFN-γ producing T cells. 
Mittrucker and Kaufmann (2000) also showed that the induction IFN-γ 
producing CD4+ and CD8+ T cells, particularly the CD4+ subset, and IFN-γ in 
immunity to Salmonella. However, the frequency of specific IFN-γ producing 
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CD4+ T cells was significantly greater than that of CD8+ cells. This has been 
also indicated by an experiment in transgenic mice model which were nude, T 
cell receptor αβ-deficient, and MHC Class II deficient. When infected with 
attenuated Salmonella, these mice could not protect themselves from 
infection (Hess et al. 1996; Sinha et al. 1997), whereas wild type mice were 
not infected by the same Salmonella strain. In contrast transgenic mice 
lacking MHC Class I restricted T cells displayed no difference from the wild 
type and therefore were not infected with the Salmonella mutant (Hess et al. 
1996; Lo et al. 1999). These data suggests that a strong CD4+ response is 
critical for immunity against Salmonella.  
 
Another study with MHC Class I deficient and B cell deficient transgenic mice 
also showed they are not infected by attenuated Salmonella. However, unlike 
wild type mice, these mice did not provide any protection against challenge 
with wild type Salmonella (Lo et al. 1999; Mastroeni et al. 2000).  These 
results indicate that for protection against wild type Salmonella a fully 
functioning immune system is required, whereas CD4 cells may be sufficient 
to resist attenuated strains. 
 
 It has been shown that vaccination of mice with attenuated Salmonella 
provides immunity against re-challenge with virulent Salmonella (Hoiseth and 
Stocker 1981). However, the protective immunity could not be transferred to 
naïve recipients unless both T cells and serum antibodies were transferred 
(Mastroeni et al. 1993). Again, this indicates the role of CD4+, CD8+ and B cell 
responses for the induction of complete immunity against Salmonella. One 
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reason for the above discrepancy in the analysis of CD8+ response might be 
due to cross presentation of antigen during activation of CTL’s. 
 
1.9.2.3 Antigen cross presentation  
Phagocytosis of pathogens by DCs Induce cytotoxic T-cell immune response 
(Guermonprez et al. 2002). In the classical pathway for antigen presentation 
endogenous antigens are presented by MHC Class I molecules to stimulate 
CTL responses, and exogenous antigens are presented by MHC Class II 
molecules to stimulate a helper T cell response. However, there can be some 
variety in this classical pathway in that  DC’s can present exogenous antigens 
on MHC Class I molecules via a process known as “cross presentation” (Sigal 
et al. 1999).  
 
Antigens from pathogenic organisms are exported into the cytosol after 
phagocytosis and degraded by the proteasome (Norbury et al. 1997; 
Rodriguez et al. 1999).  The processed peptides are translocated into the 
endoplasmic reticulum (ER) lumen by specific transporters associated with 
antigen presentation (TAP) to form MHC Class I peptide complexes which are 
transported to the cells surface through the secretory pathway. Guermonprez 
et al. (2003) showed that during the formation of phagosomes, or soon after, 
they fuse with the ER. After the antigen is exported to the cytosol and 
degradated by the proteasome, peptides are translocated by TAP into the 
lumen of the same phagosome, and loaded onto phagosomal MHC Class I 
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molecules. Therefore cross-presentation in dendritic cells occurs in a 
specialised, self sufficient, ER-phagosome compartment. 
 
The phagosome plays a very important role in antigen cross presentation 
(Houde et al. 2003). Though there is a well defined segregation between the 
MHC Class I and II pathways, antigens from intracellular pathogens such as 
S. Typhimurium, Mycobacteria, and Leshmanaia  have been shown to elicit 
an MHC Class I dependent CD8+ T cell response because phagocytosis in 
the APCs proceeds via the ER at the cell surface, a process referred to as 
ER-mediated phagocytosis (Pfeifer et al. 1993; Oliveira and Splitter 1995; 
Canaday et al. 1999). In this way an antigen from an intracellular pathogen 
could have direct access within the phagosome to the ER machinery needed 
for MHC Class I presentation (Houde et al. 2003).  
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Figure 1.1 Diagramatic representation of the induction of T cell response. In the 
endogenous pathway, proteins from intracellular pathogens, such as viruses are degraded 
by the proteasome and the resulting peptides are shuttled into the endoplasmic reticulum 
(ER) by TAP proteins. These peptides are loaded onto MHC Class I molecules and the 
complex is delivered to the cell surface, where it stimulates cytotoxic T lymphocytes 
(CTLs) that kill the infected cells. In contrast, extracellular pathogens are engulfed by 
phagosomes (exogenous pathway). Inside the phagosome, the pathogen-derived peptides 
are loaded directly onto MHC Class II molecules, which activate helper T cells that 
stimulate the production of antibodies. But some peptides from extracellular antigens can 
also be 'presented' on MHC Class I molecules. How this cross-presentation occurs has now 
been explained. It seems that by fusing with the ER, the phagosome gains the machinery 
necessary to load peptides onto MHC class I molecules. Figure and Legend reproduced (Roy 
2003) 
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 1.9.2.4 B cell response  
The critical role of T cells in the development of protective immunity against 
Salmonella challenge has been well characterised (Canaday et al. 1999; Lo et 
al. 1999; Bumann 2001; Iwasaki and Kelsall 2001; Yrlid et al. 2001; Yrlid et al. 
2001; Wick 2002; Bumann 2003; Wick 2003; Wick 2004). However, the role of 
B cells in generating Salmonella specific immune response is not so well 
studied. Most of the earlier studies report the generation of serum IgG and 
mucosal IgA responses against bacterial LPS and other antigenic 
determinants following immunisation of mice with Salmonella (Alderton et al. 
1991; Hormaeche et al. 1991).  
 
Sinha et al. (1997) in one of his experiments with T cell deficient mice showed 
that the deficient mice infected with attenuated Salmonella did not survive. He 
also showed that the humoral response in those mice was limited to IgM and 
IgG3 antibody responses, with little or no IgG1, IgG1a and IgG2b. In another 
study by Berndt and Methner (2004) it was shown that IgM and IgA responses 
are of importance in the caeca of chickens against Salmonella infection. 
Recent studies (Mastroeni et al. 2000; Mittrucker et al. 2000; al-Ramadi et al. 
2006; Menager et al. 2007) on mice deficient for the generation of B cell 
responses, has indicated that the B cell response plays an important role in 
the development of complete immunity against Salmonella.  
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1.9.2.5 Immune responses against a passenger antigen 
The rationale behind using Salmonella as a vector to deliver heterologous 
vaccine antigen is that it can induce both local and systemic immune 
responses. The understanding of S. Typhimurium pathogenicity and its 
interaction with the host immune system and associated virulence factors led 
to the generation of attenuated Salmonella vaccines and their use for the 
delivery of heterologous vaccine antigen (Bachtiar et al. 2003; Bowe et al. 
2003; Foynes et al. 2003; Baud et al. 2004; Berndt and Methner 2004; 
Capozzo et al. 2004). 
 
1.9.2.5.1 Cellular immune responses against heterologous vaccine 
antigen 
The efficacy of any live bacterial vaccine rests in its ability to present the 
passenger antigen to generate the desired protective immune responses 
against the foreign antigen. Heterologous antigens expressed from 
Salmonella can induce Th1, Th2 and CTL responses (Du and Wang 2005; 
Atkins et al. 2006; Chiu et al. 2006). However, several factors such as the 
type of strains, type of mutant and the type of antigenic protein expressed 
play a critical role in the generation of complete T cell responses (Bowe et al. 
2003; Spreng et al. 2006). The activation of a Th1 response is characterised 
by the secretion of IFN-γ and IgG2a antibody, whereas the induction of a Th2 
response is characterised by IgG1 and IL4 (Kang and Curtiss 2003). Some 
studies also demonstrate the activation of CTL responses to the guest 
antigens (Methner et al. 2004; Atkins et al. 2006; Chiu et al. 2006).   
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1.9.2.5.2 Humoral Immune responses against heterologous 
vaccine antigen 
The protective humoral response against a heterologous antigen has been 
reported in some studies against bacterial, viral and parasitic antigens carried 
by different Salmonella mutants (Karem et al. 1995; Kohler et al. 2000; Lillard 
et al. 2001; Chen and Schifferli 2003; Fouts et al. 2003; Foynes et al. 2003; 
Morton et al. 2004). Oral immunisation can lead to the induction of IgA 
antibody responses against heterologous antigen in the gut, saliva and lung 
washes (Berndt and Methner 2004; Capozzo et al. 2004; Jiang et al. 2004; 
Wyszynska et al. 2004). Other modes of inoculation such as intranasal 
inoculation, rectal or vaginal inoculation also leads to the development of 
protective IgA responses against the antigenic protein (van den Dobbelsteen 
and van Rees 1995; Garmory et al. 2003; Garmory et al. 2003; Morton et al. 
2004). Serum IgG responses against the heterologous antigen have also 
been reported following oral vaccination and also when the vaccination was 
given via other routes (Harokopakis et al. 1997; Kang et al. 2002; Wyszynska 
et al. 2004; Stratford et al. 2005). The induction of subtype IgG1 or IgG2a has 
also been observed and the presence of these subtypes is indicative of the 
activation of polarised T cell immune responses, as IgG1 an indicative of a 
Th2 response and IgG2a is indicative of a Th1 response (Harokopakis et al. 
1997; Berndt and Methner 2004; Capozzo et al. 2004; Chiu et al. 2006). 
 
These studies suggest that Salmonella can be used as a vector for the 
delivery of heterologous vaccine antigen to target T and B cell responses.  
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1.10 Salmonella Typhimurium Mutants  
Bacon, Burrows et al. (1950; 1951) were first to describe attenuated 
Salmonella strains. The mutation in these strains was due to the disruption of 
genes encoding for purine, p-aminobenzoic acid, and aspartate. These 
mutants exhibited reduced virulence in mice due to exogenous requirement of 
the metabolites. 
 
1.10.1 galE Mutants 
Nitrosoguanidine treatment was used to induce a galE mutation in S. 
Typhimurium and S. typhi. These mutants were avirulent but still 
immunogenic in mice and humans (Germanier and Fuer 1975). In the 
absence of galatose S. typhi was found to be avirulent due to loss of 
capability to synthesise complete LPS. However, LPS components were 
shown to be synthesised after the addition of galatose to the medium as 
shown in Figure 1.2 (Nikaido 1961).  The exact nature of avirulent properties 
due to disruption of galE genes is still not understood, but almost certainly 
involves the loss of the ability to synthesis complete LPS molecules and 
galactose sensitivity. 
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 Figure1.2 Metabolism of galactose. The 
galE mutants are unable to synthesise 
glucose from galactose because of the 
deficiency of enzyme uridine diphosphate 
(UDP)-galactose-4-eipmerase. (Garmory et 
al. 2002) 28
1.10.2 aro and pur mutants 
Salmonella strains harbouring mutation in the aroA gene were found to be 
nonvirulent for invasive infection due to their requirement for the aromatic 
metabolites paraaminobenzoate (for synthesising folate) and 
dihydroxybenzoate (for synthesising enterochelin) which are unavailable in 
the host tissues (Smith et al. 1984). The aroA gene directs the expression of 
the enzyme 3-enolpyruvylshikimate-5-phosphate synthetase, this enzyme 
plays a major role in the conversion of phosphoenolpyruvate and shikimate 3-
phosphate into 5-enolpyrovoylshikimate-3-phosphate which leads to the 
synthesis of chorismate, a common intermediate compound in the synthesis 
of aromatic amino acids (Figure 1.3).  
 
S. Typhimurium and S. dublin mutants with an aroA defect have been 
successfully used as a vector to deliver heterologous antigen for vaccination 
(Guzman 1991; Stocker 2000; Jespersgaard et al. 2001; Mollenkopf 2001). 
Strains harbouring mutations in the genes that affect other metabolic 
pathways have also been designed. 
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 Salmonella strains harbouring mutation in the purA gene was developed  
(McFarland and Stocker 1987). The purA gene encodes adenylosuccinate 
synthetase, the enzyme that catalyzes the conversion of IMP to AMP in the in 
the purine synthesis pathway (Figure 1.4). A secondary mutation was created 
by deleting the purA gene in existing aroA mutants to make them safer. 
However, it was found that strains harbouring a mutation in either in the purA 
gene or both in purA and aroA genes were poorly immunogenic (O'Callaghan 
et al. 1988; Sigwart et al. 1989).  
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purA gene encodes adenylosuccinate 
synthetase, the enzyme that catalyzes the 
first step of the conversion of IMP to AMP 
(Garmory et al. 2002). 
1.10.3 Cyclic AMP regulation Mutants 
A mutation in the genes encoding enzymes for the synthesis of cyclic AMP 
and cyclic AMP receptor protein renders Salmonella spp. avirulent. The 
complex these protein forms acts as a positive regulator for the transcription 
of multiple genes that possess catabolite sensitive promoters (Pastan and 
Adhya 1976). 
 
Strains carrying a mutation in cya gene (adenylate cyclase) and the crp gene 
(cyclic AMP receptor protein), were found to be less virulent. However, the 
stability to these mutants was in question as either cya or crp, reverted back 
to wild type with a frequency of 1 in 2 x 107.   This is too high a frequency for 
vaccine use. 
 
Strains harbouring mutations in both the genes were stable, whereas strains 
that had deletion in a single gene had the possibility of reverting to wild type. 
Also in comparison to aro or gal mutants the cya and crp mutant strains were 
not efficient in causing systemic infection in mice, and due to this there is poor 
induction of immune responses (Curtiss and Kelly 1987; Curtiss et al. 1988; 
Curtiss et al. 1989). 
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1.10.4 phoP and ompR mutants 
PhoP–PhoQ is a two component regulatory system that controls expression of 
several virulence properties in S. Typhimurium (Fields et al. 1989; Miller et al. 
1989; Miller and Mekalanos 1990). The virulence properties that the PhoP-
PhoQ system controls include the ability to survive inside macrophages 
(Fields et al. 1986), resistance of killing by host defence antimicrobial peptides 
(Fields et al. 1989; Groisman et al. 1992; Groisman et al. 1992), withstanding 
of  acidic pH (Foster and Hall 1990), invasion of epithelial cells (Behlau and 
Miller 1993), formation of spacious vacuoles and the ability to alter antigen 
presentation (Wick et al. 1995). 
 
 Angelakopoulos and Hohmann (2000) successfully used a S. Typhimurium 
PhoP-PhoQ mutant to deliver H. pylori urease as a vaccine antigen in mice.  
 
The product of ompR gene regulates the expression of component outer 
membrane proteins and other proteins which are uncharacterised (Dorman et 
al. 1989). The mutation in this gene renders S. Typhimurium strains avirulent. 
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1.10.5 Plasmid-cured strains 
Some non-typhoid Salmonella strains such as S. Dublin (Terakado et al. 
1983; Chikami et al. 1985; Nakamura et al. 1985), S. Enteritidis (Nakamura et 
al. 1985), and S. gallinarum (Barrow et al. 1987; Barrow and Lovell 1988) 
have been found to be virulent due to the presence of high molecular weight 
plasmids. When these strains are treated to eliminate these plasmids, thay 
are rendered avirulent. Before these cured strains can be used as vaccines 
however, it will be important to completely characterise plasmid genes and 
determine the full growth profiles of the strains. 
 
 
1.10.6 Streptomycin-Dependent Mutants 
 
A Salmonella typhi mutant developed after repeated culture in the presence of 
an antibiotic such as streptomycin has been reported by Reitman et al. (1954) 
and Mel et al. (1974). These mutants require the presence of antibiotic for 
subsequent growth. The generation of Salmonella mutants by such processes 
allows the generation of mutant Salmonella strains without exposing them to 
harsh mutagenic treatments, which might result in multiple mutations, and 
potentially destroy some key antigenic determinants. 
 
Efficacy of these mutants was tested on human volunteers and were shown to 
induce moderate protective immunity and did not result in any illness (Levine, 
et al. (1976). 
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1.10.7 Aspartate Semialdehyde Dehydrogenase Mutants 
Salmonella strains harbouring a mutation in the asd gene, which encodes for 
the enzyme aspartate semialdehyde dehyrogenase, were shown to be 
avirulent. The enzyme aspartate semialdehyde dehyrogenase catalyses the 
conversion of aspartate-4-phosphate to aspartate semialdehyde which leads 
to the synthesis of threonine, methionine, and lysine and diominopimilic acid 
(Cohen 1987). These mutants lack the capability to synthesise normal 
peptidoglycan, which is an essential component in the synthesis of the 
bacterial cell wall. However these mutant are significantly attenuated, and 
were unable to induce significant immunogenicity due to a limited survival 
time in GALT (Curtiss 1987). 
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1.10.8 Temperature-Sensitive Mutants 
S. dansyz was mutated by nitrosoguanidine treatment, and become a 
temperature-sensitive variant which was unable to grow at 37°C. These 
mutants were able to elicit immune responses after oral or intraperitoneal 
inoculation, protecting animals upon challenge with wild type (Fahey and 
Cooper 1970).  
 
In a more recent study, temperature sensitive mutants were developed by 
exposing the organism to UV rays. The majority of the mutants generated by 
this method reverted to wild type with the exception of one strain, which did 
not revert to wild type however, generated deficient immune responses in a 
mouse animal model (Ohta et al. 1987).  
 
1.10.9 Attenuated Salmonella Strains and their utility 
Understanding of biochemical pathways in Salmonella has led to the 
development of attenuated Salmonella strains for vaccine purposes either 
against the pathogenic strains (Hoiseth and Stocker 1981) or as a carrier for 
heterologous antigen (van den Dobbelsteen and van Rees 1995; Titball et al. 
1997; Wang HW 2003 Aug; Srinivasan et al. 2004; Wyszynska et al. 2004; 
Spreng et al. 2006).  
 
The most widely used metabolically attenuated strains are mutants which lack 
the capability of biosynthesis of aromatic amino acids (aroA, aroC and aroD) 
(Hoiseth and Stocker 1981; Smith et al. 1984), purine-dependent mutants 
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(purA, purE) (McFarland and Stocker 1987; O'Callaghan et al. 1988; Sigwart 
et al. 1989), or mutants deficient in the production of adenylate cyclase (cya) 
or cyclic AMP receptor protein (crp)(Curtiss et al. 1988). Other mutants which 
are well characterised for the delivery of heterologous antigens include 
mutants harbouring mutations in the two component system, PhoP/PhoQ or in 
Salmonella pathogenicity island 2 (Angelakopoulos and Hohmann 2000; Baud 
et al. 2004). The efficacy of these live vaccines relies on the ability of minimal 
survival and maximal immunogenicity.  
 
The disruption of genes encoding for enzymes in important metabolic 
pathways necessary for the survival of the organism in vivo leads to the 
generation of mutants, which are safe and have minimal survival in the host. 
Their effects on the course of infection may vary, thereby altering the quality 
of induced immune responses (Dunstan et al. 1998).  Medina et al. (1999) 
compared an aroA mutant with two Salmonella Pathogenicity Island-2 (SPI-2) 
mutants of S. Typhimurium harbouring mutations in the sseC and sseD genes 
for the ability of these mutants to induce vectored β-galactosidase specific 
immune responses. Both the SPI-2 mutants induced mucosal and systemic 
immune response against the passenger antigen that was either similar to or 
even stronger than induced by an aroA mutant. In a similar study by Valentine 
et al. (Valentine et al. 1998) the S. Typhimurium CL288, CL401, and CL554 
mutants exhibited better immune responses when compared to an aroA 
mutant. (Dunstan et al. 1998) analysed mutants such as aroA, aroAD, purA, 
ompR, htrA, and cya crp to compare their capability to colonise and induce a 
vectored antigen specific immune response. All the mutants were able to 
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colonise and persist in murine peyer’s patches and the spleen, albeit at 
different levels. The immune response was strongly dependent on the type of 
mutant. 
 
In an other study, oral administration of a PhoP mutant exhibited strong innate 
immune responses, whereas immunisation with an aroA mutant led to the 
development of strong humoral and T cell responses, specifically a Th1 type 
response (VanCott et al. 1998). These studies suggest that although the 
mutations in genes encoding for metabolic pathway enzymes might lead to 
the development of a mutant which is safe to use as live vaccine, their 
capacity to carry heterologous vaccine antigen and present it to the host 
immune response varies.  
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 1.11 Factors that influence the use of 
Salmonella as a vector to deliver heterologous 
antigen 
The use of attenuated Salmonella as a vector to deliver heterologous antigen 
is a technique with a significant potential to influence the management of 
infectious diseases on a large scale, not only with vaccines against enteric 
bacterial pathogens but also with vaccines against a variety of other bacteria, 
viruses and parasites. However, some important issues influence the utility of 
this approach for vaccine development. 
1. stabilisation of antigen expression in the Salmonella carrier, and 
2. the effect of pre-existing immune responses against bacterial vector 
 
1.11.1 Stabilisation of antigen expression in attenuated 
Salmonella strain 
The generation of recombinant Salmonella as a vaccine carrier requires the 
introduction of foreign genes on plasmid cloning vectors. However, major 
disadvantage of using plasmids to deliver heterologous antigens is, these 
plasmids generally harbour antibiotic resistance markers to facilitate selective 
pressure in favour of plasmid retention. Secondly, the commonly used cloning 
vectors induce metabolic burden on the bacterial replication machinery due to 
their size, copy number, type of repicon they harbour and the complexity. Also 
due to the expression level of plasmid-encoded genes, which affects the 
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metabolic stability of the bacterial cells (Dunstan et al. 2003). Although the in 
vitro stability of these plasmid has been found to be sufficient, in vivo stability 
in the absence of antibiotic pressure is doubtful (Cardenas and Clements 
1993). Other problems include the possibility of plasmid transfer from the 
vaccine strain to human and animal bacterial flora or to environmental 
bacteria. For these reasons it is highly unlikely that plasmid borne antigens 
will be used outside of the research setting.  
 
1.11.1.1 Use of in vivo inducible promoters 
Different strategies for addressing the issue of plasmid instability and avoiding 
the need for administration of a stabilising antibiotic have been proposed to 
enhance the stable expression of heterologous antigen, and therefore induce 
stronger immune responses. One strategy involves the use of in vivo inducible 
promoters which allows expression of the heterologous antigen only when the 
recombinant Salmonella strains is phagocytised by APC’s, indicating that 
promoters activated upon Salmonella invasion could be useful tools to 
optimise the expression of heterologous antigens in this bacterial vector 
(Hohmann et al. 1995; Chabalgoity et al. 1996). However, the use of in vivo 
inducible promoters will not affect the stability of plasmids. 
 
Chatfield et al. (1992) first reported the application of an in vivo inducible-
promoter (nirB) in attenuated Salmonella. Subsequently, the use of in vivo 
inducible promoters has been shown to enhance stable expression and 
immunogenicity of foreign antigens expressed in Salmonella, while reducing 
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the metabolic load during in vitro propagation (Newton 1995.; Dunstan et al. 
1999; Bullifent et al. 2000; Bumann 2001).  
 
In vivo-inducible antigen expression, rather than constitutive expression, 
minimally interferes with bacterial viability. This allows the maintenance of 
plasmids in recombinant Salmonella culture. Once the Salmonella reach the 
appropriate location in the tissue, these in vivo inducible promoters up-
regulates antigen expression, resulting in the efficient induction of an immune 
response to the antigen under the control of the promoters (Newton et al. 
1995). This concept has been validated in several studies demonstrating an 
enhanced stability of such expression plasmids and an increased 
immunogenicity against the heterologous antigen when expressed from a 
recombinant live Salmonella carrier (Dunstan et al. 1999; Bumann 2001).  
 
 
1.11.1.2 Chromosomal integration of genes encoding 
antigenic protein 
Integration of foreign gene into the chromosome of a carrier strains is an 
alternative method to achieve stable expression of foreign antigen. (Hone et 
al. 1988; Flynn et al. 1990; Strugnell et al. 1990). Hone et al. (1988) 
developed one system where heterologous DNA was recombined in the 
chromosome of Salmonella by homologous recombination using suicide 
plasmid. The gene from E. coli was integrated into the chromosome of mutant 
S. Typhimurium using this method. Strugnell, et al. (1990) used a similar 
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strategy to integrate a heterologous gene into the aroC gene of 
S. Typhimurium.  
 
The most recently developed method, known as the Lambda Red System 
developed by Murphy et al. (1998), takes advantage of phage in the 
recombination system. Efficient recombination between short, linear DNA 
fragments and the bacterial chromosome can be catalysed by using the 
phage recombination system (Court et al. 2002). Homologous recombination 
is very efficient in organisms such as yeast. For example, short PCR products 
have been extensively used to generate knock-out mutants in yeast 
Saccharomyces cerevisiae (Que and Winzeler 2002), where very short region 
of identity (from 25-50 bp) are sufficient for efficient recombination. In 
contrast, short linear DNA fragments can not recombine efficiently into 
bacterial genome.  
 
The phage Lambda Red locus allows homologous recombination of linear 
DNA with the aid of enzymes encoded from genes: bet (aka β), exo and gam 
(aka γ) (Datsenko and Wanner 2000; Poteete and Fenton 2000; Yu et al. 
2000; Poteete et al. 2004). “Exo is 5’-3’ exonuclease that degrades the 5’ end 
of linear DNA, bet is a single stranded DNA binding protein, which binds to the 
single-stranded 3’ end generated by exo and promotes the annealing of 
complementary DNA, and gam binds to the host RecBCD complex and 
inhibits its exonuclease activity” (Murphy 2000; Poteete and Fenton 2000; Yu 
et al. 2000).  
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This technology was extensively used in E. coli and S. Typhimurium to 
generate knockout mutants. The method involves generation of a PCR 
product containing a very short region of similarity (35-50 bp). This method 
uses the advantage of the phage recombination system to integrate the linear 
fragment of DNA into the chromosome. In the year 2000, Datsenko and 
Wanner designed temperature sensitive, low copy number plasmids pKD20 
and pKD46 (with the ampicilin resistance marker). The Lambda Red genes 
bet (aka β), exo and gam (aka γ) were expressed under the control of an 
arabinose inducible promoter from these plasmids for efficient recombination 
of linear DNA molecules.  
 
Although the Lambda Red recombination system allows recombination of 
short linear DNA fragments, the frequency of recombination is low and 
therefore a selection is required to identify desired recombinants. To allow the 
selection of recombinants, the plasmid templates have been constructed for 
the generation of PCR products flanking a selectable antibiotic resistant 
marker. Three Pi dependent suicide plasmids (pKD3, pKD4, pKD13) which 
lack similarity to any sequence in the E. coli chromosome were constructed to 
use as templates for PCR amplification (Datsenko and Wanner 2000).  
 
 The recombinase-based system also offers the possibility to precisely 
remove the antibiotic resistance marker from the chromosome (Cherepanov 
and Wackernagel 1995). The method initially described by (Szybalski 1993; 
Posfai et al. 1997) is based on the yeast FLP/FRT recombination system in 
which the FLP gene product targets FRT site (FLP recombination target), a 68 
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bp recognition sequence of the yeast FLP gene product and precisely 
removes the segment of DNA which exists between the two site. The 
antibiotic marker in these Pi dependent plasmids (pKD3, pKD4, pKD13) is 
flanked by a FRT site. The plasmid pCP20 is a temperature sensitive replicon, 
expressing the FLP recombinase enzyme of S. Cerevisiae, which targets the 
FRT sites and precisely removes the antibiotic marker from the chromosome 
allowing the generation of recombinants without antibiotic selection markers 
(Martinez-Morales et al. 1999; Uzzau et al. 2001). This system has also been 
shown to be effective in the development of recombinant Salmonella strains 
for vaccine purposes, by allowing the integration of genes at the desired 
chromosomal location. (Figure 4.1, Husseiny, et al. 2005).  
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1.11.2 Effect of preexisting immune response against the 
bacterial vector 
One aspect that must be considered in using mutant Salmonella strains for 
the purpose of antigen delivery is the affect of prior immunological memory 
against the vector strain or a related strain in the animal host. This is 
particularly in case if the same vector is used to consecutively deliver different 
antigens. A negative impact of prior immunological memory might limit the use 
of intracellular bacterial for the purpose of vaccine delivery, especially in third 
world countries where bacterial infections are common and immunity against 
the vectors may be high.    
    
Several studies have been conducted to examine the effect of pre-existing 
immune response against the bacterial vector. Bao et al. (1991) first  reported 
that both serum and mucosal antibody responses in mice primed with either 
the homologous or the heterologous serotype strain were not significantly 
different. 
 
One of the studies by Whittle et al. (1997) reported that mice primed with the 
carrier strain demonstrated enhanced serum IgG titers against the foreign 
antigen. This immune enhancement was observed up to approximately 6 
months after priming. In their findings, they suggest that previous 
immunological experience with Salmonella does not limit the immune 
response to a foreign antigen carried by the same organism. In fact, prior 
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exposure to Salmonella appears to enhance the response to the foreign 
antigen. 
 
Vindurampulle et al. (2003) in his studies suggested that the factors such as 
type of Salmonella strain and antigenic determinant that is vectored by the 
bacterium, might have an influence on the outcome of the effect of prior 
immunological memory. These authors did conclude that prior immune 
responses against the bacterial vector may remain a serious limitation in 
vectored vaccination. Similar concerns were also raised by Attridge et al. 
(1997). However, as mentioned above there are contradictory reports that 
indicate a positive effect of prior immunological responses against the 
bacterial vector, therefore, it is probable that each vector and antigen 
combination will need to be individually evaluated. 
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1.12 Conclusion 
The use of attenuated Salmonella strains as vaccine delivery vehicles for 
heterologous antigen has been extensively studied in a number of animal 
species. The use of live attenuated Salmonella strains as a delivery vector to 
express heterologous antigens to the secretory immune system constitutes a 
promising approach for the development of new vaccines against a number of 
diseases. These mutants are able to establish a limited infection in the host, 
and during the natural course of infection, the bacterial vector deliver a series 
of in vivo synthesized antigens directly to B and T lymphocytes.  
 
RMIT University developed an attenuated Salmonella vaccine to protect 
poultry, calves and adult cattle against Salmonella challenge. This vaccine is 
a derivative of S. Typhimurium and is denoted as STM-1 (Salmonella 
Typhimurium Mutant-1). The STM-1 mutant harbours an aroA mutation, which 
confers complete, non-reverting aromatic biosynthesis (aro) defects (Alderton 
et al.1981).  The aroA mutation renders STM-1 non-virulent in respect to 
invasive infection, as aromatic metabolites paraaminobenzoate (for 
synthesising folate) and dihydroxybenzoate (for synthesising enterochelin) are 
not available in host tissues (Smith et al. 1984). The STM-1 derivative has 
also been used successfully for the delivery of DNA vaccines (Bachtiar et al. 
2003).  
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The aim of this project was to evaluate the efficiency of STM-1 as a vector to 
deliver heterologous antigen for vaccine purposes. Chicken ovalbumin was 
used as a model antigen and Campylobacter jejuni major outer membrane 
protein (Momp) as a test antigen to test the efficacy of STM-1 as a vector. 
Two areas of concern which might influence the utility of this approach to 
vaccine development were also investigated (i) stabilisation of antigen 
expression in the Salmonella carrier (in chapters 4 and 5) and (ii) effect of pre-
existing immune responses against the bacterial vector (Chapter 6). 
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Chapter 2 
Materials and Methods 
 
2.1 General Procedures 
All solutions were prepared in deionised H2O filtered through a Millipore Milli-
Q® water system unless otherwise specified. All media and glassware was 
sterilised by autoclaving at 121°C for 20 mins unless otherwise specified. All 
solutions from 0.02 µL to 10 mL were dispensed using Finnpipette 
micropipettes for all volumes from above 10 mL were measured using 
measuring cylinder. Glassware was washed using Pyroneg detergent followed 
by a rinse in tap water then a final rinse in deionised H2O. 
 
2.2 General Chemicals and Equipment  
10X PCR Buffer Invitrogen, USA 
10X Ligase Buffer Promega, USA 
Acetic Acid, Glacial BDH Chemicals, Australia 
Acrylamide-bis-Acrylamide (40%) BDH Chemicals, Australia 
Acetone BDH Chemicals, Australia 
Agarose (DNA Grade) Progen Industries, Australia 
Albumin, Bovine serum Sigma-Aldritch Pty. Ltd., USA 
Ammonium acetate Ajax Chemicals Ltd, Australia 
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Ammonium chloride BDH Chemicals, Australia 
Ammonium hydroxide BDH Chemicals, Australia 
Ammonium persulfate Bio-Rad Laboratories, USA 
Ampicillin CSL, Melbourne 
Anaerogen Oxoid Australia Pty. Ltd. 
Bacteriological agar Oxoid Australia Pty. Ltd. 
Balance 
 (i) Analytical Balance Sartorius GMBH, Germany 
         (ii) Balance (0.1-500g)    U-Lab, Australia 
Bromophenol blue  BDH Chemicals, Australia 
Balb/C mice ARC, Australia 
Capillary tubes BectonDickenson & Co., USA 
Carrier ampholytes Bio-Rad laboratories, USA 
Cell counter Propper MFG Co., USA 
Cell strainer BD Biosciences, USA 
Centrifuge 
 (i) Microcentrifuge Zentrifugen, Germany 
 (ii) Bench Top Centrifuge Beckman, USA 
 (iii) High Speed Centrifuge Beckman, USA 
Centrifuge Tubes 
(i) 1.5 mL Eppendorf Tubes Sarstedt, Germany 
(ii) 10 mL Centrifuge Tubes  Greiner Labortechnik, Germany 
(ii) 15 mL Centrifuge Tubes  Greiner Labortechnik, Germany 
 (iii) 50 mL Centrifuge Tubes  Greiner Labortechnik, Germany 
4-Chloro-1-napthanol Sigma-Aldritch Pty. Ltd., USA 
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Coomassie brilliant blue R-250 Bio-Rad Laboratories, USA 
Coomassie brilliant blue G-250  Bio-Rad Laboratories, USA 
Copper sulfate Ajax Chemicals Ltd., Australia 
Coverslips Mediglass, Australia 
Criterion  Bio-Rad Laboratories, USA 
Cryovials (1.8 mL) Nalgene Company, USA 
L-Cysteine BDH Chemicals, Australia 
Deoxynucleoside triphosphates (dNTPs) Roche Diagnostics, Germany 
DIG DNA Labelling and Detection Kit Roche Diagnostics, Germany 
Dithiothreitol (DTT) Bio-Rad Laboratories, USA 
DNA ligase (T4) Roche Diagnostics, Germany 
DNA polymerase (Amplitaq)   Perkin Elmer, USA 
Dye-terminator Sequencing Mix V3.1 Monash University, Australia 
Electrophoresis Units 
(i) DNA 
  a) Mini-gel Pharmacia LKB, Sweden 
  b) Midi-gel Bio-Rad Laboratories, USA 
  c) Maxi-gel Pharmacia LKB, Sweden 
(ii) Protein 
  a) Mini Protean II gel system Bio-Rad Laboratories, USA 
  b) Maxi Protean gel system Bio-Rad Laboratories, USA 
  c) Protean IEF Cell Bio-Rad Laboratories, USA 
ELISA 96 well plate  Nunc, Denmark 
ELISPOT plates Millipore, USA 
Ethylenediamine tetra acetic acid (EDTA)  BDH Chemicals, Australia 
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Ethanol  BDH Chemicals, Australia 
Ethidium Bromide Roche Diagnostics, Germany 
0.2µm, 0.45µm Filter (Acrodisc) Gelman Sciences USA 
Folin-Ciocalteus’ reagent Ajax Chemicals Ltd., Australia 
D-Glucose BDH Chemicals, Australia 
Glycerol BDH Chemicals, Australia  
Glycine BDH Chemicals, Australia 
Goat anti-mouse IgG Bio-Rad Laboratories, USA 
Goat anti-rabbit IgG Bio-Rad Laboratories, USA 
HEPES Buffer Cytosystem Pty Ltd, Australia 
Hydrochloric Acid (32%) v/v  Eqicell products Pty Ltd, 
Australia 
Hydrogen peroxide (30%) BDH Chemicals, Australia 
IL-4 capture antibody BD Pharmingen, USA 
IL-4 biotin conjugated antibody BD Pharmingen, USA 
Incubator, for tissue culture Forma Scientific, USA 
IFN-γ capture antibody BD Pharmingen, USA 
 IFN-γ biotin conjugated antibody BD Pharmingen, USA 
Imidazole Sigma-Aldritch Pty. Ltd., USA 
Iodoacetamide Bio-Rad Laboratories, USA  
IPTG Sigma-Aldritch Pty. Ltd., USA 
Isoamyl alcohol BDH Chemicals, Australia 
Isopropanol BDH Chemicals, Australia 
Kanamycin Sigma-Aldritch Pty. Ltd., USA
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Klenow enzyme Roche Diagnostics, Germany 
Lambda DNA  Pharmacia LKB, Australia 
Lithium chloride BDH Chemicals, Australia 
Low melting point agarose Progen Industries, Australia 
Lysozyme Roche Diagnostics, Germany 
Magnesium chloride Perkin Elmer, USA  
Maleic acid BDH Chemicals, Australia 
β-mercaptoethanol Bio-Rad Laboratories, USA 
Methanol BDH Chemicals, Australia 
Mulleur Hinton broth Oxoid Australia Pty. Ltd. 
Mulleur Hinton agar  Oxoid Australia Pty. Ltd. 
Microscopes  
 (i) Light Microscope Olympus Optical 
 (ii) Phase Contrast Microscope Nikon Kogaku KK, Japan 
Microscope slides LOMB scientific Co. Australia 
Microtitre plate (96 well, flat bottom) Nunc, Denmark 
NBT/BCIP substrate solution Roche Diagnostics, Germany 
Needle (19g, 21g) Terumo Pty. Ltd., Australia  
New Calf Serum  Cytosystems Pty Ltd, Australia 
Nitrocellulose membrane (Hybond-C) Amersham, USA 
Nylon Membrane (Hybond-N) Amersham, USA 
Parafilm Pechiney Plastic Packaging, 
Inc., USA 
Penicillin/Streptomycin Thermo Trace, USA 
Petri Dish Nunc, Denmark 
 54
pH meter Radiometer, Denmark 
Phenol BDH Chemicals, Australia 
Phenol/Chloroform/Isoamyl Alcohol BDH Chemicals, Australia 
Phenylmethylsulfonylfluoride Sigma-Aldritch Pty. Ltd., USA 
Phosphate Buffered Saline (PBS) Oxoid Australia Pty. Ltd. 
Polyethylene glycol 8000 Sigma-Aldritch Pty. Ltd., USA 
Potassium acetate  BDH Chemicals, Austalia 
Potassium chloride BDH Chemicals, Australia 
Potassium hydrogen carbonate BDH Chemicals, Australia 
Restriction Enzymes 
 BamHI, EcoRI, KpnI,      Promega, USA 
 SpeI, XhoI, PstI,  Promega, USA 
 MfeI New England Biolab, USA 
RNase  Roche Diagnostics, Germany 
RPMI Thermo Trace, USA 
Salmon Sperm DNA Roche Diagnostics, Germany 
SB-14 Bio-Rad laboratories, USA 
SeeBlue Protein Standards Bio-Rad Laboratories, USA 
Sheep blood Oxoid Australia Pty. Ltd. 
Silver nitrate       Sigma-Aldritch Pty. Ltd., USA 
Skim milk Bonlac Foods Ltd., Australia 
Sodium chloride       BDH Chemicals, Australia 
Sodium citrate BDH Chemicals, Australia 
Sodium dodecyl sulphate (SDS) BDH Chemicals, Australia 
Sodium hydroxide BDH Chemicals, Australia 
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Sodium lauryl sulfate  BDH Chemicals, Australia 
Sonicator Branson Sonic Power Co., 
USA 
Spectinomycin UpJohn, Australia 
Sucrose  BDH Chemicals, Australia 
Sulfuric Acid BDH Chemicals, Australia 
Syringe (1 mL, 3 mL, 5 mL,  Terumo, Pty. Ltd., Australia 
10 mL, 20 mL, 50 mL)  
TEMED Bio-Rad laboratories, USA 
TMB substrate reagent BD Pharmingen, USA 
Tissue Culture Flask (25 cm2, 50 cm2, 75 cm2) Nunc, Denmark 
Trans-blot electrophoretic transfer cell Bio-Rad laboratories, USA 
Transilluminator (UV) Bio-Rad laboratories, USA 
Tributylphosphine Sigma-Aldritch Pty. Ltd., USA 
Tris-Base  Roche Diagnostics, Germany 
Tris-HCl Roche Diagnostics, Germany 
Triton-X 100 Sigma-Aldritch Pty. Ltd., USA 
Triton-X 114 Sigma-Aldritch Pty. Ltd., USA 
Trypan Blue Sigma-Aldritch Pty. Ltd., USA 
Trypticase soya broth Oxoid Australia Pty. Ltd. 
Tryptone Oxoid Australia Pty. Ltd. 
Tween® 20  Sigma-Aldritch Pty. Ltd., USA 
Yeast extract Oxoid Australia Pty. Ltd. 
Whatman paper Whatman, England 
X-Gal Sigma-Aldritch Pty. Ltd., USA 
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XLD Medium Oxoid Australia Pty. Ltd. 
Xylene cyanol      Bio-Rad Laboratories, USA 
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2.3 Bacteriological Methods 
2.3.1 Media and Antibiotics 
2.3.1.1 Antibiotic stock solutions 
 
Ampicillin.  Ampicillin (500 mg/vial) was dissolved in 5 mL of sterile water, 
giving a stock solution of 100 mg/mL.  One mL aliquots were stored frozen at 
–20°C.  The ampicillin was added to media or other solution at the final 
concentration of 100 µg/mL. 
 
 Kanamycin.  Kanamycin was made up as a stock solution of 50 mg/mL in 
sterile water and stored in 1 mL aliquots at -20°C. The working concentration 
of Kanamycin was 50 µg/mL. 
 
Gentamycin sulfate.  Gentamycin sulfate was made up as a stock solution of 
10 mg/mL in sterile water and stored in 1 mL aliquots at -20°C. The working 
concentration was 50 µg/mL  
 
Tetracycline.  Crystalline tetracycline was made up as a stock solution of 50 
mg/mL in sterile water and stored at -20°C. The working concentration was 
50µg/mL. 
 58
 2.3.1.2 Luria Bertoni Agar 
Tryptone (1% w/v), Yeast Extract (0.5% w/v), NaCl (0.5% w/v) and Bacteriological 
Agar (1% w/v) were dissolved in deionised H2O and autoclaved at standard 
conditions. 
 
2.3.1.3 Luria Bertoni Broth 
Tryptone (1% w/v), Yeast Extract (0.5% w/v), and NaCl (0.5% w/v) was dissolved in 
deionised H2O and autoclaved at standard conditions. 
  
2.3.1.4 Muller Hinton Agar 
Muller Hinton Agar (2.1% w/v) powder was dissolved in deionised H2O and 
autoclaved at standard conditions, and then dispensed into petri dishes. 
 
2.3.1.5 Muller Hinton Broth 
Muller Hinton Broth powder was dissolved in deionised H2O (2.1% w/v) and 
autoclaved at standard conditions. 
 
2.3.1.6 Horse Blood Agar 
Trypticase Soya Broth (3% w/v) and Bacteriological Agar (1% w/v) were 
dissolved in deionised H2O and autoclaved at standard conditions.  After the 
agar had cooled, Horse blood (5% w/v) was added to the agar and the 
medium poured into petri dishes. 
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2.3.2 Bacterial Strains and Plasmids 
The bacterial strains and plasmids used in this study are listed in Table 2.1 
and 2.2. 
Table 2.1.  Bacterial strains and bacteriophage used in this study. 
Bacterial 
Strain/plasmids Genotype or description Reference/Source 
Escherichia coli 
BW25141 
 
 
 
 
BW25113 
 
 
SY327 
∆(araD-
araB)567,∆lacZ4787(::rrnB-
3),lacIp-4000(lacIQ),∆(phoB-
phoR)580,λ-
,galU95,∆uidA3::pir+, 
recA1,endA9(del-ins)::FRT,rph-
1, ∆(rhaD-rhaB)568, rrnB-3, 
hsdR514 
∆(araD-araB)567, 
∆lacZ4787(::rrnB-3), lacIp-
4000(lacIQ), rph-1, ∆(rhaD-
rhaB)568, hsdR514 
F  araD ∆(lac-proAB) 
argE(Am) rif nalA recA56 
[Datsenko and Wanner, 
2000] 
 
 
 
 
 
 
 
 
[Datsenko and Wanner, 
2000] 
 
 
 
 
[Goldberg, 1986 ] 
DH5α supE ∆lacU169 (ф80 
lacZ∆M15) hsdR17 recA1 
endA1 gyrA96 thi-1 relA1 
[Hanahan, 1983 ] 
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TOP10F’ F' [lacIq, Tn10(TetR)], mcrA, 
D(mrr-hsdRMS-mcrBC), 
f80lacZDM15, DlacX74, deoR, 
recA1, araD139 D(ara-
leu)7697, galK, rpsL(StrR), 
endA1, nupG.  
 
Invitrogen 
 
 
 
Salmonella Enteritidis 
  
SEM2 ∆aroA ,∆aroD [Moutafis, 1996] 
Salmonella Typhimurium 
LT2-9121 leu hsdL trpD2 rpsL120 ilv452 
metE551 metA22 hsdA hsdB 
Prof P. Reeves, 
Department of Microbiology,
University of Sydney 
82/6915 Wild type parent strain of STM-
1 
RMIT Biotechnology Dept 
STM-1 ∆aroA- ∆serc- RMIT Biotechnology Dept 
 
In the table below antibiotics are abbreviated as Amp, Ampicillin; Kan, 
Kanamycin; Tet, Tetracycline. Resistance to antibiotic is abbreviated as R and 
sensitivity is abbreviated as (S).  N/A denotes information not available. 
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Table 2.2.  Plasmids used in this study. 
Vector Description Reference/Source 
pBluescript IIKS 2.96 kb phagemid, LacZ, AmpR Stratagene, USA 
pCR2.1 
 
3.9 kb PCR cloning plasmid, AmpR, 
KanR 3’ T-overhang 
Invitrogen, Australia
pCRMomp pCR2.1 containing the C. jejuni major 
outer membrane gene 
This study 
pCRnirB pCR2.1 containing nirB promoter This study 
pCRova pCR2.1 containing the chicken 
ovalbumin gene 
This study 
pCRpagC pCR2.1 containing pagC  promoter This study 
pCRnirmo pCR2.1 containing the C. jejuni major 
outer membrane gene under the 
control of the nirB promoter 
This study 
pCRnirova pCR2.1 containing the chicken 
ovalbumin gene under the control of 
the nirB promoter 
This study 
pCRpagmo pCR2.1 containing the C. jejuni major 
outer membrane gene under the 
control of the pagC promoter. 
This study 
pCRpagova pCR2.1 containing the chicken 
ovalbumin gene under the control of 
the pagC promoter 
This study 
pMW2 4.4kb phagemid, LacZ, AmpR, KanR  
pMnirmo pMW2 containing the C. jejuni major This study 
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outer membrane gene under the 
control of the nirB promoter 
pMnirova pMW2 containing the chicken 
ovalbumin gene under the control of 
the nirB promoter 
This study 
pMpagmo pMW2 containing the C. jejuni major 
outer membrane gene under the 
control of the pagC promoter. 
This study 
pMpagova pMW2 containing the chicken 
ovalbumin gene under the control of 
the pagC promoter 
This study 
pKD13 3.4kb plasmid, oriR6Kγ, tL3λ(Ter), 
bla(ApR), kan, rgn(Ter) 
[Datsenko and 
Wanner 2000]. 
pKnirmo 
 
 
pKD13 plasmid carrying the C .jejuni 
major outer membrane gene under 
the control of the nirB promoter 
This study 
 
 
pKnirova 
 
pKD13 containing the chicken 
ovalbumin gene under the control of 
the nirB promoter 
This study 
 
pKpagmo  pKD13 plasmid carrying the C. jejuni 
major outer membrane gene under 
the control of the pagC promoter 
 
This study 
pKpacova pKD13 containing the chicken 
ovalbumin gene under the control of 
the pagC promoter 
This study 
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pKD46 6.3kb plasmid, repA101(ts), araBp-
gam-bet-exo, bla(ApR), oriR101 
[Detsenko and 
Wanner 2000] 
      
 64
2.3.3 Storage of Bacterial Strains and Phage 
Long term.  All bacterial strains were stored at -70°C using the Protect bead 
storage system (Technical Service Consultants Ltd., United Kingdom). 
Short term. All bacterial strains were stored on LB or MH agar plates at 4°C.  
The bacteria were passaged every 4 weeks from single colonies.   
 
 
2.3.4 Bacterial Culture Conditions 
All E. coli and Salmonella strains were grown on solid microbiological media 
under aerobic conditions at 37°C for 16 h. In instances where broth cultures 
were used, the strains were grown aerobically at 37° C for 16 h on a Ratek 
orbital shaker at 120-150x g. 
 
 
2.4 DNA Methods. 
2.4.1 DNA Extraction Techniques. 
2.4.1.1 Buffers and Reagents 
6x Loading Buffer. Sucrose (40% w/v), Bromophenol Blue (0.25% w/v) and 
Xylene Cyanol (0.25% w/v) dissolved in deionised, sterile H2O. 
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Anti-DIG Antibody Solution. Anti-DIG antibody (1:5000 Dilution) in Blocking 
solution. 
 
Alkaline Lysis Solution I.  50mMGlucose, 10mM EDTA, 25mM Tris-Cl pH 8. 
 
Alkaline Lysis Solution II. 0.2N NaOH, 1% SDS. 
 
Alkaline Lysis Solution III. 5M Potassium acetate. 
 
Blocking reagent Stock Solution. Blocking Reagent (10 g) was added to 
100 mL Maleic Acid Buffer.  The Blocking Reagent was dissolved on a heat 
plate for 1 h at 65°C with constant stirring.   After the Blocking Reagent has 
completely dissolved, the solution was autoclaved and stored at 4°C. 
 
Blocking Solution. 1% Blocking reagent (From 10% Stock Solution) diluted 
in Maleic Acid Buffer.  
 
CTAB/NaCl.  Dissolved 4.1 g of NaCl in 80 mL H2O and added 10 g CTAB 
while heating to 65°C. 
 
Detection Buffer. Tris-HCl  (100mM, pH 9.5) and 100 mM NaCl dissolved in 
dH2O. 
 
Denaturation Solution. Sodium Hydroxide (0.5 M) and  Sodium Chloride (1.5 
M). 
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dissolved in dH2O. 
 
Depurination Solution. 0.25 M HCl diluted in dH2O. 
 
ESP solution. EDTA (0.5 M), N-lauryl sarcosine (1% w/v) and Proteinase K 
(1 mg/mL), dissolved in H2O. 
 
Fluoride/TE solution (PMSF). Phenyl methyl sulfonyl fluoride (18.6 mg/mL) 
was added to 1 mL of isopropanol.   TE (25 mL) was added aseptically, and 
the solution was warmed at 37°C for 15 min. 
 
FSB solution. MnCl2·4H2O (45 mM), CaCl2·2H2O (10 mM), KCl, (100 mM), 
Hexamminecobalt Chloride (3 mM), Potassium Acetate (10 mM), Glycerol 
(10% v/v) dissolved in H2O, pH to 6.4, filter sterilised, and stored at 4°C. 
 
Isoproply-β-D thiogalactopyranoside (IPTG) (0.1 M) Stock Solution. IPTG 
(1.2 g) was dissolved in 50 mL of sterile water, filter sterilised and stored at 
4°C. 
 
Maleic Acid Buffer. Maleic Acid (0.1 M) and Sodium Chloride (0.15 M) 
dissolved in dH2O and autoclaved. 
 
Maleic Acid Wash Buffer. Tween® 20 (0.3% w/v) in Maleic Acid Buffer. 
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Neutralisation solution. Tris-HCl (0.5 M ,pH 7.5) and Sodium Chloride (3 M) 
dissolved in dH2O. 
 
PFGE lysis buffer. Tris-HCl (6 mM), NaCl (1 M) and EDTA (100 mM) 
dissolved in dH2O.    Store at 4C and sterilise before use.   To complete buffer 
prior to use, add Sodium Deoxycholate (0.2% w/v), N-lauryl sarcosine (0.5% 
w/v) and Lysozyme (1 mg/mL). 
 
PIV buffer. Tris base (10mM) and NaCl (1 M) dissolved in deionised H2O, pH 
8.0, and autoclaved. 
 
 
Standard Hybridisation Buffer. SSC (5X), 0.1% N-lauroylsarcosine, 0.02% 
SDS and 1% Blocking Reagent (From 10% stock solution) diluted in dH2O. 
 
 
20X SSC. Sodium Chloride (3 M) and Sodium Citrate (0.3 M) dissolved in 
dH2O, adjusted to pH 7.0 and autoclaved. 
 
 
2X SSC wash buffer. SSC (2X) and 0.1% SDS diluted in dH2O. 
 
 
0.5X SSC wash buffer. SSC (0.5X ) and 0.1% SDS Diluted in dH2O. 
 
 
Substrate Solution. 200 µL NBT/BCIP substrate solution diluted in 10 mL of 
detection buffer. 
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TAE Buffer 50X. Tris-base (24.2% w/v), glacial acetic acid (5.17% w/v) and 
EDTA (1.86% w/v) were dissolved in deionised water.   This was diluted to 1X 
before use. 
 
 
TBE Buffer 5X. Tris base (0.445 M), Boric acid (0.445 M) and EDTA (12.5 
mM) dissolved in H2O and adjusted to pH 8.0. 
 
 
TE buffer. Tris-base (10 mM) and EDTA (1 mM) was dissolved in water. The 
pH was adjusted as required with HCl then autoclaved. 
 
 
X-gal Stock solution. X-gal (100 mg) was dissolved in 5 mL of N,N’-
dimethylformamide and stored at –20°C. 
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2.4.1.2 Small Scale Plasmid DNA Extraction Using Qiaprep 
Mini Spin Kit 
 
Small-scale plasmid DNA extraction was achieved by using the Qiaprep Mini 
Spin Kit (Qiagen, Germany) as per the manufacturer’s instruction. The 
purification procedure was performed according to the manufacturer’s 
instructions.  
 
Briefly, 1.5 mL of an overnight culture in LB broth with the appropriate 
antibiotic was collected by centrifugation at 5,000 x g for  5 min. The bacterial 
pellet was resuspended in 250 µL of buffer P1. Two hundred and fifty 
microlitres of buffer P2 was then added and the microcentrifuge tube was 
inverted several times and incubated for no more than 5 minutes at RT to lyse 
the cells.  Protein and chromosomal DNA were precipitated with the addition 
of 350 µL of buffer N3 and then the supernatant was collected after 
centrifugation for 10 min at 14,000 x g.  The supernatant was then applied to 
a QIAprep spin column and spin for 30 s in the centrifuge and the flow-
through was discarded.  The DNA in the spin column was washed with 750 µL 
of wash buffer PE and spin for 30 s in the centrifuge. The flow through was 
discarded and the residual wash buffer was removed from the column after 
additional 1 min centrifugation. The QIAprep column was placed in a new 
microcentrifuge tube and the DNA was eluted with 50 µL of 10 mM Tris, pH 
8.0 
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 2.4.1.3 Alkaline Lysis Miniprep 
 
The alkaline lysis method was used as an alternative to the Qiaprep method 
to isolate plasmids for the purpose of enzyme restriction analysis and is based 
on the method of Birnboim and Doly (1979).  Five millilitres of LB broth 
containing the appropriate antibiotic was inoculated with a single colony of 
bacteria and grown overnight on a shaker at 37°C.  One and a half millilitres 
of the culture was placed in a microcentrifuge tube and centrifuged at 5,000 x 
g for 5 min.  The pellet was resuspended in 100 µL of ice-cold alkaline lysis 
solution I and incubated at room temperature for 5 min followed by lysis with 
200 µL of alkaline lysis solution II.  Chromosomal DNA and protein were 
precipitated with 150 µL of ice-cold alkaline lysis solution III , the tube was 
inverted several times and cooled on ice for 5 min.  The supernatant was 
collected after mixture the centrifugation of mixture for 10 min at 14,000 x g 
and the supernatant was then transferred to a new microcentrifuge tube.  An 
equal volume of phenol/chloroform (24 chloroform: 1 isoamyl alcohol) was 
added and the contents mixed vigorously by inversion.  The supernatant was 
collected after the centrifugation at 14,000 x g for 3 min.  The DNA was 
precipitated with an equal volume of isopropanol and was collected by 
centrifugation for 10 min at 14,000 x g. The DNA pellet was washed with 1 mL 
of 70% ethanol and then air-dried by placing the tube upside down on tissue 
paper for 15 min.  The DNA pellet was finally resuspended in 50 µL of 10 mM 
Tris, pH 8.0 
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2.4.1.4 Small-Scale Genomic DNA Extraction 
Genomic DNA was prepared using the procedure described in Current 
Protocols in Molecular Biology.  Briefly, 1.5 mL of an overnight culture of 
bacteria was collected after centrifugation at 14,000 x g for 2 min.  The pellet 
was resuspended in 567 µL of TE buffer, 30 µL of SDS and 3 µL of 20 mg/mL 
proteinase K.  The tube was mixed thoroughly and incubated at 37°C for 1 h.  
One hundred microlitres of 5 M NaCl was added and mixed thoroughly 
followed by the addition of 80 µL of CTAB/NaCl. The tube was incubated at 
65°C for 10 min.  An equal volume of CI was added and after mixing the tube 
centrifugation was carried at 14,000 x g for 5 min. The aqueous phase was 
removed and mixed with an equal volume of PCI, the centrifugation was 
carried at 14,000 x g for 5 min. The aqueous phase was again removed and 
the DNA was precipitated by combining with 0.6 volumes of isopropanol. The 
DNA pellet was collected by centrifugation in a microcentrifuge at 14,000 x g 
for 10 min. The pellet was rinsed with 70% ethanol and dried upside down on 
a piece of absorbent paper for 15 min. The pellet was resuspended in 100 µL 
of 10 mM Tris, pH 8.0 
 
2.4.1.5 Large-Scale Genomic DNA Extraction 
This procedure is described in Current Protocols in Molecular Biology and is 
essentially a scale-up of the small-scale genomic extraction described above.  
One hundred millilitres of bacterial culture was grown in LB, at 37°C overnight.  
The bacteria were collected by centrifugation at 4,000 × g using a Beckman 
JA-20 rotor.  The cells were resuspended in 9.5 mL TE buffer, to which 0.5 
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mL of 10% SDS and 50 µL of 20 mg/mL proteinase K was added. The 
solution was mixed and incubated at 37°C for 1 h. Subsequently, 1.8 mL of 5 
M NaCl was added followed by 1.5 mL of CTAB/NaCl solution. The mixture 
was incubated at 65°C for 20 min after which an equal volume of CI was 
added.  The solution was mixed thoroughly and the phases were separated 
by centrifugation at 6,000 × g for 10 min at RT. The aqueous phase was 
transferred to a fresh tube and 0.6 volumes of isopropanol was added. The 
DNA precipitate was transferred into a fresh tube containing 1 mL of 70% 
ethanol by using a hook made from a Pasteur pipette that had been bent and 
sealed in a Bunsen flame. The DNA was collected by centrifugation at 10,000 
× g for 5 min. The supernatant was removed and the pellet was dried. Finally 
the pellet was resuspended in 10 mM Tris, pH 8.0. 
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2.4.1.6 Ethanol precipitation 
This method was used to concentrate DNA samples by decreasing the total 
volume. One-fifth of the sample volume of 10 M ammonium acetate and 2.5 
volumes of ice-cold absolute ethanol were added to the DNA preparation.  
The sample was stored at -70° C for 30 min. The DNA was collected by 
centrifugation in an Eppendorf microcentrifuge at 9000 × g for 15 min. The 
pellet was washed twice with 70 % (v/v) ethanol and was then air-dried. The 
pellet was resuspended in 10 mM Tris, pH 8.0. 
 
2.4.1.7 Purification of DNA from agarose  
Purification of DNA from agarose gel using the Geneclean kit was performed 
according to the manufacturer’s instruction. Briefly, the DNA band was 
excised from the gel and weighed. Sodium iodide (~5 M, 3 gel volumes) and 5 
µL of 3 M sodium acetate (pH 5.2) was added to the gel slice, and the 
agarose was melted at 55°C. Glassmilk (5 µL) was added, mixed by vortexing 
and allowed to stand for 5 min at room temperature with frequent agitation. 
The glassmilk was recovered by centrifugation at 10000 x g for 30 s. The 
glassmilk was washed 3 times with 500 µL of New Wash solution, and 
recovered by centrifugation at 10000 x g for 30 s. To recover the DNA, the 
Glassmilk was dried then resuspended in 10µL of dH2O. After 5min at room 
temperature, the Glassmilk was collected by centrifugation at 10000 x g for 2 
min and the dH2O collected. 
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2.4.1.8 Purification of PCR amplified DNA 
The PCR amplified DNA was purified using Geneclean kit according to 
manufacturer’s instruction. The volume of the solution was calculated. Sodium 
iodide (~5 M, 3 times the volume) and 5µL of 3M sodium acetate (pH 5.2) was 
added to the solution.  Glassmilk (5 µL) was added, mixed by vortexing and 
allowed to stand for 5 min at room temperature with frequent agitation. The 
glassmilk was recovered by centrifugation at 10000 x g for 30 s. The glassmilk 
was washed 3 times with 500 µL of New Wash solution, and recovered by 
centrifugation at 10000 x g for 30 s. To recover the DNA, the glassmilk was 
dried then resuspended in 10 µL of dH2O. After 5 min at RT, the glassmilk 
was collected by centrifugation at 10000 x g for 2 min and the dH2O collected. 
 
2.4.1.9 Determination of DNA concentration 
DNA concentration and purity was determined by measuring the absorbance 
of the DNA sample, diluted 1/200, in matching quartz cuvettes at 260 nm 
using a Schimadzu UV-160 spectrophotometer. An OD260 of one is equal to a 
DNA concentration of 50 µg/mL. Protein contamination of the DNA was 
determined by measuring at a second wavelength of 280nm.  An OD260/OD280 
ratio was used to measure the quality of the DNA. Ratios of 1.8-2.0 indicated 
good quality DNA. 
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2.4.2 Polymerase chain Reaction. 
2.4.2.1 Primer Design. 
Primers were designed using Sci Ed Central Primer Designer 4 V 4.2. Primers 
were designed to have a %GC content between 40-60% with a Tm˚C in the 
range of 50-80˚C. 
 
2.4.2.2 General PCR procedure. 
The PCR amplifications were carried out in 25 to 50 µL reactions containing: 
2-4 U Taq DNA polymerase, 1.5 to 2.0 mM MgCl2, 50 mM KCl, 10 mM Tris-Cl 
(pH 9.0), 0.2 mM dNTPs, 50 ng to 100 ng genomic DNA or 0.1 ng to 1 ng 
plasmid DNA and 0.2 mM of each primer. The primers used in this 
investigation are listed in Table 2.4. The PCR cycling conditions were as 
follows: 
Number of cycles Temperature Duration 
1 (denaturation) 94°C 2-5 min 
30-35 (denaturation) 94°C 30 s 
30-35 (annealing) 50-65°C 30 s 
30-35 (extension) 72°C 30 s/kb 
1 (extension) 72°C 10 min 
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2.2.2.3 Expand Long Template PCR. 
The Expand Long Template DNA polymerase was either used to amplify DNA 
segment >4 kb in size or where proof reading activity was required. The PCR 
amplifications were carried out in 25 to 50 µL reactions containing: 2-4 U 
Expand Long Template DNA polymerase, Either buffer1 or buffer3, 0.2 mM 
dNTPs, 50 ng to 100ng genomic DNA or 0.1ng to 1ng plasmid DNA and 0.2 
mM each primer. The primers used in this investigation are listed in Table 2.4.   
The PCR programme for the amplification of a DNA segment was as follows: 
 
Number of Cycles Temperature Duration 
1 (denaturation) 94°C 2-5 min 
10 (denaturation) 94°C 10 s 
10 (annealing) 50-65   30 s 
10 (extension) 68°C 1min/kb 
25 (denaturation) 94 10s 
25 (annealing)  50-65 30s 
25 (extension)  68oC 1min/kb 
1 (extension)  68°C 10-15 min 
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2.4.2.4 DNA sequence analysis. 
All DNA sequencing was carried out using the ABI PRISM BigDye Terminator 
Cycle Sequencing Ready Reaction Kit according to the manufacturer’s 
instructions using the following reagents: 
 
Reagent Volume 
Terminator Ready Reaction Mix 2.0 µL 
Buffer 3.0µL 
 
Template DNA 
Double stranded DNA 
    or 
 PCR product 
 
x µL (200-500 ng) 
 
 x µL (30-90 ng) 
Primer (100 ng/mL) 0.5 µL 
Milli-Q H2O x µL 
Total volume  25.0 µL 
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 The PCR programme used for the sequencing of a DNA segment was as 
follows: 
 
Number of cycles Temperature Duration 
25 94 10s 
25 50 5s 
25 60 4min 
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Table 2.3. PCR primers used in this study 
 
Primer 
Name 
Sequence 5’→ 3’ Amplifies/ 
Purpose 
Reference Tm°C * 
AROA3.5K
BFWD  
TGCTTCTCACTGGTCG
CACTGTCCG 
aroA 3.5 kb 
downstrean 
This study 72 
AROAEND AGGCGTACTCATTCG
CGCCAGTTG 
aroA end This study 54.7 
AROA170B
P REV 
CAGGGCATTGAGCAT
ATGGCG 
aroA 170 bp 
downstream 
rev 
This study 66 
SERCFWD TGACAGACGCTCGAA
GTATTCGCC 
serC gene  This study 68 
YCAP FWD TTGCAACGAATGGCG
CTGGATAACG 
ycaPgene  This study 70 
YCAP REV TTAGCCCGGCTTGCC
TTCGTCCA 
ycaPgene This study 72 
YCAO FWD AAGACGCCGCGCTGG
AAGACTCCAT 
ycaO gene 
fwd 
This study 74 
YCAO REV TTTGACCAGTATGCCG
CTTTCGC 
ycaO gene  
rev 
This study 68 
FCAO FWD ATAGACGCCTGCTTCT
TCAGCC 
fcaO gene This study 64 
PFLB FWD GCGTGAAGGTACGAG
TAATAACGTCC 
pflB gene This study 67 
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PFLB REV CACTCCGTATGAGGG
TGACGAGTCC 
pflB gene This study 69 
SOPD FWD GCGTCGCATTCAACG
CGCAATCAGG 
sopD gene This study 73 
SOPD REV AGGCTCCATATCAGT
GGGGC 
sopD gene This study 65 
GTRA FWD GAGCGCCGTTGTTGG
CTGGATGG 
gtrA gene This study 72 
GTRA REV TAGCAGCATTCGCGC
AGCCTGCC 
gtrA gene This study 74 
RPSA REV TCCAGGTGCAGAGTA
TCACGCACCG 
rpsA gene This study 72 
MOMP 
FWD 
TATTAGATCTTGACAA
GGAGAATTCTCATG 
C. jejuni 
major outer 
membrane 
gene 
This study 62 
MOMP REV GAGCGCTAGCCCGCC
TTGAAGTTAGCTTG 
C. jejuni 
major outer 
membrane 
gene 
This study 74 
OVA FWD GGAATTCCATGGGCT
CCATCGGTGCAG 
Chicken 
ovalbumin 
This study 73 
OVA REV GGAATTCTGGGTCTT
GTTGGAAGGG 
Chicken 
ovalbumin 
This study 67 
PAGFWD CTCTGGATCCTAATG pagC gene [Dunstan, 64 
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GGTTTATAGCG promoter 1999] 
PAGCREV AATAGATCCAATTGCA
ACTCCTTAAT 
pagC gene 
promoter 
[Dunstan, 
1999] 
60 
NIRBFWD GCCGGATCCTTGAAC
ATAGTGGTCCGC 
nirB gene 
promoter 
[Dunstan, 
1999 ] 
71 
NIRBREV GACTTTGCCAATTGTT
GCCTCGATTC 
nirB gene 
promoter 
[Dunstan, 
1999] 
67 
M13 REV CAGGAAACAGCTATG
AC 
Sequencing 
primer 
 44.5 
M13 –20 GTAAAACGACGGCCA
G 
Sequencing 
primer 
 45.8 
* Melting temperature was calculated by S.E central software. 
Green sequence indicates an EcoRI site. 
Blue sequence indicates a MfeI site. 
Purple sequence indicates a BamHI site. 
. 
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2.4.3 Recombinant DNA techniques 
2.4.3.1 Cloning of PCR product 
  
The PCR amplified genes were inserted into pCR2.1 according to the 
manufacturer’s instruction. Briefly, the PCR product was analysed by gel 
electrophoresis and the concentration of DNA estimated. The PCR product (1 
ng) was mixed with 10x ligation buffer (1 µL), pCR2.1 Vector (2 µL), T4 DNA 
Ligase (1 µL), and the reaction was made up to 10 µL with dH2O. The ligation 
was incubated overnight at 16°C. After brief centrifugation of the ligation 
reaction the tubes were placed on ice. Vials of One Shot® competent cells 
were thawed on ice. The cells were mixed with 2 µL of the ligation, and 
incubated on ice for 30 min. The cells were then heat shocked for 30 s in a 
42°C water bath. 
 
Following transformation, 250 µL of SOC was added to the vial, and the cells 
were allowed to recover at 37°C for 1 h. Transformations (10 µL and 100 µL) 
were then spread plated onto LB agar containing X-gal and either 50µg/mL 
Kanamycin or 100 µg/mL Ampicillin. Plates were incubated overnight at 37°C, 
and white colonies were selected for analysis. 
 
2.4.3.2 Restriction Enzyme Digestion 
Table 2.4 summarises the restriction endonucleases and their DNA 
recognition sequences used in this study. Usage of all enzymes was 
according to manufacturer’s instructions 
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DNA was digested using the following formula: 
 
Reagent Volume
DNA 100 ng 
10X Buffer 4 µL 
RE 1 U 
H2O Up to 40 µL 
 
 
Digestions were performed in a total volume of 40 µL and incubated at 37°C 
from 4 h to overnight 
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Table 2.4. Restriction endonucleases and their DNA recognition 
sequences used in this study 
Restriction 
Endonuclease 
Recognition Sequence 
BamHI G/GATCC 
DpnI GA/TC 
EcoRI G/AATTC 
EcoRV G/ATATC 
KpnI GGTAC/C 
MfeI C/AATTG 
NotI GC/GGCCGC 
PstI CTGCA/G 
SacI GAGCT/C 
XbaI T/CTAGA 
XhoI C/TCGAG 
 
2.4.3.3 Phophatase Treatment of vectors 
Plasmids were treated with alkaline phosphatase incubating 1 µg of digested 
plasmid DNA with 0.05 U of calf-intestinal alkaline phosphatase in the 
appropriate buffer for 1 h. The reaction was stopped by adding 0.5 M EDTA 
and heat inactivating the enzyme at 65°C for 15 min. 
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2.4.3.4 Ligation of DNA. 
DNA was ligated using the following formula: 
Reagent Volume 
Plasmid 100 ng 
Insert DNA Variable 
10 Ligase Buffer 1 µL 
T4 DNA ligase 1 U 
 
Ligations were made up to 10 µL using dH2O. The total amount of insert DNA 
was calculated using the following formula. 
 
ng of vector X size of insert (kb) X 3  = ng of insert 
 size of vector (kb)  1 
2.4.3.5 Transformation of DNA 
2.4.3.5.1 Preparation of Competent Cells 
Bacterial cells were grown in 10 mL of LB broth on a shaker at 37°C for 16 h.  
Two millilitres of this culture was used to inoculate 200 mL of pre-warmed LB 
broth in a flask and shaken vigorously at 37°C until approximately mid-log 
phase, an absorbance at 600 nm of 0.4-0.5, was reached. The cells were 
chilled on ice for 30 min and collected by centrifugation at 4000 × g for 10 min 
at 4°C. The supernatant was completely drained off before the cells were 
washed in 200 mL of ice-cold H2O and collected by centrifugation at 4000 × g 
for 10 min. This step was repeated with 100 mL of ice-cold H2O. The cell 
pellet was resuspended in 10 mL of ice-cold 10 % glycerol and centrifuged as 
 86
before. The cells were resuspended in a final volume of 1 mL of ice-cold 10 % 
glycerol and divided into aliquots of 40-50 µL each and stored at -70°C. 
 
2.4.3.5.2 Electroporation of Competent Cells 
Frozen electro-competent cells were thawed on ice for 15 min and mixed with 
DNA in a volume of up to 2 µL and transferred to an ice-cold electrocuvette 
with a 0.2 cm gap. The pulse settings used to deliver DNA into the cells were 
2.5kV, 25mF and 200Ω. After the pulse, 1 mL of SOC medium was 
immediately added to the cells and they were incubated at 37°C for 1 h.  One 
hundred microliters of transformed culture was plated out onto LB agar 
containing the appropriate antibiotic or X-gal plates. The remaining 
transformation mixture was concentrated by centrifugation at 5000 x g for 5 
min and resuspending in 100 µL of SOC medium. This was also plated onto 
LB containing the appropriate antibiotic. 
 
2.4.3.5.3 Chemical Transformation 
A 200 mL LB broth was inoculated with 2 mL of an overnight culture. The 200 
mL culture was grown for 2h-3h at 37°C until approximately mid-log phase, 
until absorbance at 600 nm was 0.4, was reached. Cells were harvested by 
centrifugation at 5000 x g for 20min at 4°C. Cells were washed in 40mL of ice-
cold FSB. After centrifugation at 5000 x g for 20 min at 4°C, cells were 
resuspended in 2 mL of FSB. Cells were dispensed in aliquots of 200 µL into 
microfuge tubes. The fresh competent cells were used for the ligation. Five to 
ten microliter of the ligation reaction or 50 ng of plasmid DNA was added to 
200 µL competent cells. The cells were mixed by pipetting, and incubated on 
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ice for 30 min. To perform the tranformation, competent cells were transferred 
to a 42°C water bath for 2 mins. The transformations were incubated on ice 
for 2 min, and then 1 mL of LB broth was added. The transformants were 
allowed to recover at 37°C for 1 h, 100 µL of the culture was spread onto an 
LB agar plate containing the appropriate antibiotic and incubated at 37°C 
overnight. 
 
2.4.3.6 Chromosomal Integration of Constructs. 
2.4.3.6.1 Lambda Red System 
STM-1 was transformed with the pKD46 plasmid after the plasmid was 
passaged through the LT2 strain. Fresh STM-1/pKD46 competent cells were 
prepared by growing STM-1/pKD46 overnight in 100 µg/mL ampicillin at 30oC. 
One hundred millilitres of overnight culture was used to inoculate 100 mL MH 
broth containing 50 mM L-arabinose and 100 µg/mL ampicillin. The culture 
was grown at 30oC until approximately mid-log phase, an absorbance at 600 
nm of 0.4-0.5, was reached. The competent cells were prepared according to 
the method described in section 2.4.4.1. The pKD13 plasmid in which all the 
constructs were ligated was used as template to generate PCR products (see 
chapter 4). The PCR product was digested with DpnI restriction enzyme to 
remove any residual plasmid template. Fifty to one hundred nanograms of 
purified PCR product was used to transform fresh STM-1/pkD46 competent 
cells. The pulse settings used to deliver DNA into the cells were 2.5 kV, 25 
mF and 200 Ω. After the pulse, 1 mL of SOC medium was immediately added 
to the cells the transformants were allowed to recover at 30oC for 2 h. One 
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hundred microlitres of the culture was spread onto an MH agar plate 
containing 50 µg/mL kanamycin and incubated at 37°C overnight. The 
remaining transformation mixture was concentrated by centrifugation at 5000 
x g for 5 min and resuspended in 100 µL of SOC medium. This was also 
plated onto MH agar plate containing 50 µg/mL kanamycin. 
 
2.4.3.7 Pulsed Field Gel Electrophoresis. 
STM-1 and the parent strain was inoculated in 5 mL LB and grown at 37°C for 
3-4 h. The bacterial cells were collected after centrifugation. The cells were 
washed in PBS. The cells resuspended in 250 µL of PIV buffer on ice. 
 
The cell suspension was mixed with an equal volume of 2% low melting point 
agarose (dissolved in PIV buffer) and poured into sterile, pre-chilled moulds. 
The plugs were allowed to set, then placed in 0.5 mL PFGE lysis buffer 
overnight at 37°C. The following day, the plugs were allowed to harden at 4°C 
for 20 min, placed in 0.5 mL of ESP solution and incubated at 50°C overnight.   
The following day, the plugs were hardened at 4°C for 20 min, and then 
incubated in 0.5 mL of Fluoride/TE solution at 37C for 2 h. The plugs were 
then washed 6 times in TE buffer over 6 h at 37°C. Plugs were stored in TE 
Buffer at 4°C for up to 6 months. 
 
A portion of the DNA plug was cut and washed in 1 X RE buffer. The plug 
portion was then placed in 80 µL of restriction enzyme solution, consisting of 
2.5 µL (25U) of XbaI, 8 µL of 10 X RE buffer, 5 µL of 1 mg/mL bovine serum 
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albumin (BSA) and 64.5 µL of sterile deionised H2O. The DNA was digested 
for 6-8 h at 37°C.  One percent agarose midigel was set in 1X TBE.  Following 
restriction enzyme digestion, the DNA plugs were inserted into the wells of the 
set, chilled agarose gel and the wells were sealed with the 2% low melting 
molten agarose. The agarose gel was then subjected to PFGE at 220 V for 22 
h with the pulse time ramped from 2.2-63.8 s. The gel was stained in ethidium 
bromide and examined by UV transillumination. 
 
2.4.3.8 Southern Blotting  
2.4.3.8.1 Probe Synthesis 
The aroA, pflB and gtrA gene products were labelled as probes. The genes 
were amplified using S. Typhimurium genomic DNA as template and the PCR 
product was purified. The labelling was performed using the DIG DNA 
Labelling and Detection kit based on the random priming system. All 
procedures were carried out according to the manufacturer’s instructions 
using digoxigenin (DIG)-dUTP as the label. The concentration of DNA was 
estimated and 3 µg of template was diluted to 15 µL with dH20. The mixture 
was heated to 100°C to denature the template and then chilled on ice.   
Klenow enzyme (1 µL) and 10x DNA labelling mix (2 µL) were then added to 
the reaction and incubated at 37°C overnight.  After incubation, the probe was 
denatured by boiling for 10 min, and diluted in Southern Blot hybridisation 
solution at a concentration of 10-25 ng/mL. 
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The concentration of the probe was determined by a spot test with DIG-
labelled control DNA. The DIG-labelled control DNA was diluted to 1 ng/µL.  
From this stock, five 1:10 serial dilutions were made, creating a set of 
standards ranging from 1 ng/µL to 0.01 pg/ µL. After estimating the 
concentration of experimental probe from the DIG System User’s Guide for 
Filter Hybridisation, the experimental probe was diluted to approximately 1 
ng/µL. From this stock, five 1:10 serial dilutions were made. 
 
A piece of nylon membrane was spotted with 1 µL of these standards in one 
row, then with 1 µL of the experimental probe on a second row. The 
membrane was then cross-linked under UV light for 5 min. The membrane 
was washed in 2 x SSC wash buffer briefly, and then incubated for 30 min in 
blocking solution at room temperature. The membrane was then incubated in 
Anti-DIG Antibody Solution for 30 min at room temperature. The membrane 
was washed twice for 15 min each with wash buffer at room temperature to 
remove any unbound antibody. The membrane was equilibrated in detection 
buffer for 2 min, and then developed substrate solution. To stop the colour 
development, the membrane was washed with dH2O. The intensity of the 
experimental probe spots was then compared to the standard DIG-Labelled 
control DNA spots to determine the probe concentration. 
 
2.4.3.8.2 Transfer of DNA to the Nylon Membrane 
STM-1 and parent strain genomic DNA was digested with SacI restriction 
enzyme. Approximately 3-5µg genomic DNA was digested in the total volume 
of 50 µL using 10 U of enzyme in a total volume of 50 µL. The digestion was 
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incubated at 37°C for 20 h. The digested DNA was subjected to 
electrophoresis in a 1% agarose gel for 2 h at 80 V. After electrophoresis, the 
gel was washed in depurination solution for 10 min then rinsed with water. 
The gel was washed twice in denaturing solution for 10 min each, followed by 
two 15 min washes in neutralisation solution. The DNA was transferred to the 
nylon membrane via capillary transfer. The transfer to the nylon membrane 
was achieved by placing the membrane on top of the gel followed by at least 
four sheets of 3MM Whatman paper, approximately 30 sheets of paper 
towels, a glass plate and a 1 kg weight on top of the glass. The baking dish 
was filled with 20 x SSC and the Whatman paper was soaked in 20 x SSC for 
capillary transfer. The transfer was allowed to proceed overnight. 
 
Following the transfer, the membrane was air dried then wrapped in plastic 
sandwich wrap and placed on top of a UV transilluminator for 5 min. to allow 
cross linking of DNA to the membrane. 
 
2.4.3.8.3 DNA Hybridisation  
The membrane was incubated at 65°C for 3 h in standard hybridisation 
solution. The denatured probe was added to the hybridisation solution at a 
concentration of 20 ng/mL and the membrane then incubated overnight at 
65°C. 
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2.4.3.8.4 Washing and Development of Membrane 
 
The membrane was washed twice with 2 x SSC wash buffer for 5 min at room 
temperature, and then washed twice in 0.5 x SSC wash buffer for 15 min at 
65°C. Following the stringency washes, the membrane was equilibrated in 
maleic acid wash buffer, and then incubated in blocking solution for 1 h at 
room temperature. The blocking solution was replaced with Anti-DIG Antibody 
Solution and incubated for 1 h at room temperature. Unbound antibody was 
removed by two washes in maleic acid wash buffer for 10 min at room 
temperature. Substrate solution was then added and the membrane placed in 
the dark until a colour precipitate had formed. 
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 2.5 Protein Methods 
2.5.1 Buffer and Solutions 
Ammonium Persulfate (10%). Ammonium Persulfate (100 mg) was 
dissolved in 1 mL of dH2O and filter sterilised through a 0.22 µM syringe filter.   
The solution was stored at 4°C wrapped in foil for up to 3 months. 
 
Bradford Coomassie Reagent. Coomassie Brilliant Blue R-250 (0.05% w/v) 
was dissolved in ethanol (25 mL, 95%) and Phosphoric Acid (50 mL, 88%), 
then diluted with water to 500 mL. Store at 4°C, filter before use. 
 
Cell lysate buffer. Tris-HCl (0.1 M, pH 6.8), SDS (2% w/v) and glycerol (15% 
v/v) were dissolved in water. 
 
Coomassie Stain. Coomassie Brilliant Blue R-250 (0.05% w/v) was dissolved 
in methanol (250 mL) and Acetic Acid (50 mL). After the Coomassie Brilliant 
Blue had dissolved, the solution was diluted to 500 mL with dH2O (Final 
concentration 50% Methanol, 10% Acetic Acid). 
 
Coomassie Destaining Reagent. Ethanol (10% v/v) and Acetic Acid (10% 
v/v) was diluted in dH2O. 
 
Lowry Folin Reagent. Folin-Ciocalteau reagent was mixed with dH2O at a 
1:1 ratio. 
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 Lowry Reagent A. Sodium Carbonate (2% w/v), Sodium Hydroxide (0.4% 
w/v), sodium tartrate (0.16% w/v) and SDS (1% w/v) dissolved is dH2O. 
  
Lowry Reagent B. Copper sulfate (4% w/v) dissolved in dH2O. 
 
Lowry Reagent C. Lowry Reagent A (50 mL) and Lowry Reagent B (0.5 mL) 
were mixed before use. 
 
Outer membrane protein (OMP) Extraction Buffer. Tris base (50 mM) and 
EDTA (10 mM) was dissolved in deionised H2O, then 0.05% TritonX-114 was 
added. 
 
10x PAGE Running Buffer. Tris Base (3% w/v), Glycine (14.4% w/v) and 
SDS (1% w/v) was dissolved in dH2O, pH 8.3. Dilution of 1x was used for 
electrophoresis. 
 
PAGE Sample Buffer. Glycerol (25% v/v), Tris Base (60 mM), SDS (2% w/v), 
β-mercaptoethanol (14.4mM), Bromophenol blue (01%) were dissolved in 
dH2O. 
 
PBS. 0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M 
sodium chloride, pH 7.4. 
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SDS-PAGE Sample Buffer. Tris-HCl (125 mM, pH 6.8), β-mercaptoethanol 
(5% w/v), Bromophenol blue (0.02% w/v) and glycerol (10% v/v) in dH2O. 
 
TBS. Tris Base (10 mM) and NaCl (500 mM) was dissolved in deionised H2O, 
pH 7.4, then autoclaved at standard conditions. 
 
TBS/Tween. Tween 20 (0.05%) was added to TBS. 
 
TE Buffer. Tris Base (10 mM) and EDTA (1 mM) were diluted in dH2O, pH 
7.5, and autoclaved at standard conditions. 
 
Western Blot Blocking Solution. Skim milk (5%) was dissolved in TBS. 
 
Western Blot Substrate Solution. The substrate, 4-Chloro-1-Naphthol (30 
mg), was dissolved in 10 mL of Methanol. This solution was added to 40 mL 
Tris (50 mM), and 30 µL of H2O2 pH 7.0. 
 
2.5.2 Protein Extraction Method 
2.5.2.1 Sonication. 
Cells were harvested by centrifugation at 5000 x g for 10 min and 
resuspended in PBS buffer. The cell suspension was then sonicated in an ice 
bath for 6 cycles of 30 s on and 30 s off. The lysate was clarified by 
centrifugation at 5000 x g for 10 min to remove cellular debris, and the 
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supernatant collected. The protein concentration was determined by the 
Bradford assay and the lysate was stored at –20°C if not used immediately. 
 
2.5.2.2 Preparation of Whole Cell Lysates 
An overnight culture of bacteria in 10 mL LB broth was collected by 
centrifugation and washed in 2 mL of Tris-HCl (10mM, pH 7.4). The cell pellet 
was lysed with cell lysate buffer and boiled for 5 min. The supernatant was 
collected by centrifugation and transferred to a new tube and the protein 
concentration was determined using the Lowry method. 
 
2.5.3 Determination of Protein Concentration. 
2.5.3.1 Lowry Assay. 
A Lowry assay was used for protein estimation when the presence of SDS 
prevented the use of a Bradford assay. A standard curve was set up from a 1 
mg/mL BSA stock at 0, 10, 20, 30, 50, 70 and 100 µg/mL in a total volume of 
200 µL in H2O. Test samples were diluted 1:200 in a total volume of 190 µL in 
H2O. Lowry Reagent C (0.6 mL) was added to each tube and incubated for 20 
min at RT. Lowry Folin Reagent (0.06 mL) was added to each tube and 
incubated for 30 min at RT. An aliquot (200 µL) of each sample was added to 
a 96 well plates and absorbances read at 600 nm. 
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2.5.3.2 Bradford Assay. 
A standard curve was set up from a 1 mg/mL BSA stock at 30, 60, 90, 120, 
150, 180 and 210 µg/mL in 0.15 M NaCl. Test samples were diluted 1/10 with 
0.15 M NaCl in a total volume of 100 µL. Bradford reagent (1mL) was added 
to each standard and test solution and incubated at room temperature for 2 
min. Samples (200 µL) were loaded in duplicate into 96 well plates, and 
absorbances read at 600nm. 
 
 
2.5.4 Recombinant Protein Expression 
Recombinant protein was expression occurred after inducing the nirB or pagC 
promoters. To induce the nirB promoter, 10 mL LB broth was inoculated from 
a glycerol stock and cultured for 8-10 h. The culture was resuspended in 50 
mL LB broth were incubated without aeration at 37°C for 4–6 h (some cultures 
were flushed with nitrogen and sealed prior to static incubation). 
 
To induce the pagC promoter 10 mL LB broth was inoculated from a glycerol 
stock and cultured for 8-10 h. The log-phase bacteria were washed once in 
M9 medium, then resuspended in M9 medium plus supplements (0.1% 
Casamino Acids, 38 mM glycerol, aromatic supplements) and grown at 37oC 
for 3-5 h under static condition.  
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2.5.5 Polyacrylamide Gel Electrophoresis. 
2.5.5.1 SDS-PAGE. 
Polyacrylamide mini-gels were prepared according to the following formula: 
 
12.5% Resolving gel. 
Reagents Volume 
Water 4.22 mL 
1.5 M Tris (pH 8.8) 2.5 mL 
10% SDS 0.1 mL 
Bis-Acrylamide (40%) 3.135 mL 
10% Ammonium persulfate 0.05 mL 
TEMED 0.01 mL 
Total volume 10 mL 
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 4% Stacking Gel 
Reagent Volume 
Water 3.580 mL 
0.5 M Tris (pH 6.8) 1 mL 
10% SDS 0.04 mL 
Bis-Acrylamide (40%) 0.375 mL 
10% Ammonium persulfate 0.01 mL 
TEMED 0.0005 mL 
Total 5 mL 
 
SDS-PAGE loading buffer was added to samples to be analysed in a 4:1 
sample to buffer ratio. Prepared samples were then heated to 100°C for 10 
min in a heat block. SDS-PAGE gel wells were loaded with 20 µL of sample 
using a syringe.  SDS-PAGE was performed at 80 V for 30 min then 180 V for 
50 min. 
 
2.5.6 Visualisation of Proteins. 
2.5.6.1 Coomassie Staining. 
The gel was stained with Coomassie Blue Stain for at least 1 h with gentle 
agitation, and then destained in destaining solution, with several solution 
changes, until protein bands were clearly visible. 
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2.5.6.2 Western Blot. 
2.5.6.2.1 Transfer of Protein to Nitrocellulose Membrane. 
Following PAGE, the gel and a piece of nitrocellulose membrane were soaked 
in western blot transfer buffer. Two scotch-brite pads and 3 pieces of 
Whatman paper were cut slightly larger than the gel and soaked in Western 
Blot Transfer Buffer. To assemble the Western Blot, a pad was placed on the 
apparatus, followed by the gel, the membrane, the Whatman paper, and 
another pad. The air bubbles were removed by using glass rod. The 
apparatus was assembled according to the manufacturer’s instructions, and 
the western blot was performed at 90 V for at least 1 h. 
 
2.5.6.2.2 Development of nitrocellulose membrane. 
The nitrocellulose membrane was blocked for 1 h in TBS/Skim milk (5% v/v) 
at RT. The blocking solution was discarded and the membrane was washed 3 
times in TBS/Tween (0.05% v/v). The Primary Antibody was diluted in 
TBS/Skim Milk (1% v/v), added to the membrane and incubated for at least 1 
h at room temperature or overnight at 4°C. The Primary Antibody Solution 
was discarded and the membrane washed twice for 10 min in TBS/Tween 
(0.05% v/v). The Detection Antibody was diluted in TBS/Skim Milk (1% v/v), 
added to the membrane and incubated for 1 h shaking at RT. The membrane 
was washed twice in TBS/Tween (0.05% v/v), once in TBS. The membrane 
was developed by the addition of western blot substrate solution and 
incubated in the dark until colour developed. 
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2.6 Animal Experimentation Methods. 
All experiments involving animals were carried out with the approval of the 
RMIT AEC. 
 
2.6.1 Buffers and Reagents. 
ACK Lysing Buffer. NH4Cl (0.15 M), KHCO3 (10 mM) and Na2EDTA (0.1 
mM) dissolved in H2O, pH to 7.3 with 1 N HCl, and filter sterilised through a 
0.2 µM filter. 
 
Carbonate Buffer 1. NaHCO3 (8.4 g) was added to 100 mL of H2O. Stored at 
4°C. 
 
Carbonate Buffer 2. Na2CO3 (10.6 g) was added to 100 mL of H2O. Stored at 
4°C. 
 
ELISA Substrate Solution.  Equal volumes of reagent A and reagents B of 
TMB substrate was mixed immediately before use. 
 
ELISPOT Blocking Buffer. Newborn Calf Serum (5% v/v) was filter sterilised 
into sterile PBS. Made fresh as required. 
 
ELISPOT Coating Buffer. Carbonate buffer 1 (4.53 mL) was added to 
Carbonate buffer 2 (1.82 mL) and diluted to 100 mL with H2O. The pH was 
adjusted to 9.6 with either Carbonate buffer 1 or 2. Made fresh as required. 
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ELISPOT Detection Solution. BCIP/NBT solution, prepared according to the 
manufacturers instructions. BCIP (100 µL) and NBT (100 µL) was added to 10 
mL of BCIP/NBT Buffer. 
 
PBS. Phosphate buffer (0.01 M), 0.0027 M potassium chloride and 0.137 M 
sodium chloride, pH 7.4. 
 
PBS/T. Phosphate buffer (0.01 M), 0.0027 M potassium chloride and 0.137 M 
sodium chloride, pH 7.4, autoclaved at standard conditions. Tween 20® 
(0.05% v/v) was then added. 
 
RPMI/NCS. Newborn Calf Serum (5% v/v) was filter sterilised, added to RPMI 
and stored at 4°C. 
 
RPMI/NCS/Abs. Newborn Calf Serum (5% v/v) was filter sterilised and added 
to RPMI. Penicillin/Streptomycin (0.1% v/v) was then added to the RPMI and 
stored at 4°C. 
 
2.6.2 Vaccination with recombinant STM-1 expressing 
heterologous antigenic protein. 
Cultures of recombinant STM-1 were grown for vaccination using the following 
method. Five millilitre LB broth containing the appropriate antibiotic was 
inoculated from a –70°C Stock of STM-1 harbouring plasmid constructs and 
chromosomal integrants and grown overnight at 37°C. The following day, a 
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100 mL LB broth containing the appropriate antibiotic for plasmid constructs 
and without antibiotic for chromosomal integrants, was inoculated with 1 mL of 
the overnight culture. This culture was incubated for 3-5 h at 37°C, until an 
absorbance at 600 nm was 0.3 was obtained. The STM-1 were recovered by 
centrifugation at 5000 x g for 15 min at 4°C. The cell pellet was washed twice 
in 10 mL of PBS, before being resuspended at a concentration of 2 x 109 
cells/mL. Mice were vaccinated with 5 x 108 CFU of recombinant STM-1 for 
oral inoculation and 1 x 106 CFU of recombinant STM-1 for intraperitoneal 
inoculation. 
 
2.6.3 Blood collection. 
Mice were bled by retro-orbital puncture, and the serum was collected by 
centrifugation at 1000 x g for 10 min. Typically 100-200 µL of blood was 
collected. The serum was seperated and stored at –20°C. 
 
2.6.4 Preparation of Faecal pellets for ELISA. 
Fresh faecal pellets were collected three weeks after the final vaccination and 
were prepared by the method adapted from deVos and Dick (1991). 
Approximately 5-6 fresh faecal pellets were collected from each group and 
stored in a microfuge tube. One millilitre of PBS was added for 0.1 g of 
faeces, and the tube was vortexed vigorously for 15 min. The supernatant 
was collected after centrifugation at 15000x g for 15 min. One millimolar 
phenyl methyl sulfonyl fluorise (PMSF) was added and the samples were 
stored at -20°C. 
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 2.6.5 ELISA to detect antibody levels. 
Purified antigen was diluted to 10 µg/mL in Carbonate Coating Buffer and 100 
µL was added to 96 well plates and allowed to incubate overnight at 4°C.   
Plates were washed in PBS/T 3 times and then blocked for 1 h at RT in 
PBS/Skim milk (5% v/v). Serum was diluted in PBS/T and Skim milk (1% v/v) 
at the appropriate concentration and 100 µL was added to each well in 
duplicate. Serum was incubated for 2 h at 37°C. Plates were washed 3 times 
in PBS/T, and any remaining liquid was removed by tapping the plates on 
paper towels. Detection antibody (mouse anti-IgG H+L or mouse anti-IgA) 
was then diluted in appropriate concentration in PBS/T and 100 µL was added 
to each well. The detection antibody was incubated for 1 h at RT. Plates were 
then washed 4 times in PBS/T and twice in PBS. Any remaining liquid was 
removed from the wells by patting the plates on absorbent paper towels. One 
hundred microliters of substrate was added to each well and allowed to 
develop for 30 min. The reaction was then stopped by the addition 50 µL of 
0.2 N H2SO4.  Absorbance were then measured on and ELISA plate reader at 
an absorbance of 450 nm. 
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2.6.6 ELISPOT assay for cytokine producing cells. 
 
2.6.6.1 Collection of Spleen Cells. 
Mice were sacrificed and their spleens collected in sterile RPMI/NCS/Abs.  
Spleens were placed in petri dishes, crushed with the end of a 3 mL syringe 
and resuspended in 5 mL of RPMI/NCS and filtered through a cell strainer. 
The cells were recovered by centrifugation at 800 x g for 5 min at 4°C and 
resuspended in 5 mL of ACK Lysing Buffer. After 5 min, 5 mL of RPMI/NCS 
was added and the cells recovered by centrifugation at 800 x g for 5 min at 
4°C. The lymphocytes were washed in RPMI/NCS 3 times, and resuspended 
in 1 mL of RPMI/NCS. Recovered lymphocytes were counted by diluting 1 µL 
of the cell suspension in 89 µL of PBS. The solution to be counted was 
prepared by adding 10 µL of Trypan Blue reagent. After 5 min, 10 µL of the 
stained cells was loaded onto a haemocytometer, and the number of viable 
cells counted under an inverted microscope. 
 
2.6.6.2 ELISPOT assay. 
The ELISPOT plate was prepared by wetting the membrane with 100% 
Methanol for 5 min, followed by three washes in sterile PBS. Capture antibody 
(100 µL) was diluted in ELISPOT Coating Buffer and added to the wells (0.5 
µg/mL IL-4, 1 µg/mL IFN-γ) and incubated overnight at 4°C. The capture 
antibody was discarded and the wells washed three times with 200 µL of 
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PBS/T. The wells were blocked with 100 µL of ELISPOT blocking buffer and 
incubated at room temperature for 3 h.    
 
The wells were washed three times with 200 µL of PBS/T, then 100 µL of 
RPMI/NCS (5 % v/v) was added and the plates were incubated for 10 min at 
37°C and 5% CO2. The RPMI was discarded and the cells were seeded in 
quadruplets with 1x106 cells in 90 µL/well. The fourth well served as an 
internal control. Ten microlitre antigen (chicken ovalbumin or C. jejuni 
membrane preparation) was added at concentration 250 µg/mL in the three 
wells. No antigen was added in the fourth well, and concavalin A was added 
to the positive control wells at a concentration of 1µg/mL. The negative control 
was unstimulated spleen cells. The spleen cells were incubated with the 
mitogen for 20 h at 37°C and 5% CO2. 
 
The following day, the spleen cells were discarded and the plates washed 6 
times in PBS/T, and twice with MiliQ water, and any remaining wash solution 
removed by tapping the plates on absorbent paper. The biotin labelled 
detection antibody was diluted at a concentration of 0.5 µL/mL PBS/NCS (1% 
v/v), and 100 µL was added to the wells and incubated at RT. After 2 h of 
incubation, the wells were washed in PBS/T 5-6 times and the remaining 
solution removed by tapping the plates on absorbent paper towel. After 
washing, 100 µL of alkaline phosphatase labelled streptavidin was added to 
the wells, and incubated at RT for 2 h. The streptavidin solution was 
discarded and the plates were washed 7 times with PBS/T and 3 times in PBS 
and any remaining liquid was removed by tapping the plates on absorbent 
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paper. The ELISPOT was developed by the addition of 50 µL of ELISPOT 
substrate solution and incubated at room temperature in the dark until blue 
spots developed. The reaction was then stopped by washing the plates 3 
times in de-ionised water. Spots were counted under a dissecting microscope. 
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Chapter 3 
Characterisation of the STM-1 strain of 
Salmonella enterica serovar Typhimurium 
 
3.1 Introduction 
Salmonella Typhimurium infects a wide variety of animals, and is one of the 
causative agents of diarrhoeal diseases in humans, and it also causes 
typhoid-like symptoms in mice (Pang et al. 1995).  Consumption of food from 
animal origin is the major cause of Salmonella spp. infection in humans. 
Orally ingested bacteria adhere to, and penetrate the intestinal mucosa 
destroying specialised epithelial M cells of the Peyer’s patches causing 
gastroenteritis (Jones and Falkow 1996; Finlay and Falkow 1997). During 
infection, Salmonella, being an intracellular pathogen, resides and replicates 
inside cells, including macrophages and dendritic cells. This changes the 
phenotype of the cells due to the recognition of bacterial products, as well as 
the action of bacterial virulence factors (Rosenberger et al. 2000) and can 
also induce both cellular and humoral immune responses. The induction of 
strong humoral and cellular responses makes Salmonella spp. an ideal 
candidate for an attenuated bacterial vaccine or for vectored antigen delivery 
(Harokopakis et al. 1997; Wijburg et al. 2002; Jiang et al. 2004).  A variety of 
S. Typhimurium mutants have been tested for their ability to induce an 
immune response in mice. S. Typhimurium harbouring mutations in aroA, 
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aroC, aroD, htrA, ompR and phoPQ genes were able to induce both humoral 
and cellular immune responses without causing any disease in mice (Dougan 
et al. 1987; Valentine et al. 1998; Bondarenko et al. 2002). Salmonella 
species have also been found to be successful as vectors capable of 
delivering heterologous vaccine antigen, effectively inducing a broad 
spectrum of mucosal and systemic immune responses against the antigenic 
proteins expressed in the Salmonella vector (Cardenas and Clements 1992; 
Hess 2000; Stocker 2000; Bachtiar et al. 2003; Foynes et al. 2003; Garmory 
et al. 2003). 
 
STM-1 is a derivative of S. Typhimurium harbouring an aroA mutation, which 
causes complete, non-reverting aromatic biosynthesis (aro) defects. This 
renders STM-1 non-virulent in respect to invasive infection, as aromatic 
metabolites such as paraminobenzoate (for synthesising folate), 
dihydroxybenzoate (for synthesising enterochelin) and aromatic amino acids 
tyrosine are not available in host tissues (Smith et al. 1984) and so are not 
available to STM-1 to support active replication (Figure 1.2).  
 
The aroA attenuation was created in a wild type strain of S. Typhimurium 
using Phage P22 packaged with transposon aroA 554::Tn10 (Alderton et al. 
1991). The STM-1 derivative has been used as a vaccine to protect poultry, 
calves and adult cattle against Salmonella challenge, and has also been used 
for the delivery of DNA vaccines (Bachtiar et al. 2003). However, to date the 
genetic basis of attenuation of STM-1 has not been fully characterised. 
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To fully utilise STM-1 as a potential delivery vector for vaccine antigens, and 
to enable specific site directed insertion of foreign gene(s) into a defined site 
to ensure continued heterologous gene expression in STM-1, it was 
necessary to determine the exact nature of the attenuation.  
 
 Introduction of Tn10 can promote several types of recombination events 
other than transposition. Shen et al., (1987) showed that when the Tn10 
element is introduced into Salmonella, IS10 right transposition is the most 
common recombination event but Tn10 promoted deletion and 
deletion/inversion can also occur. The IS10RH transposition targets sites 
randomly throughout the genome and the majority (85%) of deletion/inversion 
events due to Tn10 occur at sites less than 35kb away from the original Tn10 
insertion (Kleckner, et al. 1979; Reichardt and Botstein, 1979). This means 
there is a lower possibility of deletion/inversion events at more distant target 
sites. However, no valid reason has been found that show that inversions 
should be less than 35kb in length (Shen et al. 1987). 
 
The Polymerase Chain Reaction (PCR), Southern blot analysis, and Pulse 
Field Gel Electrophoresis (PFGE) were applied to identify the changes in the 
chromosome of the STM-1 with respect to the parent strain S. Typhimurium 
82/6915. 
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3.2 Results 
3.2.1 Amplification of PflB-aroA region 
The architecture of  S. Typhimurium LT2 is shown in  Figure 3.1a (McClelland 
et al. 2001) and 3.1b. It was assumed in this study that the parent strain of 
STM-1, S. Typhimurium 82/6915 has similar architecture to LT2. Subsequent 
experiments have shown this assumption to be correct. All primers used were 
designed according to the LT2 sequence.  
 
To characterise the STM-1 sequence upstream of aroA, the PflB-aroA region 
was amplified using the pflB forward primer and aroA reverse primer as 
shown in Figure 3.1b. The wild type S. Typhimurium parent strain was used 
as a positive control for all PCR’s. In the parent strain the amplified product 
was 8.2 kb as expected from the LT2 sequence, but the product amplified in 
STM-1 was only 4.4 kb, Figure 3.1c. 
 112
  Location 29 at 10 
mins 
 
Figure 3.1a. Circular map of the S. Typhimurium LT2 
genome  (McClelland et al. 2001). The arrows mark the 
positions at location 29 at 10 min and location 48 at 19 
mins. 
Position of pflB -aroA 
region on circular Map. 
Location 48 at 19 mins 
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Figure 3.1b. Map of the aroA region in S. Typhimurium 
LT2 at 19 minutes at location 48. The parent S. 
Typhimurium 82/6915 is assumed to have similar genomic 
architecture as LT2 sequence. 113
  
 
 
 
1            2        3
 
8.2 kb11.5kb 
 
     
 
   5.1kb 
   4.5kb 
 
  2.8kb 
4.4 kb
Figure 3.1c. Amplification of the Pflb-aroA region. The product in 
wild type is 8.2 kb whereas in STM-1 the product is 4.4 kb, a 
difference of approximately 3.8 kb.  Lanes: 1, lambda x Pst1 
marker; 2, wild type; 3, STM-1.  
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3.2.2 Sequence analysis of amplified PCR products  
The amplified PCR product was ligated into pCR2.1 (Invitrogen), to 
characterise the unknown region upstream of aroA located at 19 minutes on 
the S. Typhimurium circular map Figure 3.1a. The chromosomal walking 
method was used to sequence the entire 4.4 kb product. The sequence 
analysis indicated that there is an insertion and a deletion in STM-1, with 
respect to the parent strain, with the IS10 left hand side (IS10 LH) of the Tn10 
element (approximately 1.4 kb) inserted adjacent to aroA. Several genes 
including serC, ycaP, ycoA, fcoA and part of the pflB have been deleted. Also 
deleted is the first 90 bp of the aroA gene (Figure 3.2a). 
 
The sequence analysis also indicated the possibility of a chromosomal 
rearrangement, as the sequence adjacent to the IS10 LH completely aligns 
with S. Typhimurium LT2 sequence from location 29, at 10 minutes (Figure 
3.2b), whereas aroA lies in the location 48 at 19 minutes on the LT2 map, a 
difference of approximately 440 kb.   
 
This sequence at location 29 of LT2 at 10 minutes matches with the gtrA gene 
of phage P22.  
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 The region marked in blue matches with 
the sequence from location 29 at 10 mins 
in the LT2 sequence. Referring to Figure 
3.2b, aroA lies at location 48 at 19 mins. 
STM-1 sequence (4448 bps)
1000 2000 3000 4000
gtrA section of P22
transposase
aroA
 
The aroA region sequence of STM-
1. On the LT2 map this region lies 
at location 48 at 19 mins. 
 Figure 3.2a. Sequence analysis of STM-1 around the aroA region. The sequence 
region depicted in the red bar matches with the IS10 LH of the Tn10 element. The 
sequence depicted in blue is the S. Typhimurium sequence that matches with the 
sequence from location 29 approximately at 10 mins in the circular map of S. 
Typhimurium LT2. The aroA gene is at 19 mins, location 48, a difference of 440 kb. 
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ce (4160 bps)
1000 2000 3000 4000
XbaI BamHI
STM0555
STM0554
STM0556 STM0557
matches w ith STM-1 aroA region
yfdH
rfbI
Sequence similar 
to the Phage P22 
gtrA gene 
 Figure 3.2b. S. Typhimurium sequence from location 29 at 10 
minutes. The sequence marked in blue matches with the STM-1 
sequence from location 48 at 19 mins. The rfbI gene sequence is 
similar to the gtrA gene sequence of Phage P22; therefore it has 
been termed as gtrA in STM-1 (Figure 3.2a). S.Typhimurium LT2 sequen
From location 29 at 10 
mins 
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3.2.3 Amplification of the serC, ycaO, ycaP, fcoA, pflB and 
sopD genes  
Sequence analysis indicated that there was deletion of several metabolically 
important genes in the STM-1 sequence upstream of the aroA gene. The serC 
gene, which encodes an enzyme involved in serine biosynthesis is of 
metabolic importance for the growth of the bacterial cell, the  pfl gene 
encodes pyruvate formate lyase, which is a central enzyme in bacterial 
anaerobic metabolism catalysing the reversible reaction of pyruvate and 
coenzyme A into acetyl-CoA and formate (Hoiseth and Stocker 1985), ycaP 
encodes for a putative inner membrane protein, ycaO encodes for a putative 
cytoplasmic protein, and fcoA encodes for a putative formate transporter. All 
of these were proposed to be missing in STM-1. 
 
The ycaO, ycaP, fcoA, pflB and sopD genes were amplified individually to 
confirm the sequence analysis results (Figure 3.3a, 3.3b, 3.3c and 3.3d). The 
PCR results confirmed the deletion of genes serC, ycaP ycaO and focA from 
the aroA region in STM-1, a deletion of approximately 5 kb. However, the pflB 
and sopD genes initially proposed to be deleted, as determined by sequence 
analysis were found to be present after using the PCR to identify individual 
genes (Figure 3.3d).  
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Figure 3.3c. Amplification of the fcoA gene. The 
PCR confirms the absence of the fcoA gene. 
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3.2.4 Amplification of the pflB-aroA region with pflB and 
aroA170 bp primers 
The PCR result for individual genes indicates the presence of the pflB gene in 
STM-1, which was earlier thought to be deleted based on the sequence 
analysis data. The pflB-aroA region was amplified using the same pflB 
forward primer but a different reverse primer designed at 170 bp downstream 
of the aroA gene, for further confirmation.  
 
The result in the parent strain was as expected but there was no amplification 
in STM-1 (Figure 3.4). The PCR further confirms that although the pflB gene 
is present in the STM-1 chromosome it does not exist in the same region as in 
the parent strain, which indicates the likelihood of chromosomal 
rearrangement, which may be more complex than a simple inversion. 
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 Figure 3.4 Amplification of the pflB-aroA region with pflB 
forward and 170 bp aroA rev primers. The PCR shows 
that the pflB gene, shown to be present in the STM-1 
chromosome, does not exist at the same location as in 
the parent strain. Lanes: 1 lambda x PstI marker; 2, parent 
strain; 3, STM-1; 4, no DNA control.  
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3.2.5 Amplification of the gtrA gene  
The sequence analysis of STM-1 also showed that the sequence which exists 
at location 29 in the parent strain, now exists adjacent to the aroA gene in 
STM-1 which is at location 48. The part of this sequence was termed as gtrA 
as it also matches with the gtrA gene of phage P22 (Figure 3.2b).  
 
The PCR was used to confirm the presence of this sequence in both parent 
strain and in STM-1. As mentioned earlier the sequence of the parent strain S. 
Typhimurium 82/6915 is assumed to align with the S. Typhimurium LT2 
sequence, therefore this PCR was performed to confirm the presence of the 
gtrA sequence in both the parent strain and STM-1.  
 
The DNA segment amplified by gtrA forward and reverse primers confirms the 
presence of the sequence in both parent strain and STM-1 (Fgiure 3.5). This 
means that the presence of phage P22 DNA is a normal occurrence in these 
strains of S. Typhimurium and is not simply the result of the delivery of 
exogenous DNA in the creation of STM-1. 
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Figure 3.5 Amplification of the gtrA gene. The PCR 
confirms that the gtrA sequence exists in both the parent 
and STM-1 strains. Lanes: 1, lambda x PstI marker; 2, 
parent strain; 3, STM-1.    
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3.2.6 Amplification of pflb-aroA region using gtrA and aorA 
170 bp primers and pflB and gtrA primers 
After confirmation that the gtrA sequence is a part of the parent strain it was 
mandatory to confirm the position of that segment in both the parent strain 
and STM-1. The pflB and aroA region was amplified using the gtrA forward 
primer and aroA 170bp reverse primers. While there was no amplification in 
the parent strain, in STM-1 the size of the amplified product was 2.3 kb as 
shown in Figure 3.6, which was expected from the sequence analysis. For 
further confirmation, the PCR with pflB forward primer and gtrA reverse 
primers was performed. There was no product in either parent strain or STM-
1.  
 
These results confirm the existence of a chromosomal segment from location 
29 at 10 mins in the parent strain, in location 48 at 19 mins in STM-1. The 
result also confirms the possibility of a chromosomal rearrangement of 
genomic DNA of STM-1 other than inversion, as PCRs with pflB forward 
primers and aroA reverse primers only amplifies the region in the parent 
strain, and not in STM-1 indicating that the pflB gene does not exist in the 
same region as aroA. Also the PCR with the gtrA forward primer and aroA 
reverse primer gives the expected product in STM-1 only as shown in Figure 
3.6.  
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3.6. Amplification of the pflB-aroA region with the gtrA 
 and 170 bp aroA reverse primers. The PCR result confirms 
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3.2.7 Southern Blot analysis 
The sequence analysis and PCR results indicate that there is a deletion of an 
approximately 5 kb DNA segment and insertion of approximately 1.4 kb in 
STM-1. The PCR of individual genes also confirms the presence of the pflB 
gene, but not in the same region as in the parent strain. The sequence 
analysis and the PCR results also indicate that the sequence of DNA which 
was originally present at location 29 at 10 minutes in the parent strain, now 
exists adjacent to the aroA gene in STM-1 which is at location 48 at 19 
minutes in STM-1. However, the possibility of the existence of sequence from 
location 29 at location 48 required further evidence; it is also required to 
investigate if this change in the STM-1 genome is due to a chromosomal 
rearrangement rather than a simple inversion, as the inversion of such a large 
segment of DNA has never been reported in Salmonella spp. or E coli. 
 
To further analyse the events leading to the STM-1 chromosomal architecture, 
Southern blots, using three different probes, (aroA, pflB and gtrA) were 
performed. The genomic DNA of both the parent strain and STM-1 was 
digested with SacI after analysing the DNA sequence of LT2 from the 
database. The digestion with SacI yields a 15 kb fragment in the aroA region 
of the LT2 genome. Southern blot analysis with the pflB probe yields a 15 kb 
product in both the parent strain and STM-1 (Figure 3.7; lane, 1 &2). The size 
of the fragment when probed with aroA in the parent strain was 15 kb but in 
STM-1 the fragment size is only 12 kb (Figure 3.7; lane, 4 & 5). The yield of a 
15 kb fragment in the parent strain with both aroA and pflB probes further 
confirms that the architecture of the parent strain is similar to LT2 as 
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previously indicated by PCR, and also confirms that the pflB gene and the 
aroA gene exists in the same region in the parent strain. However, the 
difference in the fragment size amplified in STM-1 between the pflB probe and 
aroA probe indicates a possible genomic rearrangement as shown by earlier 
sequence analysis and PCR results.  
 
The Southern blot with the gtrA probe yields an approximately 4 kb fragment 
in the parent strain whereas the size of the fragment in STM-1 is 12 kb (Figure 
3.7; Lane 5 &6). This indicates the presence of the gtrA gene adjacent to the 
aroA gene in STM-1, as both the probes yield a 12 kb fragment in STM-1. 
These Southern blots indicate the following possibilities (1) a chromosomal 
rearrangement other than an inversion in the STM-1 genomic DNA, as the 
gtrA probe yields a 12 kb fragment in STM-1, the same fragment size that is 
observed with the aroA probe, whereas the gtrA probe in the parent strain 
yields only a 4 kb fragment as shown in Figure 3.7. This indicates that the 
gtrA fragment now exists in a different chromosomal location, presumed to be 
in the aroA region at location 48 at 19 minutes. The plfB gene does not exist 
in the aroA region in STM-1, as the pflB probe yields a 15 kb fragment in the 
STM-1, whereas the aroA probe yields a 12 kb fragment. These southern 
blots confirm a chromosomal rearrangement in the STM-1 genomic DNA.  
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FIGURE 3.7 Southern blot analysis with the pflB, aroA and gtrA probes. The Southern 
blot with the pflB probe yields a 15 kb fragment in both the parent strain and STM-1 (Lane 
1 & 2), the aroA probe yields a 15 kb fragment in the parent strain however, only a 12 kb 
fragment in STM-1 (Lane 3 & 4). This indicates a possible genomic rearrangement in STM-
1. The gtrA probe yields a 4 kb fragment in the parent strain and a 12 kb fragment in STM-
1 ( Lane 5 & 6), which is similar to the size of fragment yielded with the aroA probe. This 
confirms the existence of the gtrA gene adjacent to the aroA gene, which are at different 
locations in the parent strain. Lanes: 1, parent strain probed with pflB; 2, STM-1 probed with 
pflB; 3, parent strain probed with aroA; 4, STM-1 probed with aroA; 5, parent strain probed with 
gtrA; 6, STM-1 probed with gtrA. 
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3.2.8 PFGE analysis of STM-1 genomic DNA 
The PCR and Southern blot analysis indicates the possibility of a 
chromosomal rearrangement. PFGE was used to further analyse the nature of 
the rearrangement in STM-1 genomic DNA. The rationale behind this 
experiment was to study the pattern of digestion of the genomic DNA of both 
parent strain and STM-1, considering the fact that if such a large 
rearrangement (approximately 440 kb) has occurred, as the sequence 
analysis, PCR and Southern blot analysis indicate, there should be an 
observable difference after pulse field electrophoresis.  Chromosomal DNA 
was digested with XbaI to study the pattern of digestion by PFGE.  
 
The pattern of genomic DNA digestion is similar in both the parent strain and 
STM-1 as shown in Figure 3.8, which was not expected considering the fact 
that all the above sequence analysis, PCR and Southern blot results indicates 
the possibility of large chromosomal rearrangement. Such a large 
rearrangement should have produced an observable change in the pattern of 
digestion.  
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 Figure 3.8 PFGE after digestion with XbaI. The pattern 
of digestion in both the parent strain and STM-1 is 
similar, which contradicts the results of sequence 
analysis and PCR and Southern blot. Lanes: 1, parent 
strain; 2, STM-1; 3, PFGE lambda marker; 4, parent 
strain; 5, STM-1.131
3.2.9 PFGE-Southern blot analysis of STM-1 genomic DNA 
 
For further confirmation, three different restriction enzymes XbaI, SpeI and 
NotI were used for further PFGE analysis and PFGE followed by southern 
blot. This experiment was planned keeping in mind two possibilities (1) the 
rearrangement in the STM-1 genome is of a nature that cannot be visualised 
from the parent strain after XbaI digestion, but may be after digestion with 
SpeI and NotI (2) even if the pattern of digestion with other enzymes do not 
show any visible changes between the parent strain and the STM-1, PFGE 
followed by the Southern blotting might be able to show the difference in the 
pattern of digestion, if any exists between the parent strain and the STM-1. 
 
The digestion pattern after PFGE did not show any observable differences 
between the parent and STM-1 genomic DNA as shown in Figure 3.9a, but 
the PFGE followed by Southern blot with the pflB probe, yields different size 
products as shown in Figure 3.9b. This confirms that there is a rearrangement 
in the STM-1 chromosome due to the insertion of transposon Tn10.  The 
Southern blot after digestion with XbaI did not yield any fragment in either 
parent strain or STM-1. A possible explanation for this is that the fragment of 
DNA carrying sequences complementary to the probe may be very large and 
did not properly transfer onto the blotting membrane.  The reason however 
remains unknown. 
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Figure 3.9a PFGE with XbaI, SpeI and NotI. Digestion with the 
three different restriction enzymes does not reveal any 
difference in the pattern of digestion between the parent strain 
and STM-1. Lanes: 1, PFGE lambda marker; 2, parent strain; 3, 
STM-1digested with XbaI; 4, parent strain; 5, STM-1 digested with 
SpeI; 6, parent strain; 7, STM-1 digested with NotI.  
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Figure 3.9b Southern blot analysis with the pflB probe after 
PFGE with XbaI, SpeI and NotI. The observation of different 
sized fragments detected confirms a rearrangement in the 
STM-1 genome. Lanes: 1, parent strain; 2, STM-1 digested with 
XbaI; 3, parent strain; 4, STM-1 digested with SpeI; 5, parent strain; 
6, STM-1 digested with NotI.  134 97 kb
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3.2.10 Amplification of the aroA-rpsA region 
The PCR was used to determine the sequence organisation downstream of 
the aroA gene. The forward primer was designed from the aroA gene at 400 
bp and the reverse primer is designed at the end of the rpsA gene. As shown 
in Figure 3.10, there was no difference in the size of the amplified product in 
either parent strain or STM-1, suggesting that there is no rearrangement in 
the segment downstream of the aroA gene. 
 135
  
 
 
1 2        3        4  
11.5 kb 
 
 
5.0 kb 
4.5 kb 
 
 
2.8 kb 
 
 
 
1.7 kb 
 
 
 2.9 kb 
 
 
 Figure 3.10. Amplification of the aroA-rpsA region 
with aroA 400 bp fwd and rpsA rev primers. There 
is no rearrangement downstream of aroA in the 
STM-1 chromosome. Lanes: 1, lambda x PstI marker; 
2, parent strain; 3, STM-1; 4, no DNA control.  136
3.3 Discussion 
The transposon Tn10 is a composite transposable element flanked by 
inverted repeats known as insertion sequences (IS10). The two ends of IS10 
are referred to as inside and outside ends and are not genetically identical. 
Shen et al. (1987) concluded that IS10 right hand mediated transposition is 
the most common event followed by Tn10 promoted alteration of adjacent 
DNA, which is either deletion or deletion/inversion and which occurs at a 
frequency of 1% the rate of IS10 RH promoted transposition. Approximately 
10% of events are complex or/ uninterpretable. The most frequently occurring 
Tn10 mediated recombination event involves intramolecular attack of the two 
inside IS10 ends resulting in the deletion of non-repeated Tn10 with either a 
deletion or inversion of a region of contiguous DNA (Shen et al. 1987).  
 
As explained earlier, STM-1 was created by infecting S. Typhimurium with 
Phage P22 packaged with aroA 554:: Tn10 using the method described by 
Hoiseth and Stocker (1981). Initial selection was for tetracycline resistance, 
which showed integration of TetR into the aroA gene. The mutant was finally 
selected for the loss of Tn10 after biochemical selection, so generating a TetS 
and aroA auxotroph. Hoiseth and Stocker (1985) characterised the attenuated 
strains of S. Typhimurium mutants developed by a similar method and 
showed that in the Tets mutants, the effect of chromosomal rearrangement is 
either a deletion or inversion. This deletion can be in either aroA or serC or 
both the genes and may continue to the pfl gene upstream of the aroA gene, 
giving rise to an Aro-, Aro- SerC- and Aro- SerC- Pfl- phenotype all of which are 
 137
irreversible. They also showed that Tets mutants carry a residual copy of IS10 
adjacent to aroA.  Kleckner et al. (1979) and Shen et al. (1987) showed that 
the major chromosomal rearrangements can be either deletion, inversion or 
deletion/inversion in nature. 10% of events are complex or/ uninterpretable. 
One example is a major chromosomal rearrangement as shown to occur in 
this study. 
 
The sequence analysis and PCR results of the aroA region of STM-1 
demonstrates the deletion of a 5 kb DNA segment in this region. The genes 
from serC to fcoA have been completely deleted. This deletion also includes 
the first 90 bp of the aroA gene. There is an insertion of approximately 1.4 kb 
of DNA that is residual IS10.  
 
The other key area of the analysis is to determine the rearrangement in the 
chromosome of STM-1. The sequence analysis reveals the presence of a 
DNA segment from location 29 at 10 min in the region of aroA, which in the 
wild-type exists in location 48 at 19 mins, a difference of 440 kb. The PCR 
and Southern blot analysis also confirms the result of the sequence analysis, 
as the amplification of the aroA region with the gtrA forward primer and 170 
bp aroA reverse primer yields a product only in STM-1, but there was no 
product in the parent strain as shown in Figure 3.6. This confirms the 
presence of a sequence from location 29 at 10 mins to the location 48 at 19 
minutes. Also, the entire region from pflB to aroA cannot be amplified by 
forward primers designed from the pflB gene and reverse primer in the aroA 
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gene in STM-1, but the presence of the pflB gene was confirmed by PCR in 
the STM-1 strain.  
 
Southern blot analysis with the pflB probe yields a 15 kb fragment in both the 
parent strain and the STM-1, while probing with aroA yields a 15 kb fragment 
in the parent strain, identical to the pflB probe, as expected as these genes 
are predicted from the LT2 sequence to reside on the same fragment.  
Southern blot analysis with the aroA probe in STM-1 yields a 12 kb fragment 
which is different than that observed when STM-1 genomic DNA was probed 
with the pflB probe (Figure 3.7). The difference in the fragment size in STM-1 
probed with pflB or aroA indicates a possible genomic rearrangement. The 
aroA and grtA probes yield a 12 kb fragment in STM-1 as shown in Figure 3.7, 
whereas in the parent strain the product is 4 kb.  This confirms the existence 
of the gtrA gene adjacent to the aroA gene in STM-1 at location 48. All these 
results point towards the possibility of a chromosomal rearrangement other 
then an inversion. 
 
The initial PFGE analysis performed after digesting genomic DNA with XbaI, 
did not reveal any change in the pattern of digestion between the parent strain 
and STM-1 as shown in Figure 3.8. This contradicts the previous sequence 
analysis, PCR and Southern blot analysis results, as a large chromosomal 
rearrangement should have created a visible change in the pattern of 
digestion of STM-1 genomic DNA in comparison to the parent strain. 
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Further PFGE analysis performed after digesting both the parent strain and 
STM-1 with the either XbaI, SpeI, or NotI, was performed under the 
assumption that the rearrangement in the STM-1 genome is of a nature that it 
does not disturb the pattern of XbaI digestion, but other enzymes which also 
digest infrequently (but not as infrequently as XbaI) might reveal different 
patterns of digestion between parent strain and the STM-1. However, this also 
did not reveal any changes in the pattern of digestion between the parent 
strain and STM-1 as shown in Figure 3.10a. However, changes were 
observed after PFGE followed by Southern blotting. This yields different size 
fragments in STM-1 in comparison to the parent strain when the pflB gene 
product was used as a probe, as shown in the Figure 3.10b.  
 
This result supports the previous sequence analysis, PCR and Southern blot 
results.  Therefore the presence of DNA sequence from location 29 at 10 
minutes adjacent to the aroA region in STM1 can be explained best by the 
phenomenon of a genomic rearrangement other than an inversion, which was 
catalysed by the presence of the Tn10 transposable element.  
 
In S. Typhimurium, inversions from 5 kb up to >60 kb have been reported (Bi 
and Liu 1996) but the inversion of a very large fragments has never been 
reported, and is therefore considered unlikely. The PFGE result shows no 
difference between the parent strain and STM-1 after staining of the bands, 
but Southern blot analysis of PFGE patterns confirms some chromosomal 
rearrangement. A possible explanation of this chromosomal rearrangement in 
STM-1 is a crossover between two distant points on the chromosome, not due 
 140
to a specific target sequence but due to the conserved three dimensional 
structure of the bacterial chromosome. This is the phenomenon observed in 
E. coli genomic DNA due to the insertion of the Tn10 transposable element 
(Fonstein et al. 1994).  
 
In the natural state the chromosome exists in a three dimensional form and is 
in a highly twisted state; this can lead to the crossover between two unspecific 
target sequences due to the presence of Tn10 element.  
 
This concludes that the introduction of the composite transposable element 
Tn10 in the bacterial chromosome can lead to chromosomal rearrangement, 
which can be other then a deletion, inversion or simultaneous 
deletion/inversion in nature. This can also lead to the insertion of residual 
Tn10 or IS10 but can lead to more complex process where the large 
segments of DNA can exchange position, which can be sometimes 
unpredictable. 
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Chapter 4 
Construction of STM-1 as a vector to 
deliver heterologous vaccine antigen 
 
4.1 Introduction 
 The Salmonellae are Gram-negative, facultative anaerobic, motile, non-
lactose fermenting rods, belonging to the family of Enterobacteriaceae. 
Salmonella infects humans and animals generally by the oro-fecal route. 
 
Bacon, Burrows et al. (1950; 1951) were first to describe attenuated 
Salmonella strains. The mutation in these strains was due to the disruption of 
gene encoding for purine, p-aminobenzoic acid, and aspartate. These 
mutants exhibited reduced virulence in mice due to exogenous requirement of 
the metabolites. Since then the use of various S. Typhimurium mutants has 
been studied as potential vector and were found to be effective as a vector to 
deliver heterologous antigens from bacteria, viruses and eukaryotes (Dougan 
et al. 1987; Dalla Pozza et al. 1998; Dunstan et al. 1998; Bullifent et al. 2000; 
Fouts et al. 2003). These mutants have the ability to establish a limited 
infection in the host, and during the natural course of infection, the live 
Salmonella vector delivers in vivo synthesized antigens to the host immune 
system. The capability of live Salmonella vectors to strongly stimulate both the 
humoral and cellular arms of the immune system makes them an ideal 
 142
candidate as a delivery vector (Guzman 1991; Covone et al. 1998; Bullifent et 
al. 2000; Grode et al. 2001; Cochlovius et al. 2002; Capozzo et al. 2004). 
 
4.1.1 Stabilisation of antigen expression in attenuated 
Salmonella strain 
The work described in this chapter was to devise a strategy to stabilise the 
expression of heterologous vaccine antigen. The expression of heterologous 
antigens at optimum levels to elicit immune responses is a significant problem 
in the construction of recombinant Salmonella strains. Inadequately 
immunogenic vaccine due low level of protein expression can be enhanced by 
the use of a high copy number plasmid which can subsequently solve the 
problem of low expression of antigenic protein (Covone et al. 1998). However, 
the use of multicopy plasmids to deliver heterologous antigen has either failed 
or had a reduced efficacy because of the unstable expression of antigenic 
protein (Tarkka et al. 1989; Cardenas and Clements 1993). One major 
drawback of these multicopy plasmids is that commonly used cloning vectors 
induce metabolic burden on bacterial replication machinery due to the various 
reasons such as type of replicon they harbour, copy number, size and 
complexity. Also due to the expression encoded level of genes, affect the 
retention of a plasmid by bacteria during in vivo growth where drug selection 
is no longer applied (Dunstan et al. 2003).  In some circumstances expression 
of a high level of heterologous antigen has been found to be toxic (Garmory et 
al. 2002). 
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Different strategies for addressing the issue of plasmid instability and avoiding 
the necessity for the use of stabilising antibiotic have been proposed. One 
such strategy involves the use of promoters that allows expression of 
heterologous antigen at particular cellular sites, so called in vivo inducible 
promoters (Dunstan et al. 1999). 
 
4.1.2 The use of in vivo inducible promoters 
 
Several in vivo inducible promoters have been tested for their efficiency of 
protein expression. Ideally the promoters should allow increased expression 
in APCs following uptake of the Salmonella carrier. One such promoter is the 
nirB promoter, which was isolated from E. coli, where it directs the expression 
of an operon which includes the nitrate reductase gene (Jayaraman et al. 
1987). The nirB promoter is regulated by nitrate and by the changes in the 
oxygen tension of the environment, becoming active under anaerobic 
conditions (Cole 1968). The expression of heterologous antigens in 
Salmonella under the control of the nirB promoter has been shown to 
stimulate higher immune responses when compared with the expression of 
the same antigens from the same strain under the control of a constitutive 
promoter (Chatfield et al. 1992; McSorley et al. 1997). 
 
Another anaerobically induced promoter, pagC is a macrophage-inducible 
promoter isolated from Salmonella (Hohmann et al. 1995). The pagC 
promoter is controlled by the PhoP/PhoQ two component regulatory system 
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which plays a major role in Salmonella virulence. PhoP-PhoQ activates the 
transcription of genes following phagocytosis by macrophages. The 
expression of these genes is necessary for the survival of Salmonella within 
the phagosomal environment (Gunn 1998). The expression of antigenic 
protein under the control of the pagC promoter provides stable, high-level 
expression of heterologous antigen in Salmonella (Hohmann et al. 1995; 
Dunstan et al. 1999; Chen and Schifferli 2001; Chiu et al. 2006).  The pagC 
promoter when compared with other promoters such as nirB, katG, spv, tac, 
sasH, ompC was found to be superior in terms of in vivo expression of 
heterologous antigen (Bumann 2001) . 
 
 
4.1.3 Integration of constructs in the chromosomal location 
Another reason for the unstable expression of vaccine antigen in vivo is due 
to the instability of the plasmid encoding the antigen. For example, in one of 
the early experiments, gene encoded on a plasmid expressing the E. coli 
heat-labile enterotoxin subunit B was lost in vivo when the Salmonella carrier 
colonised the mouse reticular endothelial system (RES) (Maskell et al. 1987). 
Studies have aimed to address the problem of genetic instability in different 
ways.  
 
An alternative method to obtain stable antigen expression is to integrate the 
foreign genes into the chromosome of the carrier strain (Hone et al. 1988; 
Flynn et al. 1990; Strugnell et al. 1990). In 1988, Hone et al. developed one 
system whereby heterologous DNA can be recombined in the chromosome of 
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Salmonella. The system used a suicide vector to integrate the genes 
encoding K88 fimbriae of E. coli into the chromosome of a galE mutant of S. 
Typhimurium by homologous recombination. Strugnell et al. (1990) used a 
similar strategy to integrate the heterologous gene in the aroC gene of S. 
Typhimurium. This system has since been used to insert DNA encoding 
various heterologous antigen into the Salmonella chromosome (Strugnell et 
al. 1992; Everest et al. 1995). 
 
The most recently developed method, known as Lambda Red System, was 
developed by Murphy et al. (1998). The phage Lambda Red locus provides a 
platform that promotes homologous recombination of short linear DNA 
fragments. The Lambda Red locus includes three genes: bet (aka β), exo and 
gam (aka γ) (Datsenko and Wanner 2000; Poteete and Fenton 2000; Yu et al. 
2000; Poteete et al. 2004). Exo is 5’-3’ exonuclease that degrades the 5’ end 
of linear DNA, bet is a single stranded binding protein which binds to single-
stranded 3’ end generated by exo and promotes the annealing of 
complementary DNA, and gam binds to the host RecBCD complex and 
inhibits its exonuclease activity (Murphy, 1998 Poteete, 2000 Yu, 2000). 
 
This technology was extensively used in E. coli and S. Typhimurium to 
generate knockout mutants. The method involves generation of a PCR 
product containing a very short region of identity (35-50 bp), which was 
integrated into the bacterial chromosome taking advantage of the phage 
recombination system. Datsenko and Wanner (2000) designed temperature 
sensitive, low copy number plasmids pKD20 and pKD46 from which the 
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Lambda Red genes bet, exo and gam were expressed under the control of an 
arabinose inducible promoter.  
 
The recombinase-based system also offers the possibility to precisely remove 
the antibiotic resistance marker from the chromosome (Cherepanov and 
Wackernagel 1995). The method initially described (Szybalski 1993; Posfai et 
al. 1997) is based on the yeast FLP/FRT recombination system in which the 
FLP gene product targets the FRT site (FLP recombination target), a 68 bp 
recognition sequence of the yeast FLP gene product, and precisely removes 
the segment of DNA which exists between the two sites.  This system has 
also been shown to be effective in the development of recombinant 
Salmonella strains for vaccine purpose by allowing the integration of genes in 
the desired chromosomal location. (Husseiny and Hensel 2005) (Figure 4.1).  
 
The work described in this chapter was to devise the strategy to stabilise the 
expression of heterologous vaccine antigen. To achieve the stable expression 
of heterologous vaccine antigens, which are chicken ovalbumin as a model 
antigen and C. jejuni major outer membrane protein as a test antigen, the 
genes were put under the control of both the nirB and pagC in vivo inducible 
promoters. Both genes were expressed from a plasmid and also integrated 
into the aroA gene of S. Typhimurium STM-1 chromosome. Protein 
expression was analysed from both the plasmid and chromosomal location.  
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BamHI 
pKD13 
kan 
Figure 4.1. Diagrammatic representation of Lambda Red system. (A) designed constructs consist of an 
in vivo-activated promoter (Pro), a gene fragment encoding a model vaccine antigen (dotted areas), 
expression cassettes for expression of genes encoding ovalbumin as a model antigen or C. jejuni major 
outer membrane protein were inserted into the BamHI site of pKD13 plasmid. The pKD13 plasmid 
contains the kanamycin resistance gene (hatched areas) flanked by FRT sites and binding sites for 
primers (black symbols). (B) The targeting construct consisting of expression cassettes and the 
resistance gene were amplified by primers containing 40 bp of identity to the chromosomal target gene 
(grey symbols). (C) S. Typhimurium harbouring pKD46 for expression of the Red recombinase was 
transformed with linear DNA of the targeting construct, and recombinant colonies with replacements of 
a chromosomal target gene (open symbol) by the targeting construct were selected. (D) The gene 
encoding antibiotic resistance after the integration of construct can be removed by FLP-mediated 
recombination after transformation of recombinant strains with plasmid pCP20. Figure adapted from  
Husseiny and Hensel (2005). 
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4.2 Results 
4.2.1 Ligation of the pagC and nirB promoters into the pCR2.1 
plasmid 
The nirB promoter is anareobically induced, regulated by nitrate and by 
changes in the oxygen tension of the environment (Cole 1968). The promoter 
was amplified from E. coli genomic DNA as a template by using the nirB 
forward primer with a BamHI restriction site and the nirB reverse primer with a 
MfeI restriction site (Table 2.4) at 58°C annealing temperature (Figure 4.2a). 
The pagC promoter, a macrophage inducible promoter (Dunstan et al. 1999), 
was amplified from S. Typhimurium genomic DNA as a template by using the 
pagC forward primer with a BamHI restriction site and the pagC reverse 
primer with a MfeI restriction site at 60°C annealing temperature ( Figure 
4.2b). Fresh PCR product was ligated into the pCR2.1 plasmid supplied by 
Invitrogen (Figure 4.2c) and transformed into E. coli TOP10F’. The plasmid 
with the pagC promoter was termed pCRpagC and with the nirB promoter as 
pCRnirB (Table 2.2). 
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Figure 4.2c Ligation of the pagC and nirB 
promoters into pCR2.1 plasmid revealed by 
digestion of recombinant clones with EcoRI. 
Lanes: 1, lambda x PstI marker; 2, nirB 
promoter in pCR2.1 vector; 3, pagC promoter 
in pCR2.1. vector. Inserts are indicated. 
 150700 b300 b   1      2   Figure 4.2b Amplification of the 
pagC promoter. Lanes: 1, lambda 
x PstI marker; 2, pagC promoter. 
The 700 bp product is indicated.  
                       
 
Figure 4.2a Amplification of the 
nirB promoter. Lanes: 1, lambda x 
PstI marker; 2, nirB promoter. The 
300 bp product is indicated. 1       2   
4.2.2 Amplification of the C. jejuni major outer membrane 
protein and chicken ovalbumin genes 
The C. jejuni MOMP gene was amplified from the TAMomp plasmid, the 
construct designed by Ooi 2002 (Honours thesis, RMIT University), using the 
Momp forward primer with an EcoRI restriction site and the Momp reverse 
primer (Table 2.3). The gene was amplified at 55°C annealing temperature 
(Figure 4.3a). The chicken ovalbumin gene was amplified from the sOVA 
plasmid supplied by Boyle et al.(1997) using the ova forward primer and the 
ova reverse primer. The primers used for the amplification of the chicken 
ovalbumin gene carry an EcoRI restriction site. The amplification was 
achieved at 60°C annealing temperature (Figure 4.3b).  
 
The fresh PCR product was ligated into the pCR2.1 plasmid and transformed 
into E. coli TOP10F’. The pCR2.1 plasmid carrying the C. jejuni major outer 
membrane protein expressing gene was termed pCRMomp and the pCR2.1 
plasmid carrying the chicken ovalbumin gene was termed pCRova (Table 
2.2). 
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Figure 4.3a Amplification of 
the C. jejuni Momp gene. 
Lanes: 1, lambda x PstI marker; 
2-3, Momp gene; 4, no DNA 
control. The 1.2 kb product is 
indicated. 152         
Figure 4.3b Amplification of 
the Chicken ovalbumin gene. 
Lanes: 1, lambda x PstI 
marker; 2-6, ovalbumin gene. 
The 1.2 kb product is 
indicated. 1.2 kb 1.2 kb 1         2  
1        2  
4.2.3 Cloning of the C. jejuni Momp and the chicken 
ovalbumin genes with pagC and nirB promoter 
The pCRMomp and pCRova plasmids were digested with EcoRI, and the 
inserts containing Momp and ovalbumin genes were purified. The pCRpagC 
and pCRnirB plasmids were digested with MfeI. After inactivation of the 
restriction enzyme the plasmids were alkaline phosphatase treated and 
purified to minimise self ligation of the vector. The Momp and ovalbumin 
genes were then ligated into the pCRpagC and pCRnirB plasmid at the MfeI 
restriction site (as MfeI and EcoRI have compatible ends); to yield 
pCRpagMomp, pCRnirMomp, pCRpagova and pCRnirova plasmids. 
 
 The orientation of each of the four constructs was analysed by restriction 
digestion. The putative ovalbumin constructs were digested with EcoRI and 
EcoRV, and the Momp constructs were digested with EcoRI and SpeI. EcoRI 
digests just at the beginning and at the end of construct, therefore the 
digestion releases the entire insert from the plasmid. SpeI digests the Momp 
gene at 13 bp, therefore Momp constructs in the right orientation should give 
two products, a 1.2 kb product corresponding to the Momp gene and 700  bp 
corresponding to the size of pagC promoter (Figure 4.4a), and 300 bp 
corresponding to the nirB promoter (Figure 4.4c). EcoRV digests the 
ovalbumin gene at 1000 bp so the positive constructs with ovalbumin should 
give a 1.7 kb product with the pagC promoter and a 200 bp minor product 
(Figure 4.4b) and 1.5 kb product with nirB promoter and a 200 bp minor 
product  (Figure 4.4d). 
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Figure 4.4a Digestion of PagCMomp 
constructs with EcoRI and SpeI for the 
detection of correct orientation of the 
constructs. Lanes: 1, lambda x PstI marker, 2, 
3 & 9positive PagCMomp clones; 4, 5, 6, 7, &8, 
clone in opposite orientation. Diagnostic 
fragments are indicated. 
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Figure 4.4b Digestion of pagCova 
constructs with EcoRI and EcoRV for the 
detection of correct orientation of the 
constructs. Lanes: 1, lambda x PstI marker; 
2, 4 & 5, positive pagCova clones; 3, 6, 7 & 
8, clones in opposite orientation. The 
diagnostic fragment is indicated. 
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Figure 4.4c Digestion of nirBMomp 
constructs with EcoRI and SpeI restriction 
enzyme for the detection of correct 
orientation of the constructs. Lanes: 1, 4 & 
7, positive nirBMomp Clones; 2, 3, 5, 6 & 8 
clone in opposite orientation; 9, lambda x PstI 
marker. Diagnostic fragments are indicated. 
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Figure 4.4d Digestion of nirBova 
constructs with EcoRI and EcoRV 
restriction enzyme for the detection of 
correct orientation of the constructs. 
Lanes: 1, lambda x PstI marker; 4 & 5, 
positive nirBova clones; 2, 3, 6, & 7, clones in 
opposite orientation. The diagnostic fragment 
is indicated. 
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4.2.4 DNA Sequence analysis of the assembled constructs 
The restriction digestion pattern was the primary selection procedure to select 
clones in the correct orientation. DNA sequencing was employed to further 
confirm the integrity of the constructs. Each constructs was sequenced using 
the M13-20 forward primer and M13 reverse primer (Table 2.3) according to 
the method described in section 2.4.2.4. The sequence was analysed using 
the BLAST tool using Clone Manager, scientific and educational software 
version 7.11. The sequence analysis in confirmed the integrity of each 
constructs. 
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4.2.5 Analysis of protein expression from the constructs by 
western blotting  
Western blot was used to determine protein expression from the positive 
constructs assembled in plasmids to ensure correct functioning of the 
constructs prior to further experimentation.  E. coli harbouring the constructs 
were inoculated into LB broth and incubated at 37°C. The pagC and nirB 
promoters were induced as mentioned in section 2.5.4 for protein expression. 
Twenty microgram of protein was loaded for each sample after determining 
the protein concentration by Lowry assay. To detect Momp, mouse anti-C. 
jejuni antibody was used as the primary antibody, and HRP conjugated sheep 
anti-mouse, was used as detecting antibody. The expression of Momp was 
visible from both pagCMomp and nirBMomp constructs after the final 
development (Figure 4.5a). However, the band from samples with the 
pagCMomp construct was very faint, and therefore is not visible in the 
scanned photograph (Lane 4, Figure 4.4a) 
 
The detection of ovalbumin was achieved by using mouse anti-ovalbumin 
primary antibody and HRP conjugated sheep anti-mouse as the secondary 
antibody. The 45 KDa product as expected was visualised after development 
in cells harbouring both the pagCova and nirBova constructs (Figure 4.5b). E. 
coli harbouring empty plasmid was used as negative control in both the 
western blots.   
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Figure 4.5a Expression of Momp from plasmid 
constructs. Lanes: 1, seeBlue protein marker; 2, C. 
jenuni lysate; 3, E. coli carrying empty vector; 4, E. coli 
carrying Momp gene under the control of the pagC 
promoter; 5, E. coli carrying Momp gene under the 
control of the nirB promoter. The protein size is indicated.   
 
Figure 4.5b Expression of ovalbumin from plasmid 
constructs. Lanes: 1, seeBlue protein marker; 2, E. coli 
carrying ovalbumin gene under the control of the pagC 
promoter; 3, E. coli carrying ovalbumin under the control 
of the nirB promoter; 4, E. coli carrying empty vector. The 
protein size is indicated. 15845 KDa
4.2.6 Ligation of constructs from pCR2.1 into pMW2 vector 
The pMW2 vector was the choice of vector for the delivery of heterologous 
vaccine antigen from the plasmid location. In comparison to pCR2.1 vector, 
which is a high copy number vector, pMW2 is medium copy number vector.  
 
The constructs were digested from the holding pCR2.1 plasmid with KpnI and 
XhoI, and the inserts and pMW2 vector were purified before ligation. The 
ligation mixture was transformed into E. coli DH5α by electro-transformation. 
Positive clones were selected and plasmids were digested with BamHI. The 
estimated size of the digestion product was approximately 2 kb (Figure 4.6). 
STM-1 was transformed with the plasmids carrying inserts after these 
plasmids were passaged through S. Typhimurium 9121-LT2 strain. 
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Figure 4.6 Restriction digestion of pMW2 plasmid with 
BamHI to select positive clones. Lanes: 1, pagCmomp; 2, 
nirBmomp; 3, pagCova; 4, nirBova; 5, lambda x PstI 
marker. The diagnostic fragment is indicated. 
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4.2.7 Lambda Red System for the chromosomal integration of 
constructs 
The Lambda Red System, supplied by the E. coli genetic stock centre USA, 
(courtesy Dr B.L. Wanner) was used for the integration of constructs in the 
aroA gene region of the STM-1. The system takes the advantage of Phage 
Lambda recombination which allows the integration of linear PCR products 
with very short regions of identity.  
 
STM-1 was transformed with pKD46 after the plasmid was passaged through 
the LT2-9121 strain. The pKD46 plasmid carries a temperature sensitive 
conditional replicon, which allows replication of plasmid at 30°C only (Table 
2.2). The lambda red genes which drive the recombination of short linear PCR 
fragments are expressed under the control of the arabinose promoter (Figure 
4.7). The constructs assembled above were ligated into the pKD13 plasmid 
which was used as template to generate PCR products using primers with 35-
40 bp of identity with the aroA gene of STM-1 as described in section 2.4.4.4 
(Figure 4.1). 
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Figure 4.7 The pKD46 plasmid from which the 
lambda red genes are expressed under the control 
of the arabinose promoter. It has a temperature 
sensitive replicon, which allows the replication of 
plasmid at 30°C. 
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4.2.7.1 Ligation of Constructs into the pKD13 plasmid 
The pKD13 plasmid was designed to be used as template for the generation 
of PCR products to be integrated in the aroA gene of STM-1. The inserts were 
excised from pMW2 with BamHI and ligated into the pKD13 plasmid at the 
BamHI site which lies just outside the FRT site. The pKD13 plasmid replicates 
under the control of the R6K origin of replication which requires the pir protein, 
and the kanamycin antibiotic marker is flanked by FRT (FLP recombination 
target) sites (Table 2.2 & Figure 4.8). Although there are other plasmids such 
as pKD3 and pKD4 which could have been used for the generation of PCR 
products, the pKD13 plasmid was selected due to the availability of a BamHI 
restriction site just outside the FRT site, which allowed the ligation of 
constructs in the pKD13 plasmid from pMW2 plasmid without further 
processing.    
 
After ligation the pKD13 plasmid was transformed into E. coli BW25141, 
which is pir+ (Table 2.1). The plasmids carrying constructs were digested with 
BamHI to select positive clones (Figure 4.9a, 4.9b, 4.9c and 49.d). 
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 Figure 4.8. The pKD13 plasmid with the R6K origin of replication. The 
kanamycin antibiotic cassette is flanked by FRT sites. This allows the 
precise removal of antibiotic marker once the positive chromosomal 
integrants were selected. The BamHI site which exists just outside the 
FRT site was used to ligate the constructs excised from the pMW2 
vector.  164
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Figure 4.9a Ligation of pagCmomp 
constructs into the pKD13 plasmid. 
Lanes: 1, 2, 3, 4, 5, 7, 8, 9, 10 & 11 positive 
clones; 6, lambda x PstI marker. The 
diagnostic fragment is indicated.  
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 Figure 4.9b Ligation of nirBMomp constructs 
into the  pKD13 plasmid. Lanes: 2, 3, 4, 5, 8, 9, 
10 & 11 positive clones; 6, lambda x PstI marker. 
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Figure 4.9c Ligation of pagCova 
constructs into the pKD13 plasmid. 
Lanes: 1, 2, 3, 4, 7, 8, 10 & 11 positive 
clones; 6, lambda x PstI marker The 
diagnostic fragment is indicated.  
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1.7 kb Figure 4.9d Ligation of nirBova constructs into the 
pKD13 plasmid. Lanes: 3, 4, 5, 7, 9 & 10 positive clones; 
6, lambda x PstI marker. The diagnostic fragment is 
indicated. 1        2     3       4     5       6        7        8      9     166
4.2.7.2  Amplification of the constructs with the antibiotic 
resistance marker from the pKD13 vector for chromosomal 
integration.  
The pKD13 plasmid was used as a template as described in section 4.2.7.1 
for the generation of PCR products with 40 bp of identity to the aroA gene of 
STM-1. The pk forward and pk reverse primers were used. These primers are 
60-62 bp long with 20-22 bp homologous to the plasmid template and 40 bp 
homologous to the aroA gene, where the constructs were to be integrated. 
The PCR was performed using expand long template DNA polymerase at 
65°C annealing temperature ( section 2.4.2.3). The empty vector was used as 
an amplification control and the negative control was without any DNA 
template. The estimated size of the PCR product from the positive clones is 
approximately 3.2 kb including the kanamycin cassette (Figure 4.10).  
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Figure 4.10. Amplification of constructs from 
the pKD13 plasmid template. Lanes: 1, empty 
vector; 2, pagcmomp; 3, nirBmomp, 4, pagCova; 
5, nirBova; 6, no DNA control; 7, lambda x PstI 
marker. Diagnostic fragments are indicated. 168
4.2.7.3 Integration of the PCR product into the aroA gene of 
STM-1 
The PCR reaction was digested with DpnI to eliminate any plasmid template. 
Following the restriction digestion, the PCR product was purified using the 
Geneclean kit according to the manufacturer’s instruction as described in 
section 2.4.1.8. Fresh competent cells of STM-1 harbouring the pKD46 
plasmid were transformed by electroporation (refer to section 2.4.4.2). The 
transformants were plated onto MH agar containing 50 µg/mL kanamycin and 
incubated at 37°C overnight.  
 
The positive transformants were identified by PCR with the gtrA forward 
primer and aroA reverse primer using genomic DNA of colonies as template. 
STM-1 genomic DNA was used as positive control, no DNA was used as the 
negative control. The estimated size of the products in the positive control 
was approximately 5.7 kb (Figure 4.11).  
 
The suicide vector system (Hone et al. 1988) was also tested in this study to 
integrate the same constructs into the aroA gene of STM-1 to compare the 
efficiency of the two different strategies. However, no recombinant STM-1 was 
identified even when the bacterial cells were transformed with up to 500 ng of 
DNA (data not shown). In contrast 10-15 positive recombinants were identified 
per 100 ng of DNA when the Lambda Red system was used for the 
integration of constructs.  
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Figure 4.11. Amplification of constructs with gtrA forward 
primer and aroA reverse primer after chromosomal 
integration. Lanes; 1, lambda x PstI marker; 2, STM-1 positive 
control; 3, pagCmomp; 4, nirBmomp; 5, pagCova; 6, nirBova; 
7, no DNA negative control. The diagnostic fragments are 
indicated. 170
 4.2.8 Analysis of in vitro protein expression 
In vitro protein expression was analysed by western blotting from plasmid 
constructs in the pMW2 vector and from similar constructs integrated into the 
chromosome of STM-1. This experiment was primarily performed to identify 
any difference in expression of protein from the plasmid or chromosomal 
location before in vivo analysis.  
 
The promoters were induced as described in section 2.5.4. The bacterial cells 
were collected by centrifugation. The cells were disrupted by sonication 
(section 2.5.2.1) and the protein concentration was determined by Bradford 
assay (section 2.5.3.2). Approximately 20-25 µg protein was loaded in each 
well except in well 2 of Figure 4.12a where approximately 35 µg of protein 
was inadvertently loaded.  The in vitro expression analysis of C. jejuni Momp 
under the control of the pagC or nirB promoters from both plasmid and 
chromosomal location show that the level of expression from the nirB 
promoter was slightly higher when expressed from the chromosomal location. 
However, expression from the pagC promoter was slightly higher when 
compared to the expression from the nirB promoter when antigen was 
expressed from plasmid location (Figure 4.12a). It should be noted that the 
western blot analysis are indicative, rather than quantitative. 
 
The analysis of ovalbumin antigen expression was also analysed by western 
blotting. The in vitro protein expression of the ovalbumin antigen under the 
control of the nirB promoter from the chromosomal location was slightly higher 
in comparison to expression of same antigen under the control of the pagC 
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promoter. However, a similar level of expression was observed from plasmid 
location in both promoters (Figure 4.12b). The levels of protein that were 
detected in this experiment were low, and hence bands are not visible in the 
reproduced figure. 
 
In summary the level of protein expression from the chromosomal location 
and the plasmid location was similar from both promoters. However, the 
overall expression may be slightly higher when the antigens were expressed 
from plasmid vector. 
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Figure 4.12a Analysis of C. jejuni Momp antigen expression by 
western blotting. Lanes: 1, STM-1 without plasmid vector; 2, 
nirBmomp chromosome; 3, nirBmomp plasmid; 4, pagCmomp 
chromosome; 5, pagCmomp plasmid; 6, seeBlue protein marker. 
The protein size is indicated. 
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Figure 4.12b Analysis of ovalbumin antigen expression by
blotting. Protein expression was observed from all the four c
although it is difficult to observe in the reproduced figure. 
nirBova from chromosomal location; 2, nirBova from plasmid lo
pagCova from chromosomal location; 4, pagCova from plasmid l
STM-1 carrying empty vector; 6, STM-1 without vector; 7, seeBl
marker. The protein size is indicated. 
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4.3 Discussion 
Attenuated Salmonella strains have been widely investigated as a live 
bacterial vaccine to deliver heterologous vaccine antigen in a number of 
animal models (Bullifent et al. 2000; Fayolle et al. 2001; Chen and Schifferli 
2003; Chiu et al. 2006). The use of live attenuated Salmonella strains as 
delivery vectors to express heterologous antigens to the secretory immune 
system constitutes a promising approach for the development of new 
vaccines against a number of diseases, and have been found to be safe and 
establish a limited infection in the host (Basso et al. 2000; Chen and Schifferli 
2000; Bachtiar et al. 2003). These mutants during the natural course of 
infection can deliver antigen to stimulate B and T lymphocytes (Berndt and 
Methner 2004; Capozzo et al. 2004; Chiu et al. 2006). In the work discussed 
in this chapter, a registered salmonellosis vaccine, STM-1 has been evaluated 
for the potential to express heterologous antigen. 
 
For the optimal expression of chicken ovalbumin (model antigen) and C. jejuni 
Momp (test antigen) antigens, the antigen coding genes were expressed 
under the control of the in vivo inducible promoters nirB and pagC. The 
antigens were expressed from both the plasmid and chromosomal locations. 
The nirB promoter is an anaerobically induced promoter which was isolated 
from E. coli; this promoter is regulated by nitrate and changes in the oxygen 
tension (Cole 1968). The pagC promoter was isolated from Salmonella, and is 
activated once the organism reaches macrophages, and therefore has the 
potential to directly deliver heterologous antigen to the APC (Bullifent et al. 
2000). 
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 Both the promoters have been successfully used for the in vivo expression of 
antigenic protein and provide optimum level of stable expression in 
Salmonella vector; however, the expression from pagC promoter is reported 
to be significantly higher and induce better immune responses in comparison 
to the expression from the nirB promoter (Dunstan et al. 1999; Bumann 2001; 
Chen and Schifferli 2001). 
 
The constructs were designed to express chicken ovalbumin and C. jejuni 
Momp proteins from both nirB and pagC promoters. These constructs were 
expressed from a plasmid vector; however, these constructs were also 
integrated into the aroA gene of STM-1 to address the issue of instability of 
the plasmid encoding the foreign gene. This strategy to introduce the genes 
expressing foreign antigens in the chromosome will also eliminate the in vivo 
use of antibiotics, which is necessary if the expression is required from an 
unstable plasmid vector. Further, it is likely that in any future vaccine use, 
plasmid borne antigens will not be acceptable due to the potential of transfer 
of such plasmids to host bacteria.  
 
The Lambda Red system (Datsenko and Wanner 2000) and a suicide vector 
(Hone et al. 1988) were used for chromosomal integration of the constructs in 
the aroA gene of STM-1. The use of a suicide vector to integrate the foreign 
genes in the chromosome was unsuccessful (data not shown), even when up 
to 500 ng of DNA was used to transform the STM-1. A similar method using a 
suicide vector for introducing a foreign gene in the aroD gene of STM-1 was 
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attempted earlier in our laboratory by Moutafis (2003), which was also 
unsuccessful. The reason for the failure of suicide vectors for promoting 
homologous recombination in STM-1 is not fully understood.   
 
In contrast the lambda red system was successfully used to introduce foreign 
genes into the aroA location of STM-1. Also the efficiency of recombination 
was high; approximately 10-15 positive recombinants were identified when 
transformed with 100 ng of linear DNA (section 4.2.7.3). This system was 
primarily developed to create knockout mutants of E. coli and S. Typhimurium 
taking advantage of Phage Lambda recombination system (Datsenko and 
Wanner 2000; Murphy et al. 2000; Court et al. 2002; Poteete et al. 2004). The 
Lambda Red system allows linear DNA molecules with 35-50 bp identity to 
efficiently recombine in the chromosomal location of bacterial cells. The other 
advantage of this system is the precise removal of antibiotic resistance genes 
(Martinez-Morales et al. 1999). This system has been used not only to 
generate knock out bacterial mutants, but also other uses such as the epitope 
tagging of a chromosomal gene (Uzzau et al. 2001). Recently this system has 
been used for the insertion of genes expressing foreign antigen into the 
Salmonella genome (Husseiny and Hensel 2005). In our study this system 
was efficiently used for the insertion of chicken ovalbumin and C. jejuni Momp 
genes into the aroA region of STM-1 in two steps. Although STM-1 has been 
found to be a difficult strain for genetic recombination using suicide vectors, 
the use of the lambda red system was successful. 
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The semi-quantitiative in vitro analysis of protein expression indicated that the 
efficiency of heterologous antigen expression was approximately the same 
from both the promoters when expressed from the plasmid vector. A similar 
level of expression was also achieved from the chromosomal location in 
comparison to expression from the plasmid vector by using these promoters. 
This data suggest that expression can be achieved by using a single copy 
gene when expressed under the control of the nirB or pagC promoter. 
However, it is necessary to evaluate in vivo immune responses against these 
antigens when expressed from the two promoters in an animal model. 
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Chapter 5 
In vivo immune responses induced in mice 
against heterologous antigen expressed in 
STM-1 
 
5.1 Introduction 
Salmonella strains have been well characterised for the delivery of 
heterologous vaccine antigens in several animal models (Bachtiar et al. 2003; 
Baud et al. 2004; Ashby et al. 2005). The potential advantages of live 
attenuated vaccines, such as the simple mode of inoculation and generation 
of effective immune responses makes them an ideal candidate for the delivery 
of heterologous antigens (Kochi 2003). These attributes of Salmonella have 
prompted extensive research in the field of vaccine technology to evaluate the 
efficacy of Salmonella as a potential vector to deliver a variety of heterologous 
antigens (Londono-Arcila et al. 2002; Lasaro et al. 2005; Liu et al. 2006).   
 
Salmonella being intracellular can replicate inside APC’s and induce both 
humoral and cell mediated responses not only against homologous antigens 
but also against the heterologous antigen for which they act as a carrier 
(Bumann 2001; Koesling et al. 2001; Lundin et al. 2002; Garmory et al. 2003). 
The cellular immune responses are crucial both for protective immunity 
against salmonellosis and for the immunogenicity of oral vaccines which are 
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based on avirulent live Salmonella as antigen carriers. A primary infection can 
induce the production of antibodies against antigens such as 
lipopolysaccharide (LPS), flagellin and lipo-protein followed by Th1 or Th2 
type T-cell memory and also CTL responses (Jones and Falkow 1996).  Two 
types of phagocytic cells, macrophages and immature dendritic cells (DC) 
play an important role in the interface between the innate and adaptive 
immune responses to Salmonella infections. They act as antigen presenting 
cells (APC), capturing and degrading bacteria in a well-orchestrated series of 
proteolytic event. These cells process the bacterial protein into peptide 
fragments that are displayed on the APC surface by major histocompatibility 
complex (MHC) (Yrlid et al. 2001). The MHC class I and the Class II 
molecules, which are constitutively expressed on APC are responsible for the 
presentation of non-overlapping antigen-derived peptides to CD8+ CTL and 
CD4+ helper T cells (TH) respectively  (Kirby et al. 2004; Babbitt et al. 2005).  
 
Mucosal surfaces are the site of entry for most enteric pathogens, therefore 
the mucosal immunity is important for the first line of defence, and direct 
delivery of antigens to a mucosal surface can induce local immune responses 
(DiGiandomenico et al. 2004). The gut associated lymphoid tissue (GALT) 
has the largest repertoire of lymphoid tissues, and these lymphoid tissues 
contains B and T cells which can be directly targeted by oral vaccination, 
however it is not always practical or possible either due to handling involved 
or due to the toxicity of the antigen to the mucosal surface (Suckow et al. 
2000; Kidane et al. 2001). Therefore local immunity can also be induced by 
the common mucosal immune system, where all the mucosal sites are linked 
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together and can be primed by IP inoculation (Mutwiri et al. 2005).  Several 
studies have shown that Salmonella can also induce strong humoral immune 
responses against carrier antigens. In particular oral inoculation with 
Salmonella expressing heterologous vaccine antigen can lead to the 
generation of strong a IgG and IgA response (Lasaro et al. 2005).   
 
Several factors play important roles in the magnitude and type of immune 
response induced against the passenger antigen. For example the type of 
mutation that leads to the disruption of genes encoding for important 
metabolic enzymes necessary for the survival of an organism in vivo, leads to 
the generation of mutants which are safe and have minimal survival in the 
host. This may have some effects on the course of the infection, thereby 
altering the quality of the induced immune response (Dunstan et al. 1998). 
Another factor which can play an important role is the type of antigen for 
example whether the antigen translocates into the periplasmic membrane or 
resides intracellularly and is degraded and presented to the  immune system 
(Garmory et al. 2002).  
 
 In the previous chapter, work leading to the creation of a set of recombinant 
STM-1 vaccine strains was described. The aim of work described in this 
chapter is to evaluate the ability of the Salmonella STM-1 mutant to deliver 
heterologous antigen in vivo and induce both cellular and humoral immune 
responses. Chicken ovalbumin was used as a model antigen and the C. jejuni 
major outer membrane protein was used as a test antigen.  
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5.2 Results 
5.2.1 Immunisation of mice 
Two immunisation experiments were designed. In the first experiment the 
uitlity of STM-1 as a vehicle for the induction of immune responses against 
chicken ovalbumin antigen expressed from both plasmid and chromosomal 
locations was evaluated. Also the efficacy of pagC and nirB promoters was 
compared in vivo. In the second experiment in vivo immune responses 
against C. jejuni major outer membrane protein (Momp) were evaluated from 
both plasmid and chromosome locations under the control of the nirB 
promoter.   
 
In both experiments groups of 5 mice were vaccinated three times at an 
interval of two weeks with STM-1 expressing heterologous antigen either from 
plasmid or chromosome, with empty STM-1 vector and STM-1 vector 
harbouring empty plasmid as controls. Vaccination was administered both 
orally and by IP injection. 
  
Oral vaccination was performed by inoculation of 5 x 108 CFU and IP 
vaccination with 1 x 106 CFU. Serum samples were collected prior to the third 
vaccination and three weeks after the third vaccination to analyse the humoral 
immune response. Mice were sacrificed three weeks after the third 
vaccination and splenocytes were collected for the ELISPOT assay. 
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Table 5.1: Vaccine trial # 1. The Table shows the groups, vaccine 
constructs and mode of inoculation for the evaluation of immune 
responses raised against the ovalbumin protein 
Groups Vaccination Mode of 
Inoculation 
Group 1  STM-1 only IP 
Group 2 “ Oral 
Group 3 STM-1 harbouring empty plasmid IP 
Group 4 “ Oral 
Group 5 STM-1 expressing ovalbumin antigen 
under the control of the pagC 
promoter from plasmid 
IP 
Group 6 “ Oral 
Group 7 STM-1 expressing ovalbumin antigen 
under the control of the pagC 
promoter from chromosomal location 
IP 
Group 8 “ Oral 
Group 9 STM-1 expressing ovalbumin antigen 
under the control of the nirB promoter 
from plasmid 
IP 
Group 10 “ Oral 
Group 11 STM-1 expressing ovalbumin antigen 
under the control of the nirB promoter 
from chromosomal location 
IP 
Group12 “ Oral 
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5.2.2 Analysis of humoral immune responses against the 
vectored ovalbumin antigen  
In this experiment the ability of the Salmonella STM-1 mutant to raise immune 
responses against chicken ovalbumin expressed from both plasmid and 
chromosome was evaluated. Also the efficacy of the pagC and nirB promoters 
is compared in vivo for the optimal expression of heterologous antigen, 
inferred by immune responses.  
 
The distribution of groups and the mode of inoculation are shown in Table 5.1. 
Group 1 to Group 4 are negative controls, group 1 and 2 mice were 
vaccinated with STM-1 only and group 3 and 4 mice were vaccinated with 
STM-1 harbouring empty plasmid. The evaluation of humoral and cell 
mediated immune responses from other groups was compared with Group 1 
to Group 4 for analysis.  
 
Humoral responses to ovalbumin were analysed by ELISA to confirm that 
STM-1 can deliver heterologous antigen in vivo activating humoral responses. 
The reactivity of IgG antibody from sera was tested against the ovalbumin 
antigen from the collected sera. Figure 5.1 shows the results from the pooled 
sera and Figure 5.2 shows the results from individual mice sera within each 
group. The results depicted in Figure 5.1 indicates that anti-ovalbumin 
responses are induced in each test group. 
 
Significant humoral responses were observed in mice vaccinated with STM-1 
expressing ovalbumin either from plasmid or from chromosome when 
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compared with negative control (p<0.001). However no significant difference 
was observed in humoral responses when the expression from the plasmid 
location was compared with expression from the chromosomal location 
(Figure 5.2). Also no significant difference in humoral responses was 
observed when the antigen was delivered from the pagC and the nirB 
promoters.  
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Figure 5.1. Analysis of the IgG response against ovalbumin antigen from 
pooled sera collected 3 weeks after the final vaccination. Reactivity was 
measured against 1:100 dilution of sera. Low but measurable responses were 
observed in sera from all groups in which ovalbumin was delivered. No 
response was observed in sera from the control groups 1-4.  
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 Figure 5.2. Humoral responses elicited after vaccination with ovalbumin 
constructs. Significant humoral responses were observed in mice vaccinated 
with STM-1 expressing ovalbumin either from a plasmid or from chromosomal 
location when compared with negative control (P<0.001). Each of the titres in 
the last eight groups is significantly higher then that in the corresponding 
control groups.  However, no significant difference was observed in humoral 
responses when the titres induced from plasmid expression was compared with 
expression from the chromosome. Also no significant difference in humoral 
responses was observed when the antigen was expressed from either the pagC 
promoter and the nirB promoter. 187
5.2.3 Analysis of Secretory IgA response from the faecal 
sample 
The above results indicate positive IgG responses in the mice vaccinated with 
STM-1 expressing ovalbumin antigen. Faecal samples were collected from 
each group 3 weeks after the final vaccination to analyse the secretory IgA 
response. Faecal samples were processed as described in section 2.6.4. The 
ELISA was performed on these samples to test the IgA response.   
 
Figure 5.3 shows the IgA response in the test group in comparison to the 
control group. Positive responses were observed in sera from mice 
vaccinated with STM-1 expressing ovalbumin antigen when expressed under 
control of the pagC promoter from plasmid and chromosome. Also mice 
vaccinated with STM-1 expressing ovalbumin antigen under the nirB promoter 
shows higher responses from chromosomal constructs in comparison to 
plasmid constructs. In this experiment a higher sIgA response was observed 
when the mice were vaccinated by IP inoculation when compared with oral 
inoculation, although as these are pooled samples no significance could be 
evaluated. 
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Figure 5.3. Analysis of secretory IgA response in mice from pooled 
faecal samples. The IgA levels in test groups when compared with the 
control group was higher in all groups vaccinated with ovalbumin 
constructs. 
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5.2.4 Analysis of cell mediated immune response against 
chicken ovalbumin antigen 
It was established in the above experiments that the delivery of ovalbumin 
from both plasmid and chromosomal location in STM-1 can induce humoral 
immune responses. To analyse the T cell response secretion of IL4 and IFN-γ 
by stimulated splenocytes was measured by ELISPOT assay. Splenocytes 
that have been primed by vaccination will respond to the antigen. Results are 
expressed as the number of spot forming T cells per million splenocytes 
(SFC) with cells from each mouse assayed in triplicate. 
 
Mice vaccinated with STM-1 expressing ovalbumin under control of the pagC 
promoter from plasmid (IP inoculation only) and from chromosomal location 
resulted in significant responses from activated splenocytes secreting IL4 
(P<0.001). Significant responses were also observed from the mice 
vaccinated with STM-1 expressing ovalbumin under control of the nirB 
promoter from both plasmid and the chromosomal location (P<0.001) as 
shown in Figure 5.4.  
 
Significant responses were observed for IFN-γ secretion from stimulated 
splenocytes isolated from mice vaccinated with STM-1 expressing ovalbumin 
antigen under control of the nirB promoter from the chromosome (P<0.001). 
Also, mice vaccinated with STM-1 expressing ovalbumin antigen under 
control of the pagC promoter from plasmid and from the chromosomal 
location (IP inoculation) shows a significant response as shown in Figure 5.5 
(P<0.001).    
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Figure 5.5. Enumeration of IFN-γ- secreting splenocytes from mice vaccinated 
with ovalbumin constructs. Spleen cells from vaccinated mice were challenged 
with soluble ovalbumin, and the number of positive IFN-γ -secreting cells 
determined. Compared with control groups, mice vaccinated with ovalbumin 
constructs, except those vaccinated with STM-1/pagCOva (plasmid location and 
chromosomal location, oral delivery) and STM-1/nirBOva (plasmid location, both 
IP and oral delivery) yielded significantly higher numbers. 
(* P < 0.05, ** P < 0.001) 
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5.2.5 Analysis of humoral responses against C. jejuni Momp 
antigen in vaccinated mice 
In this experiment the ability of STM-1 was tested to deliver C. jejuni Momp 
antigen under control of the nirB promoter from both plasmid and 
chromosomal location. It was established from the above experiments that 
mice vaccinated with STM-1 expressing ovalbumin antigen under the nirB 
promoter from the chromosomal location induces both arms of immune 
response when inoculated both orally and intraperitoeneally. 
 
The experimental design is shown in Table 5.2. Group 1 to group 4 are 
negative controls group 1 and 2 mice were vaccinated with STM-1 only and 
group 3 and 4 mice were vaccinated with STM-1 harbouring empty plasmid. 
The evaluation of humoral and cell mediated immune responses from other 
groups was compared with group 1 to 4 for the analysis.   
 
Serum samples were collected three weeks after the final vaccination for 
ELISA to test the humoral immune responses. Reactivity of IgG antibody was 
tested against the Momp antigen.  Mice vaccinated with STM-1 expressing 
Momp antigen under control of the nirB promoter shows a statistically 
significant response (P<0.001) when expressed from both plasmid and 
chromosome when compared with the control group. However, no significant 
difference in the reactivity of IgG was observed when the delivery of antigen 
was compared between plasmid encoded expression and chromosomal 
encoded expression (Figure 5.6).   
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Table 5.2:  Vaccine trial # 2. The shows the groups, vaccine constructs 
and mode of inoculation for the evaluation of immune responses raised 
against the Momp antigen 
Groups Vaccination Mode of inoculation
Group 1 STM-1 IP 
Group 2 “ Oral 
Group 3 STM-1 harbouring empty plasmid IP 
Group 4 “ Oral 
Group 5 STM-1 expressing momo under the 
nirB promoter from plasmid 
IP 
Group 6 “ Oral 
Group 7 STM-1 expressing momo under the 
nirB promoter from chromosome 
IP 
Group 8 “ Oral 
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Figure 5.6. Induction of IgG responses against C. jejuni Momp antigen in 
vaccinated mice. Serum from vaccinated mice was used to test the 
reactivity of IgG against C. jejuni outer membrane preparation. Compared to 
control groups, all groups of mice vaccinated with Momp constructs yielded 
a significantly higher response. 
(** P < 0.001) 
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 5.2.6 Analysis of cell mediated responses against C. jejuni 
Momp antigen in vaccinated mice 
The above result indicates the ability of STM-1 to deliver heterologous antigen 
to effectively induce a modest humoral response. To analyse the T cell 
response, secretion of IL4 and IFN-γ by stimulated splenocytes was 
measured by ELISPOT assay. Cells were re-stimulated with a C. jejuni outer 
membrane preparation. Results are expressed as the number of spot forming 
T cells per million splenocytes with cells from each mouse assayed in 
triplicate. 
 
The result analysis for the secretion of IL4 indicates significant response in 
mice vaccinated with STM-1 expressing Momp antigen under control of the 
nirB promoter from both plasmid (P<0.001) and from the chromosomal 
location (IP inoculation only) at P<0.005 when compared with the control 
groups as shown in Figure 5.7.  
 
 Analysis of IFN-γ secreting splenocytes indicates statistically significant 
response (P<0.001) in mice vaccinated with STM-1 expressing Momp antigen 
under control of the nirB promoter from both plasmid and the chromosomal 
location when compared with controls as shown in Figure 5.8. However, one 
group of mice vaccinated with nirBMomp constructs from plasmid location 
(oral inoculation) did not produce any observable response.  
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These results indicate that STM-1 expressing heterologous vaccine antigen 
can induce both IL4 and IFN-γ responses, however spot forming counts were 
relatively low from the splenocyltes secreting IL4 in the mice vaccinated with 
STM-1 expressing Momp antigen from the nirB promoter, with means ranging 
from below four to just over eight SFC per million cells. This would suggest 
that cells secreting this cytokine are less prevalent after Momp vaccination 
than after ovalbumin vaccination (compare Figure 5.7 and 5.4).  
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Figure 5.7. Enumeration of IL4- secreting splenocytes from mice vaccinated with 
Momp constructs. Spleen cells from vaccinated mice were challenged with 
soluble C. jejuni outer membrane preparation, and the number of positive IL4-
secreting cells determined. Compared with control groups, mice vaccinated with 
Momp constructs, except those vaccinated with STM-1/nirBMomp (chromosomal 
location, IP delivery), yielded significantly higher numbers. 
(* P < 0.05, ** P < 0.001) 
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Figure 5.8. Enumeration of IFNγ- secreting splenocytes from mice vaccinated 
with Momp constructs. Spleen cells from vaccinated mice were challenged with 
soluble C. jejuni outer membrane preparation, and the number of positive IFNγ-
secreting cells determined. Compared with control groups, mice vaccinated 
with Momp constructs, except those vaccinated with STM-1/nirBMomp (plasmid 
location, oral delivery), yielded significantly higher numbers. 
( ** P < 0.001) 
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5.3 Discussion 
 
The utility of live attenuated Salmonella strains as a vector for the delivery of 
heterologous antigen has been shown in different studies (Bachtiar et al. 
2003; Chen and Schifferli 2003; Ashby et al. 2005). The capability of the 
Salmonella vectors to target both cellular and humoral immune responses and 
present heterologous antigen makes them an ideal candidate for the delivery 
of passenger antigen and induction of the long lasting immune responses 
(Kang et al. 2002; Fouts et al. 2003; Foynes et al. 2003; Du and Wang 2005).  
 
The aim of work described in this chapter is to analyse the optimal expression 
of passenger antigen in vivo from Salmonella mutant STM-1 in order to 
characterise the optimal conditions which can be further utilised for the 
efficient delivery of heterologous antigen by using STM-1 as a vector. STM-1 
is an aroA mutant of S. Typhimurium, which is a commercially available 
livestock vaccine for poultry to protect against Salmonella infection. Further 
exploitation of this mutant as a carrier vaccine is a desirable outcome. The 
efficiency of two well characterised in vivo inducible promoters was evaluated 
to achieve optimal expression from multi-copy plasmids and the chromosomal 
location.  
 
As demonstrated by work described in the previous chapter, these promoters 
were evaluated for their expression efficiency and stable protein expression 
when the expression was allowed from multi-copy plasmid, also their ability to 
induce expression from the single copy gene by integrating the constructs in 
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the aroA region of STM-1. Analysis for the expression of proteins in vitro by 
western blotting indicates very low expression from both plasmid and 
chromosomal location however, in vitro expression may not be the true 
indicator of in vivo expression due to difficulty in replicating the anareobic 
conditions required to activate these promoters. As it was impractical to 
directly measure expression of vectored proteins in vivo, immune responses 
were measured and assumed to reflect expression of the antigen. 
 
Animal experiment demonstrates that STM-1 expressing the ovalbumin 
antigen under control of the pagC promoter or nirB promoter can induce anti-
ovalbumin immune responses. In the analysis of humoral immune responses, 
significant responses were observed in mice vaccinated with STM-1 
expressing ovalbumin either from the plasmid or from the chromosome when 
compared with negative control (p<0.001). However no significant difference 
in humoral responses was observed when the delivery of antigens was 
compared between the plasmid and the chromosomal location (Figure 5.2). 
Therefore, there was no obvious advantage in having multiple copies of the 
gene. Additionally no significant difference in the immune responses was 
observed against the delivered antigen from either the pagC and nirB 
promoter, which indicates similar expression efficiency from the two 
promoters. The IgA response in the test group when compared with the 
control group shows positive responses in vaccinated mice. However, the IgA 
response in the mice receiving vaccination by IP injection shows higher 
responses then mice which received vaccination orally. The reason for this is 
unknown as the mice vaccinated orally were expected to show higher IgA 
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responses. However, the establishment of infection is different between the 
two routes (reflected by the different CFU given) hence direct comparision is 
not possible.  
 
Similarly cellular immune responses, as measured by enumeration of 
cytokine-secreting splenocytes indicates significant responses for the 
secretion of IL4 and IFN-γ from the stimulated splenocytes isolated from mice 
vaccinated with STM-1 expressing ovalbumin. This is appaent from both pagC 
and nirB promoter constructs (* P<0.05, **P<0.001). Exception are mice 
vaccinated orally with STM-1 expressing ovalbumin from the plasmid location 
under control of the pagC promoter, which did not show an IL4 response, and 
mice vaccinated both orally and IP with STM-1 expressing ovalbumin from the 
plasmid location under control of the nirB promoter, which did not show any 
IFN-γ response. However, both IL4 and IFN-γ count was higher in groups 
where the antigen was delivered under control of the nirB promoter from the 
chromosomal location, therefore the Momp antigens expressed under control 
of the nirB promoter was the choice for the second set of vaccine 
experiments.  
 
Humoral and cellular responses were evaluated to test the utility of STM-1 to 
express C. jejuni major outer membrane protein as test antigen under the nirB 
promoter from both plasmid and chromosomal location. Significant IgG 
reactivity against the Momp antigen was observed in mice vaccinated with 
STM-1 expressing Momp antigen under control of the nirB promoter when 
compared with the control groups. However, no difference in the reactivity 
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was observed when the expression between plasmid and chromosomal 
location was evaluated (Figure 5.6), again indicating no advantage of multiple 
gene dosage. 
 
Evaluation of cell mediated responses from stimulated splenocytes indicates 
positive response for the secretion of both IL4 and IFN-γ in the mice 
vaccinated with STM-1 expressing Momp from both plasmid and the 
chromosomal location, when compared with the control groups. However spot 
forming counts were relatively low for IL4 secreting splenocyltes, indicating 
that the Momp antigen may preferentially induce T cells that secreted IFN-γ, 
indicative of a Th1 type response in mice. 
 
This study indicates that the STM-1 mutant can be used effectively as a 
carrier to deliver the heterologous vaccine antigen. The expression of 
heterologous vaccine antigen under the control of in vivo inducible promoters 
such as pagC and nirB can induce immune responses from both plasmid and 
chromosomal location. However, the nirB promoter was found to be more 
efficient in the expression of heterologous antigen when the expression was 
analysed from the single copy gene from the chromosome.  
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Chapter 6 
The effect of prior immunological 
experience against the bacterial vector on 
the immune responded against a 
heterologous antigen 
 
6.1 Introduction 
One of the recent advances in the field of vaccine technology is the use of 
attenuated Salmonella strains to deliver heterologous vaccine antigen The 
possibility that prior immunological experience of animals with homologous or 
related strains might compromise the efficacy of Salmonella vector to deliver 
foreign antigen has long been considered (Dougan et al. 1987).   
 
Bao et al. (1991) first reported the consequences of prior exposure of animals 
to the vector strain and showed that both serum and mucosal antibody 
responses against the foreign antigen up-regulated after the animals were 
exposed to the vectored strain. Whittle et al. (1997) reported similar findings 
where mice immunised intraperitoneally with  an S. dublin aroA mutant 
expressing heterologous antigen after being exposed to the same vector 
showed a higher immune response to the vectored antigen in comparison to 
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mice without any immunological experience against the vector Bao  et al. 
(1991).  
 
Most of the studies (Kohler et al. 2000; Jespersgaard et al. 2001) indicate the 
up-regulation of immune responses after animals have been exposed to either 
homologous or related strains of the vector before the delivery of 
heterologous antigen in the vector.  One of the recently conducted studies by 
Metzger, et al. (2004) on human volunteers using S. typhi as a vector 
suggested that there was no change in the immune response against the 
heterologous antigen in human volunteers who were exposed to empty vector 
in comparison the volunteers who did not have prior immunological 
experience with the vector strain. Taken together, these results indicate that 
pre-existing immunity may not compromise immunogenecity of vectored 
antigen at a subsequent vaccination. 
 
However, there are some conflicting reports. Attridge et al. (1997) reported 
that a pre-existing immune responses against the bacterial vector prior to the 
delivery of antigenic protein in the vector can down-regulate immune 
responses in mice against the antigenic protein. Similar concerns were raised 
by Roberts, et al. (1999) and Vindurampulle et al.  (2003) who reported that 
prior exposure of animals to homologous or related strains reduced the 
subsequent immune response in mice against the vectored foreign antigen.  
 
These studies indicate that the prior exposure of animals to bacterial vector 
can certainly affect the immune responses against the heterologous antigenic 
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protein in animal models. However, most of the studies indicate that the 
immune response was up-regulated after the animals were exposed to either 
homologous or related strains of the vector before the delivery of 
heterologous antigen in the vector.   
 
These findings lead to the conclusion that the pre-existing immune responses 
against the bacterial vector or related strains may positively influence immune 
responses against the heterologous antigen, however, there are a number of 
factors such as the Salmonella carrier strain used and the type of the foreign 
antigen which may influence the outcome (Vindurampulle and Attridge 2003). 
These findings have only reported the affect on humoral immune responses, 
as there are no studies which report the affects on T cell immune responses. 
This is important as one of the advantages of using Salmonella (an 
intracellular pathogen) is that strong cellular responses can be induced.  
 
Work described in the previous chapter demonstrated that the Salmonella 
aroA mutant can be efficiently utilised for the delivery of heterologous antigen 
expressed from both the plasmid and chromosomal location. Both humoral 
and cellular immune responses were shown to be induced against the 
heterologous antigen. In the work described in this chapter, the influence of 
pre-existing immunity on such responses is examined. S. Enteritidis was used 
as a model for the pre-existing immunity to a related, but not identical vector.  
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6.2 Results 
To analyse the impact of pre-existing immune response, both short term and 
long term, 6-8 week old female BALB/c mice were divided into eight groups, 
each group consisting of five mice.  Each mouse was orally inoculated with 
5x108 CFU of bacterial culture. The experiment was designed to test immune 
responses to vectored antigen in mice with pre-existing immunity to a 
homologous or a heterologous strain. Table 6.1 shows the vaccination 
protocol. Basically, the effects of pre-existing immunity were tested after a 
short period before vaccination (3 weeks) or a longer period (12 weeks). 
 
The first vaccination was administered at week 0, with Groups 1 and 5 as 
controls, therefore not receiving inoculation in week 0. These groups were 
then inoculated with STM-1 in week 3 and week 12 respectively. Group 2 and 
Group 6 were not exposed to either vector strain or related strains, therefore 
these groups were also not inoculated on week 0, but were inoculated on 
week 3 and week 12 respectively with STM-1 expressing ovalbumin antigen 
from the pKKOva plasmid. Group 3 and Group 7 were exposed to STM-1 at 
week 0, to stimulate pre-existing immunity against the homologous strain. In 
week 3 or 12 these groups were inoculated with STM-1 expressing ovalbumin 
from the pKKOva plasmid. Similarly Group 4 and Group 8 were exposed to 
the related strain (S. Enteritidis) in week 0 and in weeks 3 or 12 were 
inoculated with STM-1 expressing ovalbumin from the pKKOva plasmid. 
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Table 6.1 Protocol for the vaccine trial to test the effect of pre-existing 
immunity. 
Group Vaccination 
1st dose 
Vaccination 2nd 
dose week 3 
Vaccine 2nd dose 
week 12 
Gruop1  None STM-1  None  
Group 2 None STM-1/pKKOVA  None 
Group3  STM-1 STM-1/pKKOVA  None 
Group4 S. Enteritidis STM-1/pKKOVA  None 
Group5  None None STM-1 
Group6  None None STM-1/pKKOVA  
Group7  STM-1 None STM-1/pKKOVA  
Group8   S. Enteritidis None STM-1/pKKOVA  
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6.2.1 Initial evaluation of humoral immune responses against 
ovalbumin. 
ELISA analysis was performed to detect the IgG responses against the 
vectored ovalbumin antigen as described in section 2.6.5. Serum samples 
were collected from all groups at week 6. Although the Group 5-8 mice had 
not been exposed to ovalbumin (Table 6.1), the serum was collected to 
confirm negative immune responses in these groups. Initially serum samples 
from each mouse within a group were pooled for detection of IgG antibodies. 
There was no reactivity in sera from mice vaccinated with STM-1 only (Group 
1), and mice in the groups which did not receive the second dose of 
vaccination at week 3 (Group 5 -8). However a positive response was 
detected against ovalbumin in groups vaccinated with STM-1 expressing 
ovalbumin antigen from the pKKOva plasmid. (Groups 2-4). 
 
These results from pooled sera indicate that immune responses to ovalbumin 
are induced in the vaccinated groups in relation to the control group (Figure 
6.1). Responses are low however, and as the sera was pooled, titres and 
statistical significance was not calculated. However, there appears to be no 
obvious difference between the groups which were pre-exposed to the 
homologous and related strains when compared to the unexposed group 
(group 2).  
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 Figure 6.1 Estimation of IgG responses at week 6 in all groups. Sera taken 
from mice were pooled within a group and the reactivity of IgG to ovalbumin 
was measured. The reactivity show a positive response in mice which were 
vaccinated with STM-1 expressing ovalbumin in comparison to groups of 
mice which were vaccinated with STM-1 only.  
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6.2.2 Evaluation of humoral immune responses against the 
ovalbumin antigen from individual sera 
The initial assessment of IgG responses against ovalbumin from the pooled 
sera did not show any obvious difference between the pre-exposed mice to 
either homologous or related strains of Salmonella when compared with the 
unexposed groups.  
 
Further analysis was performed from individual serum samples collected 3 
weeks after the second dose of vaccination to Group 1 to Group 4 mice (i.e 
week 6). Titre was calculated for sera from each mouse. The IgG reactivity 
was compared using the non recombinant STM-1 group (Group 1) as control 
using student’s T Test (P<0.001 and P<0.05). 
 
A significant difference was observed at the 99% confidence level between 
mice vaccinated with STM-1 expressing ovalbumin from the pKKOva plasmid 
(Group 2 to Group 4) when compared with the control group which was 
vaccinated with non recombinant STM-1 (Group 1). Also a significant 
difference was observed between groups pre-exposed to the vector strain 
(Group 3) when compared to the unexposed group (Group 2) (Figure 6.2). 
However no significant difference was observed between the group which 
was exposed to a related strain (Group 4) when compared with the 
unexposed group (Group 2). This analysis indicates that the prior exposure of 
animals to the vector strain enhances the subsequent humoral immune 
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response to a vectored antigens carried by the same strain, delivered 3 weeks 
later.  
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Figure 6.2. Evaluation of humoral immune responses against the carrier antigen (chicken 
ovalbumin) at week 6 in groups 1-4.  Mice were first vaccinated (week 0) with nothing 
(Group 1 and group 2), STM-1 (Group 3) or S. Enteritidis (Group 4), followed by 
vaccination at week 3 with non-recombinant STM-1 (Group 1) and STM-1 expressing 
ovalbumin from the pKKOva plasmid (Group 2 to Group 4). Serum samples collected 3 
weeks after the second vaccination were tested for IgG responses. Significant 
differences in titre were observed between Groups 2 –4 and Group 1 (**P<0.001), also a 
significant difference was observed in the groups which were pre-exposed to the vector 
strain (Group 3) when compared with the unexposed group (Group 2) (**P<0.001). 
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6.2.3 The effect of a longer time period between exposure and 
vaccination with vectored antigen 
Serum samples from all mice were collected at week 15, which is 3 weeks 
after the second vaccination to Group 5- 8 with STM-1 carrying the pKKOva 
plasmid. The titre was calculated and the reactivity against chicken ovalbumin 
antigen was compared against mice vaccinated with non-recombinant STM-1 
as the control using Student’s T-test (P<0.001 and P<0.05). 
 
Analysis of humoral responses induced against the heterologous antigen after 
the animals were first vaccinated with the vector strain or a related strain 
indicates significant responses in both exposed and unexposed animals when 
compared with mice vaccinated with non-recombinant STM-1 (Figure 6.3). 
This is similar to the observation at week 6. However, no significant difference 
was observed when the exposed groups were compared with the unexposed 
groups. 
 
The analysis of longer term exposure of animals to either vector strain or 
related strain indicates up-regulation of humoral immune response not only 
when compared to the control group (P<0.001), but also when compared with 
the unexposed group and mice exposed to STM-1 prior to vaccination 
(P<0.05) as shown in Figure 6.4. The immune response in the unexposed 
group was also significantly higher when compared with the control group. 
 214
  
0
50
100
150
200
250
 Group-1
(None/STM -1)
Group-2
(None/STM-
1pKKOva)
 Group-3 (STM -
1/STM-1pKKOva)
 Group 4 (S.E/STM-
1 pKKOva)
Ti
tr
e
 
**
**
**
Figure 6.3. Evaluation of humoral immune responses against the carrier antigen 
(chicken ovalbumin) at week 15 in groups 1-4.  Mice were first vaccinated (week 0) 
with nothing (Group 1 and group 2), STM-1 (Group 3) or S. Enteritidis (Group 4), 
followed by vaccination at week 3 with non-recombinant STM-1 (Group 1) and STM-
1 expressing ovalbumin from the pKKOva plasmid (Group 2 to Group 4). Serum 
samples collected 12 weeks after the second vaccination were tested for IgG 
responses. Significant differences in titre were observed between Groups 2 –4 and 
Group 1. (**P<0.001) 
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Figure 6.4. Evaluation of humoral immune responses against the carrier antigen 
(chicken ovalbumin) at week 15 in groups 5-8.  Mice were first vaccinated (week 0) 
with nothing (Group 5 and 6), STM-1 (Group 7) or S. Enteritidis (Group 8), followed by 
vaccination at week 12 with non-recombinant STM-1 (Group 5) and STM-1 expressing 
ovalbumin from the pKKOva plasmid (Group 6 to Group 8). Serum samples collected 
3 weeks after the second vaccination were tested for IgG responses. Significant 
differences in titre were observed between Groups 6-8 and Group 5 (**P<0.001), also a 
significant difference was observed in the groups which were pre-exposed to the 
vector strain (Group 7) when compared with the unexposed group (Group 2) 
(**P<0.05). 
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6.2.4 Effect of prior immunological experience with carrier or 
related strains; cellular immune responses 
The effect on carrier protein immunogenecity due to pre-existing immune 
responses against the homologous or related strains has been previously 
analysed (Roberts et al. 1999; Jespersgaard et al. 2001; Vindurampulle and 
Attridge 2003; Metzger et al. 2004). Although there are conflicting reports, 
most of the studies so far have only reported the effects on humoral 
responses. The purpose of using Salmonella strains as a vector to deliver 
heterologous vaccine antigen is to target cellular immune responses so that 
long lasting immunity can be induced. 
 
Mice were sacrificed in week 15, which is 12 weeks after the second dose of 
vaccination in Group 1-4 and 3 weeks after the second dose of vaccination in 
Group 5-8. Splenocytes were prepared for the ELISOPT assay as described 
in section 2.6.5.1. The number of cytokine secreting cells in each group was 
compared using Student’s T test (P<0.001 and P<0.05). Results were 
reported as spot forming cells (SFC). 
 
Results of this experiment are presented as for the humoral responses, with 
groups 1-4 compared and groups 5-8 compared. For groups 1-4 (designed to 
test the effects of prior exposure followed by vaccination 3 weeks later), 
exposure of mice to either the vector or related strain results in significantly 
increased IL4 response in mice which were exposed to STM-1 at week 0 
(Figure 6.5, compares group 3 vs group 2) but not when exposed to the 
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related S. Enteriditis (group4 vs Group 2).  All groups (2-4) yielded 
significantly higher numbers than the control, group 1. 
 
The analysis of IFN-γ secreting cells indicates a significant increase in 
responses in animals which were exposed to either vector strain (group 3) or 
related strain (group 4) before being vaccinated with STM-1 expressing 
ovalbumin when compared with mice which were not vaccinated  at week 0 
(group 2) (P<0.001) as shown in Figure 6.6. All groups (2-4) yielded 
significantly higher numbers that the control, group 1. 
 
Groups 5-8 received the 2nd dose vaccination in week 12, which was 9 weeks 
after being exposed to the vector strain or related strain. All the mice 
vaccinated with ovalbumin constructs showed a statistically significant IL4 and 
IFN-γ cell count when compared to mice vaccinated with non-recombinant 
STM-1 (compares groups 6-8 with group 5) at P<0.001 as shown in Figure 6.5 
and Figure 6.6. Additionally exposure to the vector strain or related strain prior 
to vaccination with the vectored antigen in week 12 yielded a statistically 
significant increase in cytokine secreting cells for both IL4 and IFN-γ 
(P<0.001), when compared with mice vaccinated with STM-1 expressing 
ovalbumin from the pKKOva plasmid without being exposed (compare groups 
7 and 8 with group 6). 
 
These data indicate that exposure to the vector or related strain can 
upregulate subsequent responses to a vectored antigen, with little differences 
between those in which the vaccination was given 3 or 12 weeks after the 
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exposure (except in the case of exposure to S. Enteriditis, where there was no 
significant increase in the IL4 response where the vaccine was given 3 weeks 
after exposure) 
 
The result of IL4 and IFN-γ responses in response to challenge with 
ovalbumin correlates with the analysis of humoral immune responses in 
groups 1-8. Humoral immune responses against the foreign antigen were 
significantly higher in mice which were pre-exposed to the vector strain or 
related strain, not only in comparison to mice vaccinated with non-
recombinant STM-1 but also in comparison to mice which were vaccinated 
with STM-1 expressing ovalbumin from the pKKOva plasmid without being 
exposed. 
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Figure 6.5. Enumeration of IL4- secreting splenocytes from vaccinated mice in groups 
1- 8.  Spleen cells from vaccinated mice were challenged with soluble ovalbumin, and 
the number of positive IL4-secreting cells determined. Compared with the control 
groups (1 and 5), mice vaccinated with ovalbumin constructs yielded significantly 
higher numbers (groups 2-4 and 6-8) (**P<0.001). A significant difference was also 
observed between groups which were pre-exposed to the vector strain (group 3 and 7) 
when compared with unexposed groups (2 and6)  (**P<0.001) and the groups which 
were pre-exposed to the related strain and vaccinated 9 weeks later (group 8) when 
compared with group 6 (**P<0.001). 
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Figure 6.6. Enumeration of IFN-γ- secreting splenocytes from vaccinated mice in 
groups 1-8. Spleen cells from vaccinated mice were challenged with soluble 
ovalbumin, and the number of positive IFN-γ -secreting cells determined. Compared 
with the control groups (1 and 5), mice vaccinated with ovalbumin constructs yielded 
significantly higher numbers (**P<0.001). A significant difference was also observed 
between groups pre-exposed to the vector and related strain respectively (group 3 -4 
and group 7-8) when compared with group 2 and 6, the unexposed groups (**P< 
0.001). 
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6.3 Discussion 
The construction of Salmonella based vaccines where the Salmonella strain 
can deliver heterologous vaccine antigen to the host immune response is 
based on the notion that long term T-cell immune responses can be induced 
efficiently against the passenger antigens (Hess et al. 2000; Kang et al. 
2002). However, the practicality of this approach still needs to be tested in the 
field trials. 
 
 Major issues regarding the use of the proposed technique in the 
management of infectious disease emerge when considering the effect of pre-
existing immune responses against the bacterial vector or related strains in 
the host. Also, the consequences of repeated use of the same vector to 
deliver different foreign antigens needs to be considered.  
 
Several studies have shown conflicting results regarding an impact of vector 
priming and its effect on the efficiency to generate protective immune 
response against the heterologous antigen (Bao and Clements 1991; Attridge 
et al. 1997; Roberts et al. 1999; Metzger et al. 2004).  Vindurampulle et al. 
(2003) in one of his studies showed that several variable factors, such as the 
animal model, vector strain, the type of mutation in vector strain etc plays an 
important role in the generation of efficient immune responses against the 
heterologous antigens after the prior exposure of animals to either carrier 
strain or related strain. In all studies conducted to date only report the effect 
on the generation of humoral immune responses. 
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The rationale behind using Salmonella to deliver heterologous vaccine 
antigen is that as an intracellular pathogen, Salmonella efficiently induces T 
cell responses giving rise to Th1 and Th2 helper cells and CTL’s against 
Salmonella and vectored foreign antigen (Wang HW 2003 Aug; Wyszynska et 
al. 2004).  
 
This study was conducted to mimic the effect of prior exposure of the animal 
host to the vector strain or a related strain, and analyse the effect this 
exposure has on the induction of both humoral and cellular immune 
responses against a passenger antigens. Two parallel experiments were 
performed one with a 3 week gap between exposure and vaccination, and 
one with 12 week gap. The results indicate that the prior exposure of animals 
to the vector strain or related strain, at 3 and 12 weeks prior to vaccination, 
significantly enhances the humoral immune responses not only in comparison 
to mice vaccinated with non-recombinant STM-1 but also in comparison with 
mice vaccinated with STM-1 expressing ovalbumin without prior exposure.  
Similarly, cellular immune responses as measured by enumeration of cytokine 
secreting splenocytes, are generally increased.  
 
These results suggest that both humoral and cellular immune responses are 
up-regulated if the animal host which were exposed to either the vector strain 
or related strain when compared to animals with no immunological memory 
against the vector or related strain.  
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This study indicates that Salmonella strains may be effective carriers for the 
delivery of heterologous antigen to the host immune response in the field. The 
immunological memory against the bacterial vector or related strains in target 
hosts will not jeopardise the use of Salmonella as a vector to deliver 
heterologous antigens. In fact the immunological memory against the bacterial 
vector may enhance the immune responses against passenger antigens.  
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Chapter 7 
Conclusion 
Live attenuated bacterial strains provide unique alternatives in terms of 
antigen delivery and immune presentation, however, they also show promise 
as potentially useful vectors for heterologous antigen delivery. The efficiency 
of any live bacterial vector rests with its ability to present sufficient foreign 
antigen to the human or animal immune system to initiate the desirable 
protective immune response. The most obvious choice in the case of live 
bacterial vaccines can be those candidates, which can strongly activate both 
the humoral and cellular immune response. Intracellular residing organisms, 
which can invade macrophages or dendritic cells, have the capability to 
markedly elevate B and T cell responses. 
  
Attenuated bacterial strains such as Salmonella, Mycobacterium, Shigella and 
Listeria spp have been found to be suitable for this purpose. Initial studies 
using Salmonella mutants reported that these mutants can establish limited 
infection, induce long lasting immune responses and were also suitable for 
the delivery of heterologous antigen to the host immune system (Clements 
and El-Morshidy 1984; Dalla Pozza et al. 1998; Ward et al. 1999; Wyszynska 
et al. 2004).  Since then the use of Salmonella mutants has been widely 
studied for use as a potential vector to deliver antigenic proteins from 
bacteria, viruses, and eukaryotes (Dougan et al. 1987; Dalla Pozza et al. 
1998; Dunstan et al. 1998; Coynault and Norel 1999; Bullifent et al. 2000; 
Fayolle et al. 2001; Fouts et al. 2003). 
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The STM-1 mutant, developed by RMIT University, harbours a mutation in the 
aroA gene and is a well characterised vaccine strain currently in use to protect 
livestock against Salmonella infection. This mutant was tested for its potential 
to deliver heterologous vaccine antigen expressed from plasmids and found 
suitable as vector for this purpose (Bachtiar et al. 2003) 
 
In order to progress to any commercial application, the use of plasmid-borne 
antigen shouls be eliminated. This is for two main reasons; (1) to ensure 
stability of antigen expression in the absence of antibiotic selection, and (2) to 
eliminate the possibility of environmental contamination of resident bacterial 
flora by horizontal transmission of plasmids. 
 
However, one limitation in using STM-1 for this study was uncharacterised 
nature of the aroA region of this mutant, where the genes of interest were 
planned to be integrated. As described in the results from chapter 3 the lesion 
in STM-1 is due to the deletion of several genes, including first 90bp of aroA 
gene. However, there is also an insertion and chromosomal rearrangement 
which is not an inversion, but may be a crossover between two points not due 
to any specific target sequences. The exact mechanism of this rearrangement 
is not known, but may be due to the conserved three dimensional structure of 
bacterial chromosome (Fonstein, et al. 1994) 
 
Once the architecture of the genome in STM-1 was determined, strategies to 
incorporate genes into the chromosome were developed. Constructs were 
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designed with genes encoding chicken ovalbumin (model antigen) and C. 
jejuni  Momp (test antigen) with both genes placed under the control of two 
promoters, either pagC or nirB The pagC promoter is a macrophage inducible 
promoter found to be most efficient in terms of in vivo expression of 
heterologous antigen (Dunstan et al. 1999). The nirB promoter was isolated 
from E. coli (Jayaraman et al. 1987), and this promoter has also been shown 
to be efficient in term of in vivo expression and antigen delivery (Chatfield et 
al. 1992). Therefore these two promoters were the promoters of choice in this 
study.   
 
Plasmid constructs were designed with genes encoding ovalbumin and Momp 
proteins were put under the control of one of the promoters. Similar constructs 
were integrated into the aroA gene of the STM-1 chromosome. The Lambda 
Red system which is based on the phage recombination system was used for 
the integration of constructs in the STM-1 chromosome (Murphy 1998; 
Datsenko and Wanner 2000). This system proved to be relatively efficient at 
generating recombinants in STM-1, whereas a parallel strategy employing 
suicide vectors was unsuccessful.   
 
The results details in chapter 4 and 5 indicate that expression of heterologous 
vaccine antigen, sufficient to induce both humoral and T cell immune 
responses, can be achieved using these two promoters from either plasmid or 
chromosomal location. Although the pagC promoter has been reported to be 
more efficient in comparison to nirB (Dunstan et al. 1999), results from this 
study indicates that both the promoters are equally efficient in inducing 
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immune responses and therefore optimal expression of heterologous 
antigens. In fact immune responses were some what higher (although not 
significant) from chromosomal constructs, incorporating the nirB promoter.  
 
It was thought that the higher gene copy number afforded by the use of 
plasmids may be reflected in the induction of higher immune responses, 
however this was not observed. This might be due to the inability of the STM-
1 mutant to retain the plasmid in vivo due to the metabolic burden imposed 
and the absence of drug selection. As stated above the mutation in STM-1 is 
due to the deletion of several metabolically important genes. In vivo 
propagation of plasmid will put the additional metabolic burden on bacterial 
replication machinery, so there may in effect be selection for the loss of 
plasmid in vivo. 
 
The effect of pre-existing immune responses against the bacterial vector or 
related strains is a concern which may jeopardise the use of STM-1 vector or 
the use of other Salmonella mutants as vector to deliver heterologous vaccine 
antigen in the field. Studies conducted to date indicate conflicting reports. 
some studies reported up-regulation of humoral immune responses against 
heterologous vaccine antigen in animals which were pre-exposed to the 
vector strain or related strains (Bao and Clements 1991; Whittle and Verma 
1997), while other studies suggests that immune response against the 
vaccine antigen might suffer in animals pre-exposed to such strains (Attridge 
et al. 1997; Roberts et al. 1999; Vindurampulle and Attridge 2003). Some, 
recent studies concerning the impact of vector priming indicates induction of 
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greater humoral immune responses (Kohler et al. 2000; Jespersgaard et al. 
2001; Metzger et al. 2004). All studies to date analyse only humoral immune 
responses. 
 
The experiments described in Chapter 6 were designed to mimic the effects of 
pre-existing immunity. Animals were left either 3 or 12 weeks after exposure 
to either the vector strain (STM-1) or a related species, S. Enteritidis, prior to 
administration of a second dose with STM-1 expressing ovabumin. Analysis of 
the resulting immune responses against ovalbumin indicates that prior 
immunological memory against the bacterial vector or related strains 
enhances both humoral and cellular immune responses against the 
passenger antigen.  
 
 
Taken together, these results indicate that heterologous antigen can be 
expressed from the chromosomal location in STM-1, and immune responses 
to these antigens can be induced. The Lambda Red system allows efficient 
recombination of inserts into the bacterial chromosome at the desired location 
and also provides the option to precisely remove the gene encoding for the 
antibiotic resistance. Both these observations should facilitate further research 
into the use of STM-1 as a vaccine vector. 
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